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Abstract 
Parasitic helminths are able to survive within their hosts due to their ability to 
dampen immune responses by secreting molecules with anti-inflammatory and 
tissue repair properties. Reflecting this, there is increasing evidence of an 
inverse correlation between parasitic worm infection and the incidence of 
allergic and autoimmune disorders on a global scale. Such epidemiological 
evidence has led to the “hygiene hypothesis” which postulates that the recent 
rapid eradication of parasitic worms in developed countries has resulted in 
unbalanced hyper-reactive immune systems and consequently, inflammatory 
disease. As “worm therapy” per se is not ideal, this in turn triggered the idea 
that exploiting the ability of helminth-derived “immunomodulators” to dampen 
pathological host inflammation would potentially allow identification of the key 
pathogenic events in models of human inflammatory disease and hence provide a 
starting point for development of new and safer therapeutics. Consistent with 
this, as a serendipitous side-effect of its anti-inflammatory actions, ES-62, a 
phosphorylcholine (PC)-containing glycoprotein secreted by the filarial 
nematode, Acanthocheilonema viteae exhibits therapeutic potential in mouse 
models of inflammatory disorders such as asthma, lupus and rheumatoid arthritis 
(RA).  
RA is a chronic autoimmune inflammatory disorder that affects 1 % of the 
population in industrialized countries, with no known cure. This disorder causes 
joint destruction and leads to reduced mobility and disability. Deregulation of T 
cell activation has long been considered to be a major force driving inflammation 
and thus to date, therapies have focused on systemic anti-inflammatory 
treatments, which generally leave individuals immunosuppressed and open to 
infection. Thus, interest has begun to focus on the role(s) that synovial 
fibroblasts (SF) in the joint play in the early onset of the disease, the maintenance 
of established inflammation and even in the spread of disease to unaffected joints. 
This reflects that despite not being part of the immune system, SF produce pro-
inflammatory cytokines during the pathogenesis of RA and also directly mediate 
joint destruction by secreting matrix metalloproteinases (MMPs) that damage 
cartilage and bone. Indeed, there is increasing evidence that the local pro-
inflammatory environment pertaining in the joints drives SF to become 
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imprinted pathogenic aggressors that initiate, drive and spread joint 
inflammation and bone resorption during development of collagen-induced 
arthritis (CIA), a mouse model of RA. Intriguingly, therefore, whilst it is established 
that protection afforded by ES-62 against joint inflammation and bone destruction 
in CIA is associated with reduced production of the pathogenic cytokine, IL-17 by 
 and CD4+ T cells, recent evidence suggested that ES-62 could also act directly 
to suppress the aggressive hyper-inflammatory phenotype of SF in the joint. The 
molecular mechanisms involved were not defined but interestingly, given that SF 
express the ES-62 target TLR4 and are the only cells in the joint to express the 
IL-22 receptor, the parasite product appeared to harness the inflammation-
resolving and/or tissue repair actions of IL-22 to suppress SF responses during the 
established phase of disease.    
Thus the core goal of this thesis was to advance our fundamental understanding 
of how SF become imprinted pathogenic aggressors that initiate, drive and 
spread joint inflammation and bone resorption in the CIA mouse model, as a 
surrogate for the pathogenic events in the joints in RA. In particular, the primary 
major aim was to investigate the impact of the local pro-inflammatory 
environment pertaining during disease, specifically focusing on the signalling and 
epigenetic mechanisms by which IL-17 and IL-22 potentially (counter)regulate the 
pathogenic phenotype of SF. Complementing this, another major aim was to 
establish whether ES-62 acted directly to modulate the phenotype of SF and 
thus, to identify the key mechanisms by which ES-62 could prevent SF from 
promoting inflammation and bone destruction and in this way render them 
insensitive to pro-inflammatory signals. From a therapeutic point of view, being 
a large immunogenic molecule, ES-62 is not suitable for use in the clinic and thus 
candidate small molecule analogues (SMAs) of ES-62, based around its active PC 
moiety have been designed, some which mimic its therapeutic potential in a 
variety of inflammatory disorders. Thus, it was also important to address 
whether ES-62 and its SMAs were similarly able to affect SF and prevent their 
pathogenicity.  
These studies revealed that the microenvironment of the joint during induction 
and progression of CIA did indeed result in remodelling of the epigenetic 
landscape of SF and that such cell reprogramming was associated with the 
acquisition of a hyperinflammatory, tissue destructive phenotype.  Such 
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reprogramming could be recapitulated in vitro, at least in part, by chronic 
exposure of normal SF to pro-inflammatory cytokines such as IL-17 and IL-1 
pathogenic mediators that are found at high levels in the arthritic joint. Such 
reprogramming was dependent on ERK and STAT3 signalling converging on miR-
155-mediated regulation of inflammatory networks via global DNA 
hypomethylation. ES-62 was able to counteract this by suppressing the levels of 
ERK, STAT3 and miR-155 signalling but rather surprisingly, this did not result in 
abrogation of this hypomethylated epigenetic landscape.  Rather, whereas the 
SMA 12b appeared to act simply by preventing/reversing global DNA 
demethylation to suppress the induction of genes that drive pathogenesis in CIA, 
ES-62 induced further global DNA hypomethylation and modulation of the 
epigenetic landscape by inducing HDAC1: collectively these findings suggested 
that ES-62 might additionally induce (homeostatic) inflammation-resolving and 
tissue repair genes that would have translational impact in established disease. 
In any case, these studies suggest that the proposal to use the global DNA 
methylation status of RA patients as a biomarker of disease should be treated 
with caution. 
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1. General introduction  
1.1 Rheumatoid arthritis 
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by 
symmetrical polyarticular inflammation of the synovium that causes pain, 
swelling and stiffness in the joints, usually the small joints of the hands, wrists 
and feet. However, it is increasingly recognised that various co-morbidities are 
associated with RA such as cardiovascular defects and increased risk of cancer as 
well as osteoporosis. RA affects nearly 1 % of the global population, mainly 
women between 40 and 50, but disease is evident in either sex at any age1. 
Currently, there is no cure for RA, but the recent increase in our knowledge of 
disease pathogenesis has enabled the development of earlier diagnostic 
methods1 and a variety of treatments that can slow the disease process. 
However, such therapies still give rise to long-term treatment challenges, such 
as notable side effects, loss of efficiency or the need for combination with 
multiple treatments. Therefore, there is still an unmet need for the 
development of more specific, safe and efficient therapies as well to the 
improvement of the early diagnosis tools to facilitate efficient treatment. 
Current therapies for RA aim either to relieve pain or slow/stop disease 
progression2. To relieve pain, patients are generally given a combination of 
paracetamol and codeine, but such painkillers do not treat the joint 
inflammation. Thus, Non-steroidal Anti-Inflammatory Drugs (NSAIDs) such as 
ibuprofen are also used to reduce the inflammation in the joints. However, none 
of these drugs will prevent the arthritis from getting worse over time. To 
prevent disease progression many drugs are available and are often divided into 
two categories, namely Disease Modifying Anti-Rheumatic Drugs (DMARDs) and 
Biologics. Typical DMARDs are steroids, such as methotrexate, which by 
suppressing immune responses, either alone or in combination with other drugs, 
can diminish inflammation and the joint destruction process. Even when these 
drugs are effective for many patients they can exhibit some serious side-effects 
including tiredness, stomach and liver issues and induction of birth defects.  
Biologics are newer treatments than DMARDs that can target specific immune 
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responses that are responsible for the inflammation as well as bone and cartilage 
destruction: however, these therapies can also immunosuppress patients and 
leave them at higher risk of potentially catastrophic infection. Although the use 
of these therapies can be effective when all are used in combination, some, 60% 
of patients seem to have some kind of persistent disease and a substantial 
number of patients remain completely unresponsive to the various treatments 
available to block disease progression3. There is therefore still a strong need for 
further understanding of pathogenesis and consequent development of new 
alternative therapies to suppress disease activity in a safe way. 
RA occurs as a result of both genetic and environmental factors, as identical 
twin studies3, showing that only 15% of both twins have RA, have highlighted the 
importance of environmental factors. Nevertheless, for non-identical twins, only 
4% of both twins will develop RA underlining the significant role that genetic 
factors can play. Certainly, a number of disease-associated genes have been 
identified so far, with two clearly implicated in the development of RA. Indeed, 
the HLA-DRB1 gene is the strongest risk factor associated with disease, with 
some of its many variants acting as severe risk factors. Likewise, the protein 
tyrosine phosphatase 22 gene (PTPN22) is strongly associated with the 
development of RA, despite not much being known about its pathogenic actions. 
Potential environmental factors that have been well-investigated are smoking, 
obesity, stress, insecticides and, since 70% of patients are women, female 
hormones. Indeed, the best known environmental contribution to RA is smoking, 
and this can increase patient susceptibility by up to 20-40 fold4. 
Although some susceptibility factors have been discovered, the molecular and 
cellular events underpinning initiation of RA pathogenesis are still far from being 
fully understood: it is absolutely necessary to delineate these in order to enable 
early diagnosis and thereby increase the chance of remission and avoid 
irreversible joint damage. Nevertheless, the most accepted hypothesis is that 
initiation of RA relies on repeated, aberrant activation of the immune system, 
which somehow at some point tips the balance towards the clinical form of the 
disease. Some elements have been identified as being characteristic of the pre-
clinical phase, such as the high production of two types of autoantibodies, 
namely rheumatoid factor and anti-citrullinated peptide antibodies (ACPA)5. 
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Rheumatoid factor comprises autoantibodies against the Fc portion of IgGs 
(fragment crystallisable of immunoglobulin G), that result in the formation of 
immune complexes which drive inflammation and hence presumably contribute 
to initiation of RA. Certainly high levels of rheumatoid factor are found in 
patients and these are associated with the severity of symptoms and the 
development of destructive articular arthritis. ACPAs are not properly 
autoantibodies since they target a protein modification, rather than the protein 
itself, that is found in many matrix proteins like fibrinogen, keratin enolase or 
vimentin, which are all highly expressed in the joint. Indeed, half of all patients 
appear to exhibit antibodies against anti-citrullinated alpha enolase, and 
intriguingly, this citrullination (conversion of the amino acid arginine in a protein 
into the amino acid citrulline) is associated with PTPN22 (Protein Tyrosine 
Phosphatase, Non-Receptor Type 22) and HLA-DRB1 (Major Histocompatibility 
Complex, Class II, DR Beta 1) variants. Moreover, smoking can increase 
citrullination in lung tissue leading to the production of ACPAs. Rheumatoid 
factor and ACPA autoantibodies are now used for diagnosis especially since they 
can develop more than 10 years before the clinical onset of disease. However, 
even if they contribute to the initiation or enhancement of synovitis they are 
probably not the leading cause of RA, and more investigations are still 
necessary6.  
Once autoimmunity is initiated, T cells become activated and invade the joint, 
where they constitute 30 to 50% of invading cells. Such T cells are induced to 
differentiate to Th17 and Th22 cells, to produce the cytokines IL-17 and IL-22 
that are particularly implicated in promoting joint inflammation and bone 
destruction7,8. In addition, depending of the particular stimuli, T cells can 
secrete TNFα and IL-4 within the joint and these cytokines have also been 
reported to be crucial in RA pathogenesis9-12. B cells become activated after 
being in contact with such T cells and cytokine stimulation. B cells not only 
differentiate into plasma cells to produce auto-antibodies and  rheumatoid 
factor, but also contribute to cytokine production. Moreover, macrophages 
produce IL-1 and TNF cytokines that activate chondrocytes to promote bone 
resorption in patients13,14. Therefore many of the therapies developed 
selectively target the cytokines, TNF, IL-1, IL-17 or IL-6. However, such 
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cytokines are involved in many processes and inhibiting them can cause many 
side effects and immunosuppression. This is the reason why there is a need to 
understand better joint biology to develop more specific and targeted therapies. 
1.2 Inflammation and destruction of the synovial joint 
1.2.1 Synovial joint biology 
The main site affected in RA is the joint, where inflammation and bone 
destruction occurs. In addition to providing mechanical support, joints are the 
connectors of the skeletal system that allow movement, those found in hands 
and feet having a large capacity of movement and are called diarthrodial or 
synovial joints. Synovial joints, relative to cartilaginous and fibrous joints15, are 
the most complicated structure ( 
Figure 1-1A) being characterized by the presence of a synovial cavity filled by 
synovial fluid; a fibrous joint capsule, composed of collagen and fibronectin that 
provides structural support and a synovial membrane that connects the articular 
cartilages. The synovial fluid, produced by the synovial membrane, has both a 
lubricating and nourishing function whilst the synovial membrane is involved in 
the absorption of joint cavity debris and blood synovial fluid exchanges16,17.The 
synovial membrane is composed of two different layers of cells, the intimal and 
subintimal layers ( 
Figure 1-1B). The intima is a continuous layer of cells, one or two cells thick, 
that is in contact with the intra-articular cavity and produces the synovial fluid 
important for the lubrication process. The subintimal layer comprises the loose 
fatty connective tissue underneath the intima and although it is still relatively 
acellular and mainly composed of extracellular matrix, it contains a variety of 
cell types, mainly resident fibroblasts and macrophages but some infiltrating 
immune cells, adipocytes and blood vessels as well18. 
Normal synoviocytes comprise two different cell types called type A and type B 
synoviocytes: type A are macrophage-like whilst type B are fibroblast-like 
synoviocytes18. Macrophage-like synoviocytes are present mainly in the intimal 
21 
 
layer and are derived from bone marrow via circulating monocytes that migrate 
to the synovium where they differentiate and become resident19. They strongly 
express the same markers as other resident macrophages populations such as 
Major Histocompatibility Complex (MHC) Class II, CD68, CD163 and FcRɣ and, to 
a lesser extent, CD1416. They actively phagocytose debris and waste from the 
joint cavity as well as exhibiting an antigen-presenting capacity. By contrast, 
fibroblast-like synoviocytes (FLS) are present in both layers of the synovial 
membrane and whilst their origin is still controversial, they are considered to be 
derived from mesenchymal cells16 and exhibit most of the characteristics of 
other fibroblast populations. Thus, they express markers such as type IV and V 
collagens, vimentin and CD90, as well as adhesion molecules such as ICAM-1 
(intracellular adhesion molecule), CD44, β1 and β3 integrins (albeit these last 
three molecules are expressed at higher level than in other fibroblasts 
populations), and VCAM-1 (vascular cell adhesion molecule 1), which is absent in 
most fibroblast populations20-23. They are also characterized by the presence of 
an abundant and rough endoplasmic reticulum, reflecting their important role in 
the production of matrix and specialised synovial fluid components like 
hyaluronan, collagens or fibronectin. Perhaps unexpectedly, in normal synovium, 
FLS are found to produce pro-inflammatory cytokines but at lower levels than 
during inflammation. Indeed, IL-1, IL-6 and TNFα (interleukine 1,6 and tumor 
necrosis factor alpha) can be observed in normal synovium in addition to anti-
inflammatory cytokines such as IL-1 receptor antagonist. Similarly, FLS also 
secrete a low level of the osteoclastogenesis inducer RANKL (receptor activator 
of nuclear factor kappa-B ligand) but, in the absence of inflammation, the 
effects of this appear to be compensated by the production of osteoprotegerin21 
and such expression presumably reflects homeostatic mechanisms of tissue 
repair and homeostasis. 
1.2.2 The synovial joint in RA 
During RA, joint inflammation (synovitis), cartilage and bone destruction occur ( 
Figure 1-1C). Synovitis is characterized by the hyperplasia of the synovial 
membrane resulting from hyperproliferation of synovial fibroblasts (SF) as well 
as the massive invasion of cells to the site of inflammation. In addition, 
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angiogenesis occurs in the subintimal layer as a consequence of angiogenic 
factors produced in response to the local hypoxic environment further 
facilitating the inflammatory cell invasion. In the intimal layer, the fibroblast 
and macrophages proliferate leading to the expansion of this structure from 1-2 
cells up to 10-20 cells thick16. In terms of the inflammatory cell infiltrate, up to 
approximately half of the cells found in the inflamed synovium have been 
reported to be CD4+CD45RO+ memory T cells although a smaller proportion of 
CD8+ T cells are found as well24. However, B cells, dendritic cells, macrophages 
and neutrophils are also observed. 
Activation of both the SF and the infiltrating cells leads to the accumulation of 
proinflammatory cytokines responsible for inducing and maintaining the 
inflammation in the RA joint. The cytokines proposed to be particularly involved 
in the pathogenesis of RA are TNFα, IL-1β, IL-6 and IL-1725. The key role of TNFα 
in RA is well known now and is highlighted by the development of anti-TNF 
therapies that are effective for many for RA patients26. The more recent 
emergence of an important role for IL-17 (and Th17 cells) in RA was first 
indicated by the increased levels of IL-17 found in patient sera and synovial 
fluids27. Moreover, and directly indicative of a pathogenic role, IL-17 deficient 
mice were found to be protected against collagen-induced arthritis (CIA). In 
addition, overproduction of Th17 cells was found to enhance the pathogenicity 
of arthritis28,29 presumably reflecting, at least in part, that via their production 
of IL-17, Th17 cells are involved in regulating osteoclast differentiation and 
matrix metalloproteinases (MMPs) secretion30-32. IL-1β is also highly abundant in 
the joint of patients and has been identified as one of the susceptibility genes 
for RA13. Consistent with this, whilst overexpression of IL-1β in rabbit knee joints 
causes arthritis with clinical features of RA, IL-1β blockade significantly reduces 
arthritis score33. Similarly, IL-6 is another pleiotropic cytokine of major 
importance in RA that is abundantly found in the synovial fluid and serum of 
patients and for which, expressions levels correlate with disease score. Indeed, 
IL-6 has been shown to promote synovial inflammation and joint destruction by 
stimulating osteoclast maturation, pannus proliferation and migration of 
neutrophils34. Interestingly, therefore, both Type A and B synoviocytes can 
produce these cytokines. 
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1.2.3 Pannus formation 
Interestingly, during RA pathogenesis, leukocytes appear to infiltrate the 
synovium before proliferation of the synovial membrane occurs suggesting that 
this leukocyte invasion induces a reorganization of the synovial architecture and 
a change in the SF phenotype. Such formation of this new fibrovascular tissue or 
granulation tissue at the joint surface commonly called pannus. However, the 
precise mechanisms underpinning pannus development remain unsolved. 
Nevertheless, pannus tissue in RA patients has been described as an invasive 
granulation tissue covering the articular cartilage35  and it appears that at the 
beginning of inflammation,  the synovial membrane starts thickening to form this 
tissue called pannus, which drives inflammation and invades cartilage and bones. 
Due to these characteristics, the pannus is sometimes thought of as being a 
tumor-like tissue although mitotic figures are rare and metastasis does not 
occur. Closer analysis of this tissue revealed that it is composed of macrophages 
and fibroblasts-like mesenchymal cells, macrophage-like cells, other 
inflammatory cells and osteoclast precursors36. Moreover, those pre-osteoclasts 
were found to be induced in response to proinflammatory mediators such as M-
CSF and RANK ligand, produced by the interactions of fibroblasts and T 
lymphocytes. Once stimulated, such osteoclast-precursors migrate and attach to 
the bone surface where they differentiate into active osteoclasts and mediate 
bone resorption by producing tissue destructive enzymes able to destroy 
cartilage and bone and thereby perpetuate the inflammation37. Indeed, in RA the 
macrophage-like synoviocytes display a strongly activated phenotype, producing 
a wide range of pro-inflammatory cytokines, chemokines and growth factors that 
participate in the activation and “transformation” of SF to an aggressive 
pathogenic phenotype.  
1.3 Synovial fibroblasts in rheumatoid arthritis (RASF) 
1.3.1 Tumor-like characteristics of RASF 
Pathogenesis in RA is driven by the concerted action of different cell types: 
thus, whilst it is clear that autoimmunity and resultant aberrant inflammation is 
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central to RA, it is increasingly evident that in addition to T cells and 
macrophages driving such inflammation in the joint that the activated aggressive 
SF play a key pathogenic role. 
In RA, activated SF display new characteristics that are reminiscent of tumor-
like mesenchymal cells: indeed, the proliferative pannus appears to behave like 
a locally invasive tumour, with the SF exhibiting the capacity to migrate and 
then attach to, and invade, bone and cartilage38, functional responses not 
observed with other fibroblasts. Reflecting these characteristics, they 
upregulate proto-oncogenes involved in cell cycle regulation, like c-Fos, Ras, 
Raf, Myc, and Myb whilst displaying low levels of expression of tumor suppressor 
genes, such as p53 and PTEN39-41. Thereby, the cells become resistant to 
apoptosis and lose the property of contact inhibition and have been shown not 
only to migrate within the joint, but also to be able to migrate and spread the 
inflammation to other sites. Such "transformed" fibroblasts were first observed 
by Fassbender in the 1980s when he noticed the presence of “immature-looking 
synovial cells” that attached to the cartilage and were responsible for its 
degradation in articular tissue from patients42. Consistent with their functional 
phenotype, these cells display large and pale nuclei and abundant cytoplasm 
containing numerous lysosomes. He hypothesized that these “transformed 
fibroblasts” are immature mesenchymal cells that can return to the synovial 
membrane and re-differentiate into fibroblasts once they have resorbed bone 
(Figure 1-2). 
What makes fibroblasts change their behaviour to an aggressive pathogenic 
phenotype during RA? Whilst it has been suggested that they are simply passive 
responders to the pro-inflammatory milieu, it has also been proposed that they 
act as active drivers of pathogenesis43. These suggestions are not necessarily 
mutually exclusive, as fibroblasts appear to directly respond to the extracellular 
signals found in the synovial fluid (such as pro-inflammatory cytokines or TLR 
ligands), before quickly returning to a quiescent non-aggressive state if not 
further stimulated. Increasing data however suggest that some fibroblasts retain 
phenotypic features consistent with their  “transformation” to an active 
pathogenic form, as SF extracted from patients' synovium and cultured in vitro 
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appear to be "imprinted", being aggressive hyper-responders to pro-inflammatory 
stimuli 20. 
1.3.2 Characteristics of the aggressive SF phenotype 
SF are highly differentiated and specialised cells, therefore their role in the 
joint is very precise and their functions limited. These comprise producing the 
synovial fluid, regulating the leukocyte movement within the joint and 
maintaining the joint capsule. Once “transformed” the SF acquire functions 
driven by the production of a wide range of new factors summarized in Figure 
1-3 and developed here, below. 
 
1.3.2.1 Adhesion molecules: anchorage and migration 
One of the most important features of the aggressive phenotype of RASF is their 
capacity to express a wide number of adhesion molecules that allow them to 
acquire motility and facilitate their anchorage to cartilage. Amongst these, 
integrin α5β1, VCAM-1, ICAM-1 and cadherin-11 are particularly highly 
expressed44-47. Integrins by interacting with fibronectin, collagen or cartilage 
matrix proteins not only promote the anchorage of RASF to the cartilage 
extracellular matrix (ECM) but also, the signalling resulting from the interactions 
between integrins and fibronectin induces the expression of MMPs and of pro-
inflammatory cytokines such as IL-6, IL-8 as well as chemokines CCL2 and 
CXCL148-50 that by remodelling the ECM will further facilitate migration to, and 
tissue damage at, the site of erosion. The importance of these properties is 
reflected by reports of the ability of RASF to migrate and spread inflammation: 
indeed, Lefèvre et al. have demonstrated, by transferring "transformed" 
fibroblasts into an immunodeficient mouse, that active RASF can migrate in vivo 
to sites of implanted healthy human cartilage and actively degrade it and hence 
spread disease38. 
26 
 
1.3.2.2 Tissue destruction 
Bone and cartilage destruction is the effector end-stage consequence of 
autoimmune pathogenesis in RA and RASF have been shown to promote cartilage 
degradation, even in absence of T cells and monocytes in a SCID mouse (severe 
combined immunodeficiency mouse) engrafted with human cartilage51. Firstly, 
they act directly to erode bone and cartilage by secreting cathepsins and MMPs, 
specifically the two collagenases, MMP-1 and MMP-13 as well as the stromelysin, 
MMP3 and the gelatinases, MMP-2 and MMP-952. However, such production of 
MMPs appears to be strongly increased by interactions of RASF with T cells53 
whilst RASF can also act indirectly to induce bone and cartilage damage by 
stimulating osteoclastogenesis via their secretion of RANK ligand (RANKL) as 
wells as vascular endothelial growth factor (VEGF), that can substitute for M-CSF 
for such differentiation during pathogenesis54.  
1.3.2.3 Secretion of a large panel of growth and chemotactic factors 
RASF are also involved in perpetuating inflammation by driving cell infiltration 
and survival, angiogenesis and cell activation by their responses to the pro-
inflammatory milieu of the joint. Thus, many important pro-angiogenic cytokines 
and growth factors have been shown to be released by SF, such as transforming 
growth factor-β, interleukin (IL)-8, platelet derived growth factor (PDGF), 
granulocyte-macrophage colony stimulating factor (G-MCSF), epidermal growth 
factor (EGF), fibroblast growth factor (FGF) and one of the most potent 
angiogenic factors, VEGF (Vascular endothelial growth factor)55, the constitutive 
secretion of which is augmented by hypoxia and IL-1 stimulation56. Angiogenesis 
is accompanied by vasculature leakage that facilitates the immune cell 
infiltration that perpetuates the inflammation of the joint. SF impact on the 
attraction of leucocytes into the joint by producing a variety of chemoattractant 
molecules following their exposure to pro-inflammatory cytokines or via CD40-
mediated contact with T cells3,57. Specifically recruitment of monocytes to the 
synovium is due to the secretion of CCL2 (macrophage chemotactic protein 
[MCP]-1) and CCL3 (macrophage inflammatory protein [MIP]-1α) whilst the 
release of IL-16, CCL5 (Rantes) and CXCL8 (IL-8) is responsible for the infiltration 
by T cells, eosinophils and neutrophils58. Interactions amongst these cells result 
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in their (further) activation and the maintenance of inflammation, for example, 
with the release of IL-1β, IL-6 and TNF-α acting to maintain the activated 
phenotype of inflammatory cells via induction of pathogenic cytokines14. 
Amongst these, IL-15 and IL-7 drive (auto-reactive) T cell activation whilst GM-
CSF promotes the survival and differentiation of hematopoietic cells and their 
precursors59. 
 
1.4 Inducing cell transformation and dedifferentiation 
It is increasingly clear that the aggressive SF found in the inflamed joint display 
features distinct from those in healthy synovium and these are maintained even 
when the cells are isolated from their pro-inflammatory environment43. The 
acquisition of this aggressive pathogenic phenotype appears to be enabled by 
mutations and/or epigenetic modifications resulting in their “imprinting” by 
permanent modification of their gene expression. 
1.4.1 Somatic mutations 
Fibroblasts like synoviocytes (FLS) from RA patients have been shown to contain 
somatic mutations of genes regulating cell cycle, proliferation and apoptosis, 
characteristic of transition mutations resulting from damage caused by high 
levels of reactive oxygen species (ROS) or reactive nitrogen oxide (RNS)60. A key 
example is the inactivation mutation of the tumor suppressor, p5361,62, but not 
PTEN, gene although Ras and HPRT genes have also often been reported to be 
affected in patients63,64. Although the precise mechanisms leading to such 
somatic mutations have not been fully defined, it appears that the presence of 
ROS and RNS in the inflamed joint leads to the inhibition of the MSH6 gene 
(methyl-directed mismatch repair protein homolog 6), involved in the repair of 
transition mutations and perhaps explains the high rate of microsatellite 
instability displayed by some patients65. Interestingly, mitochondrial DNA 
damage is suspected to be particularly involved in RA pathogenesis: thus, as 
many mitochondrial proteins have a bacterial homologue, it has been proposed 
that during their presentation by MHC complexes, mutated peptides might 
appear as bacterial peptides and thereby act to induce aberrant immune 
reactions66. 
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1.4.2 Epigenetic modifications 
Some cellular events other than of somatic mutation can be responsible for a 
stable and heritable transcriptome modification. Such events are named 
epigenetic modifications and involve modifications of the DNA structure that do 
not involve the nucleotide sequence. Humans have 46 molecules of DNA 
(chromosomes) that have been predicted to measure approximately 2 m long. 
Such a large amount of DNA is tightly packed in the nucleus, that measures on 
average 6 mm in diameter, thanks to the nucleosome structure. Indeed, in DNA, 
approximately 147 base pairs are coiled in 1.67 left-handed superhelical turns 
around an 8 histones core (pairs of the histones H2A, H2B H3 and H4) to 
comprise the nucleosome unit67. All nucleosomes are then folded through 
different levels of higher structures to ultimately form the chromosome. 
Therefore, modifications in such nucleosomes (affecting the histones or the DNA) 
can affect the position of the nucleosome within its structure: in turn, this can 
lead, in part through a change in the electrostatic charge of the nucleosome, to 
either a tightening-up of the structure resulting in the formation of closed 
untranscriptable ‘heterochromatin’ or its loosening to a ‘euchromatin’ form 
which enables the DNA to be more accessible to transcription factors.  
It is well established that such epigenetic modifications play important roles in 
cell differentiation and transformation in cancer and other disorders68,69.  This 
reflects that, for example, post-translational modifications of histone proteins 
impact on the interactions between the DNA and histone complexes to regulate 
the transitions between euchromatin and heterochromatin, or recruit various 
factors important for the control of gene expression. Such modifications usually 
occur in the N-terminus flexible tail of the histone that is exposed while the 
globular part of the protein is compacted in the nucleosome. Various post-
translational modification can occur, amongst them acetylation, methylation 
and sumoylation, all of which have been shown to be important in the regulation 
of RASF responses. 
Histone acetylation is a modification that targets specific lysine residues present 
on histones, H3 and H4: this is usually associated with transcriptional activation 
probably due to the change in the electrostatic charge of the histone tail 
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resulting in a change of structural conformation that loosens the chromatin 
structure and facilitates the formation of euchromatin. Perhaps counter-
intuitively, therefore, given the upregulation of pro-inflammatory genes in RA, 
histone deacetylase (HDAC) inhibitors have been reported to display beneficial 
effects in vivo in a diverse range of animal models of RA70-72. Moreover, when 
such inhibitors have been exploited to unravel the importance of dysregulated 
histone acetylation in RA, they indicated that HDACs may exert positive and 
negative effects in RA. For instance, in a recent study, the class I deacetylase 
inhibitor, Largazole,  suppressed some pathogenic mediators like MMP2 but 
enhanced TNF-α induced ICAM-1 and VCAM-1 expression in RASF. Furthermore, it 
is difficult to assess the role of specific classes of HDACs in RA pathogenesis 
since most of the drugs available so far are not sufficiently specific. However, 
and perhaps consistent with the in vivo inhibitor data, expression of HDAC1 and 
HDAC2 was found to be increased in RASF compared to that in osteoarthritic SF 
(OASF) and silencing of these two enzymes affected the RASF gene expression 
profile resulting in a reduction of their proliferative capacity and increased 
susceptibility to apoptosis73,74. Nevertheless, the situation is complex as even 
though deacetylation seems to play an important role in the RA process, 
aberrant acetylation of some promoters has been found as well. Indeed, the 
MMP-1 gene is found to be hyperacetylated in RASF and the stimulation in vitro 
of RASF by TNFα and IL-1β leads to high acetylation levels of the promoter of the 
p21 gene involved in cell cycle regulation75,76.  
Collectively, therefore, these findings may suggest that HDAC-I may act to 
prevent downregulation of homeostatic induction of anti-inflammatory genes to 
effect resolution of inflammation. Nevertheless, in the absence of information 
regarding the selectivity of different HDAC for particular promoters, these 
studies do not explain how the potential stabilisation of gene induction of pro-
inflammatory genes may be protective. Perhaps of relevance, RASF also seem to 
display high levels of small ubiquitin-like modifier (SUMO) 1 that is associated 
with a decrease in the SUMO-specific protease SENP1. Interestingly, therefore, 
overexpression of SENP1 in RASF leads to the decrease in histone H4 acetylation 
in the MMP-1 promoter and this is associated with a decreased invasiveness of 
the cells. These data are suggestive of an active sumoylation post-translational 
modification of histone proteins process in RASF, but the targeted proteins have 
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yet to be identified75 Moreover, and by contrast to the focus on histone 
acetylation/deacetylation generated by HDAC-I, little is known regarding the 
consequences for RA of histone methylation, a modification that affects the 
lysine and arginine residues mainly on H3 and H4 histones. For example, 
although it has been shown recently that the histone methyl transferase (HMT) 
enhancer of zeste homologue 2 (EZH2) is overexpressed in RASF, compared to 
OASF, the consequences of this for RA pathogenesis remain unknown77. 
Collectively, therefore, given the conflicting data relating to the role of HDACs 
in RA, it is plausible that the differential and combinatorial profiles (acetylation, 
methylation and sumoylation) of histone modification at particular promoters, as 
well as the specific classes of HDACs and HMT involved will dictate pathological 
outcome.  
By contrast, DNA methylation is an epigenetic modification controlling gene 
expression that is generally associated with gene silencing. It occurs by the 
direct addition of a methyl group (predominantly) to cytosine, resulting in the 
formation of 5-methylcytosine. In humans, 5-methylcytosines constitute about 
1.5% of the whole genome and are almost always found in CpG islands78. Such 
DNA methylation appears to repress gene induction by directly interfering with 
the binding of transcription factors as well as by the recruitment of proteins, 
containing methylated-DNA binding domains (MBD) notably such as HDAC, that 
promote transition to the heterochromatin structure79. Addition of methyl 
groups to cytosine is catalysed by DNA methyltransferases (DNMTs)80. DNMTs 
constitute a highly conserved family of proteins with the three, DNMT1 DNMT3a 
and DNMT3b found in mammals being essential for development and the 
maintenance of genome stability. Indeed, DNA methylation is the most studied 
epigenetic modification as a consequence of its importance in many biological 
processes such as embryonic development, chromosome stability and genomic 
imprinting79. In adults, DNMT1 is the most abundant DNA methylase, which as a 
‘maintenance DNMT’, binds to the hemi-methylated DNA found after DNA 
replication to add methyl groups to the newly synthetized strand to maintain the 
DNA methylation pattern through cell division. By contrast, DNMT3a and DNMT3b 
are ‘de novo DNA methylases’ that add methyl groups to new cytosine sites in 
response to specific stimuli. Consistent with these key cellular roles, aberrant 
expression of DNMTs and consequent disruption of normal DNA methylation 
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profiles has been implicated in many disease states, especially that of 
cancer81,82. 
Thus although a number of epigenetic mechanisms are in place to control gene 
expression, DNA methylation appears to be the easiest way to silence genes as 
high levels of methylcytosine promotes the formation of heterochromatin 
structure67,81. The DNA methylation status is therefore of importance to stem 
cell differentiation, the process by which cells lose pluripotentiality and acquire 
specialisation and cell identity83. Thus, DNA methylation is strongly associated 
with potency as stem/progenitor cells (low genome methylation) are typically 
able to activate a larger set of genes than a terminally differentiated cell (high 
global DNA methylation) that can only accomplished a specialised set of 
functions due to silencing of genes irrelevant to its differentiated cell function84. 
Thus, cell reprogramming is generally associated with changes in DNA 
methylation patterns and serves to explain why carcinogenesis is often 
associated with a global loss of DNA methylation and acquisition of a 
dedifferentiated or pluripotent state. 
Cells, particularly FLS, from RA patients have been reported to exhibit DNA that 
is hypomethylated compared to that from OA patients and healthy individiuals85: 
this global hypomethylation of DNA appears to be due to an increased polyamine 
metabolism in RASF that causes a decrease in S-adenosyl-L-methionine levels86. 
Following on from this, a more complex picture has emerged as DNA methylome 
studies revealed that whilst genes involved in migration, adhesion or matrix-
degradation are hypomethylated in RASF, certain promoters such as that of the 
death receptor 3 gene (DR3; a member of the pro-apoptotic Fas gene family) are 
hypermethylated in some RA patients87. Neverthless, more direct evidence 
supporting the importance of hypomethylation in mediating fibroblast 
transformation to an aggressive phenotype was provided studies demonstrating 
that normal FLS cultured under conditions inducing global hypomethylation of 
DNA acquired a hyper-activated phenotype similar to that observed in RASF85. 
32 
 
1.5 The therapeutic potential of helminth-based 
immunomodulators 
1.5.1 Hygiene hypothesis 
In developed countries, RA affects 1-2% of the population and the prevalence is 
increasing every year. Although the reasons for this increase in incidence of RA 
and other autoimmune disorders have not been fully defined, it is clear that it 
has coincided with the rapid eradication of infections by pathogens, through 
improved hygiene, vaccines and antibiotics. The ‘hygiene hypothesis’ was 
originally formulated by Strachan in 1989 after noticing the rise of childhood 
immune related disorders such as asthma and eczema during the post industrial 
revolution88. He observed a link in hay fever epidemiology and family size, 
concluding that unhygienic contact amongst siblings is an important protective 
factor and hence, the dramatically increased incidence of immune-mediated 
diseases may reflect, the great improvement in general hygiene, over the past 
century. Consistent with this, there is increasing evidence that in developing 
countries, where parasitic helminth infection is endemic, such inflammatory 
disorders are infrequent. From these observations it has been hypothesized that 
infection with helminth parasites might protect against development of 
autoimmune disorders89. There has indeed been increasing evidence showing 
that infection by parasitic worms can be protective in a number of animal model 
for immunopathological diseases90,91. Moreover, some preliminary clinical trials 
exploiting “worm therapy” in patients were promising for inflammatory bowel 
diseases like Crohn’s disease92,93, coeliac disease94 or ulcerative colitis95 as well 
as for other inflammatory disorders such as severe asthma96 and rhinitis97. 
 
1.5.2 Immunomodulators produced by helminths 
The word "helminth" is derived from the Greek "helmins" for worm and a third of 
the world population is infected by parasitic helminths. Their eggs contaminate 
food, water, air and faeces, maintaining life cycles mediated by intermediate 
invertebrate hosts like blackflies. Although many of these parasitic worms reside 
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in the gut, others reside in other body sites like blood (schistosome) and lymph 
(Wuchereria bancrofti, Brugia malayi, and Brugia timori)98. Over millenia of co-
evolution, these parasites have developed numerous strategies both to evade 
the host immune system by dampening inflammation and create a favourable 
environment to enhance their survival, without leaving the host 
immunosuppressed and hence vulnerable to other infections. A key strategy 
appears to be the secretion of immunomodulatory molecules that are able to 
silence or selectively modulate immune responses and promote tissue repair98. 
From a therapeutic point of view, these anti-inflammatory, tissue repair-
promoting molecules are very interesting since their actions may identify more 
selective and hence safer therapeutic targets for treatment of disorders 
associated with aberrant inflammation like RA99. Certainly their potential, unlike 
most of the current immunosuppressive drugs such as glucocorticoids used in 
treating autoimmune disorders, to target only “harmful”, leaving “safe”-
infection-fighting inflammation, represents a potential starting point in a novel 
therapeutic approach100 
1.5.3 ES-62 a helminth-derived immunomodulator 
Amongst the increasing number of parasite-derived products identified with 
therapeutic potential, ES-62, the major secreted glycoprotein of the rodent 
filarial nematode Acanthocheilonema vitae with homologues found in human 
filarial nematodes, is one of the most well-characterized helminth 
immunomodulators. it is a 62kDa phosphorylcholine (PC)-containing glycoprotein 
secreted as tetramer that exhibits various immunomodulatory activities, 
suppressing inflammation and pathology in a range of models of allergic or 
autoimmune disorders such as asthma, lupus or RA101-104. ES-62 appears to sense 
and modulate aberrant inflammation, mainly through the disruption of TLR4 
signalling. For example, in the CIA mouse model of RA, ES-62 is protective 
through its inhibition of pathogenic IL-17 production104. Indeed, ES-62 acts in a 
TLR4-dependent manner to downregulate MyD88 expression in dendritic cells 
(DC), macrophages and T cells to prevent pathogenic inflammatory responses, in 
particular by regulating DC priming of Th17 lymphocyte and IL-17-producing T 
cell differentiation.  Since IL-17 is a major effector cytokine driving arthritis in 
animal models, as well as being over-produced in the joints of RA patients, IL-17 
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was therefore considered to be one of the most promising targets for the 
development of new therapies105. Various IL-17 blockers, such as the monoclonal 
anti-IL-17A  (secukinumab and ixekizumab) and anti-IL-17 receptor sub-unit A 
(brodalumab) antibodies have been successfully evaluated in phase II clinical 
trials and secukinumab is even in phase III clinical trials for patients 
unresponsive to methotrexate, a TNFα inhibitor106. However, such treatments 
can immunosuppress the patients and are not always efficacious107. By contrast, 
although ES-62 reduces the levels of IL-17-producing Th17 and ɣδT cells it does 
not induce immunosuppression104 as it does not target NK and NK T cells that can 
still produce IL-17 allowing the host to fight the common opportunistic infections 
that are proving to be a problem with current IL-17-blockers108. Thus, the ability 
to selectively modulate distinct cellular pools of IL-17 potentially makes ES-62, 
or drugs that mimic its action, a safer therapeutic for IL-17-based inflammatory 
diseases109. 
1.5.4 Small molecule analogues (SMAs) of ES-62 
ES-62 is secreted as a tretrameric molecule of approximately 240 kDa and as it is 
generally immunogenic, it is therefore likely not suitable for therapeutic use. 
However, the Harnett group has identified the PC moiety of ES-62 as being 
responsible for the most of the immunomodulatory effects of the parasite 
product110, with indeed PC-conjugated to BSA (or ovalbumin [OVA]) being 
sufficient for protection against CIA111. Thus, a library of low molecular weight, 
non-immunogenic SMAs based on the PC moiety are being developed for drug 
discovery, with candidates selected by a primary in vitro screen in macrophages 
aimed to identify compounds able to downregulate the production of pro-
inflammatory cytokines promoting Th1 (IFNɣ)/Th17 (IL-17) responses that are 
elicited in response to pathogen associated molecular patterns (PAMPS)112. Two 
SMAs, 11a and 12b were especially effective and were selected for further 
investigation of their anti-inflammatory potential, in vivo. Both proved to be 
protective in the CIA model with 11a mimicking the actions of ES-62 in 
decreasing IFNɣ and IL-17 production113, as well as in its mechanism of action by 
downregulating MyD88 expression. Surprisingly, although 12b also downregulated 
MyD88 and inhibited IL-12p40 production in response to PAMPS, it did not 
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suppress Th1/Th17 responses: rather analysis of the genes modulated by 12b in 
macrophages revealed its capacity to downregulate a number of genes involved 
in inflammasome signalling, especially IL-1β and it did so in an manner involving 
NRF2114, a transcription factor that is a master regulator of cytoprotective anti-
oxidant genes and is well established not only to counteract the inflammasome 
but also to protect against CIA115. 
 
1.6  Conclusions and discussion 
It is now well established that ES-62, and its SMAs 11a and 12b, afford protection 
in the CIA model. Consistent with deregulation of T cell activation being 
considered to be a major force driving inflammation, the protection afforded by 
ES-62 (and 11a) is associated with downregulation of Th1/Th17-type responses. 
Moreover, 12b (and to a lesser degree ES-62 and 11a) antagonises IL-1 
responses, which in addition to driving pathogenic inflammation is also critical to 
Il-17 responses114. However, further studies examining the IL-23/IL-17 
inflammatory axis demonstrated that ES-62 not only suppressed the pathogenic 
actions of the related cytokine, IL-22 during initiation of disease but also 
harnessed the tissue repair ability of IL-22 to promote resolution of established 
inflammation in the joint. These dual activities focused on SF, the major cell 
population in the joint116.  
These findings were timely as increasingly, many studies were strongly 
suggesting that such fibroblasts play key roles in the early onset of the disease, 
the maintenance of inflammation and even in the spread of the disease to the 
unaffected joints, as well as mediating joint destruction, directly by secreting 
MMPs that damage the cartilage and bone and indirectly, by promoting 
osteoclastogenesis. Interestingly, despite the fact that SF are not part of the 
immune system, they appear to act as a bridge perpetuating inflammatory 
effector cells responses as they are known to produce pro-inflammatory 
cytokines during the pathogenesis of RA and they express TLR4, a well-
characterised target of ES-62 and are the only cell in the joint that expresses the 
IL-22 receptor. 
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Hence, from a therapeutic point of view it became important to address 
whether the protection afforded by ES-62 and its SMAs, 11a and 12b reflected 
their ability to affect SF and prevent their pathogenicity. Indeed, if this were to 
be the case, it opens the door for targeted topical joint therapies that could 
circumvent many problems associated with those blocking inflammation, 
systemically. Thus, as the microenvironment of the joint during induction and 
progression of arthritis exposes SF to many different cytokines and interactions 
with inflammatory cells that results in their pathogenic transformation to an 
aggressive phenotype, it was imperative to investigate whether ES-62 could 
prevent this by changing the joint microenvironment in CIA in vivo. Specifically, 
therefore, the aims of this thesis were to: 
- Further characterise the therapeutic potential of ES-62 and its SMAs in a 
mouse model of RA, in particular to understand whether they can directly 
target joint-specific cells such as SF 
- Delineate how ES-62 can desensitize such SF from the external pro-
inflammatory environment, specifically by regulating ERK and STAT 
pathways implicated in their “transformation” 
- Understand whether CIA SF are intrinsically different from naïve SF and 
undergo epigenetic modifications, especially DNA methylation, 
downstream of their transformative signalling pathways. Relating to this it 
was also planned to determine whether ES-62 impacts on the epigenetic 
landscape to prevent such cell transformation? 
Collectively in this way the inter-related aims were designed to inform not 
only on the capacity of ES-62 to modulate immune cells but also stromal 
cells. In particular, the aim was for this new approach to uncover how ES-62 
might condition the cells such that they either do not initiate and/or 
maintain inflammatory responses, central events to the development of RA. 
This process should also allow for the identification of the key mechanisms 
responsible for the establishment and maintenance of the aggressive 
phenotype of SF during CIA. 
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Figure 1-1 Synovial joints in health and RA 
A: Synovial joints allow the maintenance of the mobility between linked bones: 
their special characteristics comprise a joint capsule that maintains the joint 
architecture, a synovial cavity containing the lubricant synovial fluid and a 
synovial membrane that produces the synovial fluid and cleans it. 
B: The synovial membrane is composed of intimal and subintimal layers defined 
by their indicated differential cell constituents. The intimal lining is composed 
of intimal fibroblasts and macrophages and is 1 to 2 cells thickness. The 
subintimal lining is a looser tissue composed of a variety of cell types: SF, 
resident macrophages and adipocytes, surrounded by extracellular matrix. 
Capillaries present in the subintimal lining allow the infiltration of immune cells 
within the synovial membrane. 
C: During RA, and CIA mice, three events are responsible for the observed 
pathogenesis, namely joint inflammation and synovial membrane 
hyperproliferation resulting in the pannus formation that leads to bone and 
cartilage destruction. 
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Figure 1-2 Fassbender model of SF dedifferentiation into mesenchymal stem 
cells inducing bone and cartilage resorption degradation  
Fassbender hypothesized that SF from the intimal layer become activated and 
undergo dedifferentiation into mesenchymal stem cells to acquire properties 
such as cell proliferation and loss of contact inhibition to allow them to initiate 
pannus formation, motility and tissue invasion and attach to the bone to induce 
its degradation. Once bone resorption has occurred the dedifferentiated cell has 
the capacity to return to the intimal layer and redifferentiate into a SF. 
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Figure 1-3 Scheme summarizing the major functions of SF in the joint and 
their tumor-like capacities acquired during inflammatory arthritis. 
SF exhibit diverse characteristics depending on their local environment. Thus, in 
healthy joints they are specialised producers of the lubricating synovial fluids, 
particularly hyaluronic acid and lubricin, as well as acting to maintain capsule 
strength by the generation of collagen and fibronectin, and regulating leukocyte 
infiltration of the joint through their surface expression ICAM and VCAM. By 
contrast, during RA or CIA, the apoptosis-resistant, hyper-proliferative 
phenotype of SF drives synovial membrane hyperplasia and contributes to the 
inflammation by producing a wide range of pro-inflammatory cytokines, 
stimulating angiogenesis and as well contributing to bone destruction directly by 
secreting MMPs and by inducing osteoclastogenesis with RANKL. 
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2. Material and Methods 
2.1 Mice 
DBA/1 and BALB/c (Harlan Laboratories) animals were maintained in the 
Biological Services Unit of the University of Glasgow in accordance to the Home 
Office UK Licence PPL60/26532 and PIL70/26532 and the Ethics Review Board of 
the University of Glasgow. 
 
2.2 Purification of the filarial nematode product ES-62 
ES-62 was purified as previously described117. ES-62 is secreted by the adult 
filarial nematode, Acanthocheilonema viteae and was purified at the University 
of Strathclyde by Drs Lamyaa Al-Riyami, Justyna Rzepecka and Felicity Lumb. 
Briefly, adult parasites were recovered from the jird, Meriones libycus and  
transferred to Petri dishes and cultured in RPMI medium (endotoxin free RPMI 
1640 (Life Technology) with added glutamine (2 mM), penicillin (100 U/ml), 
streptomycin (100 µg/ml)). Larval forms were removed by filtering the 
conditioned medium with a 0.22 µm filter (Sigma). The ES-62-containing medium 
was then concentrated by ultracentrifugation (Millipore) units containing a YM10 
membrane (Amicon) before purifying ES-62 using a sepharose column fitted to an 
isocratic fast protein liquid chromatography system (Pharmacia). The purity and 
identity of each batch were assessed by SDS-PAGE and the absence of endotoxins 
was confirmed using the Endosafe Kit (Charles River Laboratories). 
 
2.3 CIA mouse model of RA 
Male DBA/1 mice (8-weeks old) were used in the CIA model. Each mouse 
received on day 0, 100 µg of 2 mg/ml Bovine Type II collagen (CII; MD 
biosciences) emulsified with equal amount of complete Freunds adjuvant (CFA) 
containing 4 mg/ml of Mycobacterium tuberculosis (MD biosciences) injected 
intra-dermally just above the tail base. On Day 21, mice were administered 200 
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µg of type II collagen in PBS via intra-peritoneal injection117. Mice were 
monitored every two days for signs of arthritis, which was determined according 
to the following articular scores: 0 = normal; 1 = digit(s) involvement; 2 = 
erythema; 3 = erythema and swelling; 4 = extension/loss of function. For each 
mouse the total score was recorded, representing the sum of the severity scores 
of the 4 limbs. In addition, hind paw swelling was measured by callipers (POCO 
2T, Kroeplin Längenmesstechnik). 
For prophylactic regime treatment, ES-62 (2 µg) or the SMAs 11a and 12b (1 µg) 
in PBS were administered subcutaneously in the scruff on days -2, 0 and 21. 
Moreover, on a therapeutic regime injections of ES-62 (2 µg)  and SMAs (1 µg) 
where injected subcutaneously every 3 days from the apparition of the first 
symptoms.  Mice were sacrificed using CO2. Paws were harvested and used for 
analysis of pathology or for SF and infiltrating inflammatory cell extraction and 
analysis. 
All CIA models were managed and monitored in collaboration with Dr M.A. 
Pineda.  
 
2.3.1 Hypoxia analysis 
Ex vivo analysis of in vivo hypoxia status was realised by following the 
HypoxyprobeTM_1 plus kit protocols. Briefly, Pimonidazole HCl was dissolved in 
PBS at a concentration of 20 mg/ml and a dose of 60 mg/kg mouse body weight 
was injected intra-peritoneally (e.g. 1.5 mg/25 g mouse). The mouse was 
sacrificed 24 hours after the injection118. Paws were dissected and joint cells 
were extracted then fixed in chilled 70% ethanol and stored at -20ºC for 24 
hours. Cells were then resuspended in PST (PBS with 4% serum and 0.1 % Triton) 
and stained in PST using the FITC-conjugated Mab1 (diluted 1:1000) antibody for 
2 hours at 37ºC prior to analysis by flow cytometry. 
 
2.3.2 Vasculature permeability analysis  
To analyse vasculature permeability occurring in vivo, Evans blue dye (Sigma;  
0.5% in PBS) was prepared and filter sterilized. Evans Blue solution (200 µl) was 
45 
 
injected intravenously in the mouse lateral tail. After 30 minutes the mouse was 
sacrificed and paws were collected119. Once the skin was removed from the 
paws, pictures were taken. Inflamed paws with vasculature permeability are 
stained blue by the dye while the healthy paws remain clear since the dye does 
not leak out of the vasculature (Figure 2-1). 
 
2.3.3 Isolation and culture of SF 
Isolation and culture of murine SF was performed according to the protocol of 
Armaka et al120. To summarize, once hind and front paws were recovered from 
the mice, skin was peeled and paws were washed using 100% ethanol and then in 
DMEM medium containing antibiotics (penicillin and streptavidin at 50 units/ml) 
before dissection and crushing of the joints. Fresh and filtered collagenase IV 
from Clostridium histolyticum (Sigma) was prepared (2 mg/ml) and an equal 
volume of collagenase was added to the ground joints to generate a final 
concentration of 1 mg/ml and incubated in a shaking waterbath at 37ºC for 1 
hour. Following completion of the digestion incubation time, cells were released 
by vigorously vortexing the tissue samples. Cells were then resuspended in DMEM 
medium (Lonza), supplemented with 10% FBS, 2mM L-glutamine, 50 units/ml 
penicillin and 50 µg/ml streptomycin (denoted 10% FCS DMEM), and plated in 100 
mm dishes. After 24 hours, non-adherent cells were removed and used for 
infiltrating cell phenotype analysis by flow cytometry. The medium was replaced 
twice weekly and once the cells reached 90% confluence, they were trypsinized 
and passaged. SF were expanded for 3 to 4 weeks before analysis. The 
phenotype of the explant fibroblasts was confirmed by flow cytometry as being 
CD54+ CD11b+ CD90.2+ (Figure 2-2). 
 
2.3.4 Histology 
Paws harvested were fixed with 10% formalin, changing the fixative every day 
for one week. Bone decalcification, paraffin sectioning and staining with H&E or 
Trichrome solutions was realized with the assistance of Mr Jim Reilly of the 
Institute Histology Service. Briefly, bones were decalcified in hydrochloric 
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acid/formic solution (8% each) for a couple of days. Once decalcification was 
complete, acids were neutralized using an ammonia solution for 30 minutes. 
Bones were then washed under running tap water for 24 hours and were then 
ready for routine paraffin embedding and sectioning. In the H&E staining, 
hematoxylin is a violet stain that binds to basophilic substances such as DNA, 
therefore it is used to reveal nuclei in purple. Eosin is a red stain that binds to 
acidophilic substances such as positively charged amino acid side chains (e.g. 
lysine, arginine). It colours collagen in pale pink, cytoplasm in red, erythrocytes 
in cherry red and muscles in dark red. The trichrome staining reveals muscle 
fibres in red, collagen in green/blue and erythrocytes in orange. 
 
2.4 Flow cytometry 
Cells were seeded at a concentration of 0.5 x 106 cells per well in round bottom 
96-well plates. Cells were washed three times with PBS at 400 x g for 5 minutes 
at 4ºC and then stained with the fixable viability dye eFluorⓇ 780 (eBioscience) 
at 1 µl/ml for 30 minutes at 4 ºC and protected from light. Cells were then 
washed three times with FACS buffer (PBS + 0.5% FCS 2mM EDTA) and Fcɣ 
receptors were blocked using 100 µl of hybridoma 2.4G2-conditioned 
supernatant containing CD16/CD32-specific antibody for 10 minutes at room 
temperature. Primary antibodies or their relevant isotype controls (Table 2-1) 
were added to the wells and incubated for 30 minutes at 4ºC, again protected 
from light. The cells were then washed 3 times with FACS buffer before 
incubation with the relevant secondary antibody or streptavidin-conjugated 
fluorophores where necessary. Cells were washed another 3 times with FACS 
buffer then passed through a nitex gauze into FACS tubes. 
For intracellular cytokine staining, cells were first stimulated with 50 ng/ml PMA 
plus 500 ng/mg ionomycin (both Sigma-Aldrich) and after 30 minutes incubation 
at 37ºC, 10 µl/ml of Brefeldin A (Sigma-Aldrich) was added for a further 5 hours 
incubation at 37ºC with 5% CO2. Then after staining for surface antigens, 100 µl 
of Fixation buffer (Biolegend) was added to the cells for 20 minutes at room 
temperature. Cells were then washed in permeabilization buffer (eBioscience) 3 
times. Intracellular staining was realised by incubation with appropriate 
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antibodies in permeabilization buffer in the dark at room temperature for 20 
minutes. Then cells were washed 3 times with FACS buffer and passed through a 
nitex gauze into FACS tubes. 
All samples were acquired using the BD LSR II and analysed by FlowJo. In the 
flow Jo analysis program when result graphs are presented as overlays, the Y-
axis is presented as percentage of maximum (% of Max) as opposed to cell 
number. This is useful if the two experiments overlaid have different cell counts 
as it allows normalization and direct comparison of the data. 
 
2.5 ELISAs 
Cytokine secretion was measured using the relevant ELISA kits as instructed by 
the manufacturers. Cells were plated in 96-well plates or in 6-well plates 
(Corning) at respectively 1 x 104 and 0.3x106 cells per well. After an overnight 
incubation in DMEM medium containing 1% FCS (1% FCS DMEM) to synchronize the 
cells, the FCS was increased to 10% (10% FC DMEM) and the cells were stimulated 
for 24 hours with LPS (1 µg/ml, Sigma-Aldrich), BLP (Pam3Cys-Ser-(Lys)4; 0.5 
µg/ml, Enzo), IL-1β (10 ng/ml, Immunotools), IL-17 (25 ng/ml, Immunotools), IL-
22 (25 ng/ml, Immunotools) or IFNβ (10 ng/ml R&D systems). Supernatant was 
collected and analysed using ELISA kits detecting IL-6, CCL-2 and IL-1β (Ready-
SET-Go!® from eBioscience). Briefly, 96-well plates were coated overnight with 
the relevant capture antibody. Wells were then blocked for an hour, and 
samples and standards were added to the plate for incubation overnight at 4ºC 
or 2 hours at room temperature. Samples were washed and incubated with 
detection antibody for a further 1 hour and then streptavidin conjugated 
horseradish peroxidase was added for 30 minutes.  Plates were then washed a 
final time prior to being incubated with TMB substrate and then once colour 
developed, stop solution (1M H2SO4) added. Absorbance was read at 450nm using 
a Tecan Sunrise plate reader. 
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2.6 FACE assays 
Fast-activated cell-based (FACE) ELISA assays were performed as developed and 
described previously by Versteeg et al121 Cells were plated and synchronised by 
1% FCS DMEM overnight in 96-wells plate at 1 x 104 cells per well. Cells were 
then stimulated for the indicated time points (from 0 to 120 minutes) before 
being treated with fixative buffer (Biolegend) according to the manufacturer 
recommendations. Once the cells are permeabilized, an ELISA-like protocol is 
followed e.g. using as detection antibodies, antibodies specific both for ERK and 
the dually phosphorylated active form of ERK (P-ERK) (Cell Signalling 
Technology) for 1 hour before addition of streptavidin-conjugated horseradish 
peroxidase for 30 minutes (anti-rabbit HRP, Cell Signalling Technology). Plates 
were then washed a final time and incubated with TMB substrate for 
approximately 15 minutes before addition of stop solution (1M H2SO4). 
Absorbance was read at 450 nm using a Tecan Sunrise plate reader. 
 
2.7 Western blots 
Cells were plated at 1x106 cells per well in 6-well plates and synchronised 
overnight in 1% FCS DMEM before being treated for 24 hours (or the indicated 
time) with various inflammatory stimuli: LPS (1 µg/ml, Sigma-Aldrich), IL-1β (10 
ng/ml, Immunotools), IL-17 (25 ng/ml, Immunotools), IL-22 (25 ng/ml, 
Immunotools) or IFNβ (10 ng/ml R&D systems). After stimulation, cells were 
washed twice with cold PBS, and cells pelleted. Cells were lysed by addition of 
100 µl of RIPA buffer (50 nM Tris buffer (pH 7.4) containing 150 mM sodium 
chloride, 2% (v/v) NP40, 0.25% (w/v) sodium deoxycholate, 1 mM EGTA, 1x Halt
TM 
protease inhibitor and 1x Halt
TM 
phosphatase inhibitor (Pierce)) and incubation 
for 30 minutes on ice. Lysed cells were then centrifuged at 16,000 x g for 15 
minutes at 4ºC and the supernatant containing the solubilised proteins kept with 
protein concentration measured by the BCA protein assay kit (Pierce). Proteins 
(20 µg) were mixed with 4 x loading buffer (Novex, life technologies) and 10 x 
reducing agent (Novex, life technologies) then incubated for 10 minute at 70ºC 
to denature the proteins. Proteins were separated by gel electrophoresis, on 4-
49 
 
12% Bis-Tris gradient gels, using the NuPAGE Novex system (Invitrogen). Gels 
were run in NuPAGE MOPS buffer, with addition of antioxidant, at 180V until the 
protein bands reach the bottom of the gel. Proteins were then transferred onto 
nitrocellulose membranes (GE) using the wet transfer NuPAGE system. Quality of 
the transfer was assessed using Ponseau red staining (Thermo scientific). The 
membrane containing the proteins was then washed with TBS-T (0.5 mM sodium 
chloride, 20 mM Tris-HCl (pH7.4) and 0.1% (v/v) Tween-20). Membranes were 
blocked for 1 hour in 5% non-fat milk protein in TBS-T and then incubated with 
the primary antibody in 5% BSA TBS-T overnight at 4ºC. The list of primary 
antibodies used in this study is presented in Table 2-2. After washing 3 times 
with TBS-T, the relevant secondary antibody conjugated with HRP was added in 
5% milk for 1 hour at room temperature. After a final 3 washes in TBS-T, ECL 
Western blotting substrate (Thermo Fisher Scientific) was added for 1 minute 
then exposed to X-ray film (Kodak). Membranes were stripped using Restore 
Western Blot stripping buffer (Thermo Fisher Scientific) for 1 hour for further 
reuse and conserved in TBS-T. 
2.8 mRNA and miRNA analysis 
Total RNA and miRNA were isolated and separated using the miRNeasy kit 
(Qiagen) following the manufacturer’s instruction. For miRNAs, the miScript 
Reverse Transcription Kit (Qiagen) was used for cDNA preparation. miScript SYBR 
green qPCR kit (Qiagen) and miScript primer assay (Qiagen) were used for semi-
quantitative determination of the expression of mouse miR-19b-1 (MS00005915), 
miR19b-1* (MS00024493), miR-19b-2* (MS00024500), miR-23b-2 (MS00032606), 
miR-24-1* (MS00011543), miR-34a (MS00001428), miR-124*(MS00011081), miR-
125a (MS00001533) miR-146 (MS00001638), miR-155 (MS00001701), miR-203 
(MS00001848), miR-203* (MS00011452) and miR-346_2 (MS00032753). The 
expression of Hs-RNU6-2_11 (MS00033740) was used as endogenous control122. 
For mRNAs, retrotranscription was realized using the high capacity cDNA reverse 
transcription kit (Invitrogen) and qPCRs were performed using TaqmanⓇ gene 
expression assay kits, with all primers obtained from Life Technologies. The 
following genes were studied CCL2 (Mm00441242_m1), DNMT1 
(Mm01151063_m1), DNMT3a (Mm00432881_m1), GAPDH (Mm03302249_g1), IL-6 
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(Mm00446190_m1), IFN (Mm00439552_s1), MMP9 (Mm00442991_m1) and MMP13 
(Mm00439491_m1). 
 
2.9 DNA methylation analysis and induction of DNA 
demethylation 
2.9.1 Measurement of global DNA methylation 
Global DNA methylation levels can be determined via the measurement of 
methyl cytosine levels using specific antibodies. Briefly, genomic DNA was 
extracted from cells (PureLink Genomic DNA Mini Kit, Invitrogen) and methyl 
cytosine levels assessed following the manufacturer’s instructions (Imprint® 
Methylated DNA Quantification Kit-Sigma). Thus, genomic DNA was added to the 
wells and left to adhere for 2 hours before methyl cytosine was detected by the 
primary antibody (mouse anti-methyl cytosine antibody), and revealed by a 
secondary HRP-conjugated antibody and its tetramethylbenzidine (TMB) 
Substrate Solution. Reactions were stopped and Absorbance values read at 
optical density (OD). Those OD values were used to compare levels of global 
methyl cytosine in the various samples. 
 
2.9.2 Inducing DNA demethylation with the DNMT1 inhibitor 5-
azacytidine 
First synthesized about 40 years ago, 5-azacytidine is a commonly used drug that 
exhibits many anti-metabolic activities and in particular is used as chemotherapy 
for cancers such as myelogenous leukemia123. Mechanistically, 5-azacytidine is a 
commonly used DNMT1 inhibitor that induces global DNA demethylation. SF 
treatment with 5-azacytidine was realised according to previous 
publications124,125. Fibroblasts were first synchronized overnight in 1% FCS DMEM 
and then cultured for 7 days with DMEM - 10% FCS and 5-azacytidine (1 μM, 
Sigma-Aldrich). The media was changed everyday. After one week, global methyl 
cytosine was substantially reduced (Figure 2-3). 
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2.9.3 In vitro treatment with cytokines for the induction of global 
DNA demethylation  
SF were first synchronized overnight in 1% FCS DMEM and then cultured for 14 
days in 10% FCS DMEM and stimulated daily with the following cytokines. IL-1β 
was used at 1 ng/ml, IL-17 at 2.5 ng/ml and IL-22 at 2.5 ng/ml (all Invitrogen) 
(these chronic exposure studies used concentrations of stimuli10 times less than 
those typically used for acute functional inflammatory response assays over 24 
hours stimulation). This protocol follows that published for SF from RA patients 
using IL-1β in vitro to induce global DNA demethylation126. 
2.10 Statistical analysis  
All statistical analyses were performed using Prism software (GraphPad 
Software). For data sets with two groups: parametric data were analysed using 
the one-tailed Student’s t-test; for the analysis of non-parametric data, the 
Mann-Whitney test was used. For data sets with more than 2 groups, one-way 
ANOVA analysis with Tukey’s post-test was used and in experiments where two 
variables were measured, the two-way ANOVA test was used with the Tukey’s 
post-test. Statistical significance is shown as *=p<0.05, **=p<0.01 and 
***=p<0.001. 
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Figure 2-1 Vasculature permeability assay using Evans Blue dye reveals 
vasculature leakage in the joint during CIA induced inflammation. 
Evans Blue dye binds to albumin: thus, healthy vasculature, which is 
impermeable to albumin, will retain the dye. However, once vasculature 
permeability is induced during pathological conditions such as inflammation, 
proteins such as albumin leak into the local tissue. Therefore, the Evans blue 
dye allows clear visualisation of the location of leakage in vivo. Here, it is clear 
that the inflammation induced during CIA drives vasculature leakage in the joint,  
as revealed by the blue staining of the tissue in the paw with CIA (score 4) 
relative to the healthy control (score 0). 
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Figure 2-2 Strategy for phenotyping SF according to Armaka et al120  
After extraction from the paws and expansion in culture, SF were confirmed as 
being positive for CD54 (ICAM-1), CD106 (VCAM-1) and CD90.2 (Thy1.2). Positive 
staining (black) is shown by reference to the relevant isotype control 
represented in grey. 
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Table 2-1 List of FACS antibodies used in this study 
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Table 2-2 List of Western blot primary antibodies used in this study 
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Figure 2-3 5-azacytidine treatment efficiently induces global DNA 
demethylation. 
The DNMT1 inhibitor, 5-azacytidine, was added (at 1 μM daily for 7 days) to bone 
marrow derived macrophages. Since DNMT1 is inhibited, the cells dividing are no 
longer able to maintain their global DNA methylation status leading in the = long 
term to global DNA hypomethylation. Here, the level of methyl-cytosine 
expression was revealed by staining with a anti-methylcytosine antibody (Novus 
Biologicals) and counter-staining of the nucleus revealed by DAPI staining. After 
7 days treatment with 5-azacytidine, a strong global DNA demethylation is 
observed. Data are represented as merged for DAPI (red) and methyl cytosine 
(green) and individual staining for methyl cytosine is as well represented in grey 
scale for more clarity.  
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3. ES-62 and its SMAs prevent the development 
of CIA 
3.1 Introduction  
Research investigating the host-parasite relationship has revealed the 
potential of immunomodulators produced by helminths to modulate the host 
immune system. Such molecules are the result of long co-evolution that has 
enabled the parasite to safely downregulate inflammation to avoid being 
attacked without inducing immunosuppression, therefore maintaining the 
host’s ability to react against other infections. Those molecules are 
particularly interesting in terms of their potential as therapeutics in 
autoimmune disease since on the one hand there is a close relationship 
between the absence of parasite and the rise of autoimmune disorders as 
explained by the Hygiene Hypothesis98,127,128, whilst on the other hand, most 
therapies for autoimmune disorders, like RA, are strongly immunosuppressive, 
placing patients at risk129. ES-62 is a helminth immunomodulator produced by 
the filarial nematode Acanthocheilonema viteae, that is the best-
characterized helminth immunomodulator to date98. It has already provided 
proof of concept of the therapeutic potential of such molecules as indeed, ES-
62 protects against the development of CIA, OVA-induced airway 
hypersensitivity and lupus development in mice101,104,113. ES-62 protects 
against CIA development through modulating Th17/Th1 priming and effector 
responses104. Importantly, as ES-62 is itself unsuitable as therapy not only 
because of its size, ES-62 is a 62 kDa protein secreted as a tetramer, but as 
well because of its phosphoryl choline moiety found in various peptides such 
as bacterial peptides. Therefore, the SMAs of ES-62, 11a and 12b have been 
shown to be protective in various model of autoimmune disease and allergies 
and as well as displaying therapeutic potential in CIA103,113,114,130-132. Moreover, 
investigation of the mechanisms by which ES-62 and its SMAs protect against 
CIA has brought new insight to our understanding of RA disease pathogenesis, 
particularly in terms of the importance of IL-22, IL-17 and IL-1β104,114,133. 
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Nevertheless, the pathway(s) to pathogenesis is still not fully understood and 
therefore in this chapter, the therapeutic potential of ES-62 and its SMAs, 
especially 12b, is further explored in the mouse CIA model to reveal new 
characteristics of the protective mechanisms of ES-62 and 12b, in particular in 
reducing the aggressive phenotype of SF. 
The SF is the major cell population found in the joint and over the last decade 
the importance of this cell type in the development, spread and maintenance 
of pathogenicity has been proven134,135. Once activated, SF seem to play a key 
role not only in the perpetuation of inflammation but also in driving the bone 
and cartilage damage. Therefore, they represent an excellent therapeutic 
target since controlling their aggressiveness would enable modulation of the 
two main clinical symptoms of RA, namely joint inflammation and bone 
destruction. Such a target might provide new therapies for patients not 
responding to the usual treatment of systemic suppression of immune 
responses3 as well as, and more importantly, safer and cleaner strategies 
since this cell population is specific to the joint avoiding bone marrow 
suppression, which at present is a major cause of mortality associated with 
current therapies. 
The specific aims of this chapter are therefore to confirm and extend the 
initial observations104,133 that ES-62 can act to dampen down the aggressive 
phenotype of SF, In particular, the objectives were to: 
- Characterise the protection afforded by ES-62 and 12b in the CIA 
model, particularly in terms of reducing joint infiltration by pro-
inflammatory cells and consequent bone degradation. 
- Investigate whether the protection provided by ES-62 and 12b 
treatment is associated with modulation of the pathogenic features of 
SF, namely the capacity to produce mediators of inflammation and 
bone destruction. 
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3.2 Characteristics of CIA joint pathology 
Understanding the pre-clinical onset of the disease is key to diagnosing and 
treating patients to prevent disease. However, it is not possible to understand 
the mechanisms resulting in the increase in ACPAs (Anti Citrullinated protein 
antibody) and rheumatoid factor and consequent pathogenesis in patients 
with established disease, retrospectively. Thus relevant experimental animal 
models are essential and necessary in order to understand the various 
mechanisms, pathways and kinetics that need to be further explored to reveal 
potential therapeutic and diagnosis targets in RA. Moreover, even when 
human tissues are useful in defining important ongoing pathways their use 
remains limited, as relevant tissue such as bone marrow, spleen or lymph 
nodes are not generally and ethically obtainable, and even for synovial tissue, 
the targeted lesion is not always available. Various animal models have 
therefore been developed to recapitulate different aspects of the disease and 
include both induction or spontaneous, genetically-modified arthritis models 
that offer different advantages136,137. Nevertheless in this thesis, the focus has 
been on CIA as it is not only one of the most commonly used animal models 
but also because it is considered the gold standard, since it recapitulates 
many aspects of RA138. CIA in mice relies on an induced break in self-tolerance 
which is dependent on both B and T cell responses and produces collagen-
specific autoantibodies and inflammation such that the animals develop an 
acute asymmetric polyarthritis characterized by synovial infiltration, synovial 
hyperplasia, cartilage and bone erosion. CIA initiation is associated with the 
production of anti-type II collagen IgG, reflecting that in patients disease is 
associated with the production of autoantibodies against self type II collagen 
as well as citrullinated proteins (inducing ACPAs) and IgG (inducing the 
rheumatoid factor). Indeed, serum transfer from a CIA mouse is able to induce 
arthritis in naive mice, revealing the importance of humoral immunity for the 
initiation of pathogenesis and confirms the hypothesis that type II collagen 
might be an important autoantigen138,139. The most common mouse strain used 
for CIA is DBA/1, although to allow easier assessment of the effect of genetic 
modification on disease development, C57BL/6 mice can also be used. 
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In this thesis, CIA mouse model was used to assess the prophylactic and 
therapeutic potential of ES-62 and its SMA. Under our animal house 
conditions, the first joint symptoms begin to appear after challenging the 
mice at day 21 (with collagen type II) such that by day 30 mice will typically 
have an average clinical score of 4.7 ± 1.48 (SEM) with, approximately 60 % of 
mice displaying affected joints and amongst these, 50 % will be characterized 
as exhibiting a serious clinical score, as indicated by a total articular score ≥4 
(Figure 3-1). This model recapitulates various key features of RA such as joint 
infiltration by polymorphonuclear and mononuclear cells, synovitis and pannus 
formation leading to bone and cartilage degradation as revealed by 
immunohistochemistry of joint sections using H&E and trichrome staining 
(respectively Figure 3-2A and   
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Figure 3-2B). Here, immune cell infiltration and pannus formation is clearly 
visualised by H&E and trichrome staining as well as some cartilage and bone 
degradation being clearly visible in the trichrome stained sections. One of the 
main contributors to this influx of hyperactive immune cells is the local loss of 
vasculature integrity, which facilitates cell infiltration. To measure such 
potential vasculature permeability, mice were injected with Evans Blue, a 
non-toxic dye commonly used to inspect vasculature leakage (  
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Figure 3-2C). It is injected into the tail vein prior to cull and vasculature 
leakages are immediately detected by a blue coloration of the tissue. Here a 
preliminary study was performed to evaluate the relationship of this 
experimental protocol to articular score. The inflamed paws were clearly 
stained in blue indicating localized vasculature leakage and the importance of 
the vasculature leakage and the multiplication of leakage sites correlated 
with the clinical score. 
 
3.3 Aggressiveness of SF during CIA 
SF from naïve (naive fibroblasts) and CIA (CIA fibroblasts) mice can be 
extracted and cultured ex vivo for up to 4-5 weeks. As such cells are 
therefore isolated from their pro-inflammatory environment; this enables 
assessment of whether the cells are intrinsically rewired or simply responding 
to the pro-inflammatory milieu. This approach has suggested that it appears 
that CIA fibroblasts are intrinsically different to naïve cells, since over this 
time in culture they retain at least some of their aggressive features in terms 
of maintaining hyper-production of mediators of inflammation and bone 
degradation43. Indeed, their capacity to produce pro-inflammatory cytokines, 
such as IL-6, or chemokines, such as CCL2, remains significantly higher 
compared to that of cells from naive mice even after 4 weeks ex vivo, even in 
the absence of external stimuli (Figure 3-3A and Figure 3-3B, respectively). 
Moreover, it seems that the hyper-secretion of such molecules in the absence 
of external stimulation is directly regulated at the gene expression level since 
the mRNA levels of IL-6 and CCL2 are similarly significantly increased in CIA 
fibroblasts compared to the naïve cells (Figure 3-3C and Figure 3-3D 
respectively). Furthermore, CIA fibroblasts, even once isolated ex vivo, still 
exhibit an enhanced capacity to induce tissue and bone destruction as they 
display a significantly higher expression of MMP9 mRNA in the absence of 
stimulation and more MMP9 and MMP13 mRNA in response to IL-17 (Figure 
3-3E, Figure 3-3F respectively), a key pathogenic mediator in the joint105. 
 
66 
 
3.4 ES-62 and 12b prevent development of CIA 
3.4.1 Prophylactic treatment with ES-62 protects against CIA in 
DBA/1 mice 
ES-62 is a homotetramer, comprising 62 kDa PC-containing glycoprotein 
subunits, that exhibits various immunomodulatory properties on a number of 
cell types, resulting in anti-inflammatory activities conferring its therapeutic 
potential in models of allergic or autoimmune disorders such as asthma or 
RA104,140,141. It has been previously shown that in the CIA model of RA, 
treatment with ES-62, both prophylactically and therapeutically, significantly 
reduces CIA disease severity104,117. ES-62-mediated protection is associated 
with the downregulation of IL-17 responses achieved by targeting dendritic 
cells and the IL-17-producing Th17 and ɣδ T cells resulting in decreased level 
of the pro-inflammatory cytokine IL-17 in the joint104. Complementing this 
action, more recently it has been demonstrated that ES-62 upregulates the 
levels of IL-22 in the joints during established disease, and this appears to be 
crucial for the protective effect of the parasite molecule142. At the time, this 
was a rather surprising finding as IL-22 had previously been shown to be 
pathogenic in the early stages of the disease133: however, as ES-62 acted to 
dampen IL-22 responses during the initiation phase, these studies were 
amongst the first to identify that IL-22 plays a dual role during CIA, also being 
involved in the normal homeostatic inflammation resolution and tissue repair 
process once disease has been established. ES-62 is therefore protective in 
CIA by both downregulating pathogenic IL-17 responses and promoting the 
inflammation resolution potential of IL-22. 
Corroborating the published findings that prophylactic treatment with ES-62 
reduces joint inflammation and prevents development of CIA, here exposure 
to the parasite product reduces both articular score (Figure 3-4A) as well as 
disease incidence (Figure 3-4B), with about half of PBS-treated disease 
control CIA mice (CIA) presenting with severe arthritis (articular score ≥4) 
(Figure 3-4C) whilst most of the mice undergoing CIA but treated with ES-62 
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(≥80%) exhibited low or no disease scores. Reflecting the low clinical scores of 
ES-62-treated CIA mice, joint sections stained with H&E and trichrome reveal 
suppression of pro-inflammatory cells infiltration and bone degradation 
(Figure 3-2). As the inflammation and tissue damage occurring in CIA mice 
induces hypoxia that can create a pro-arthritogenic environment and 
perpetuates pathology in the joint143, preliminary experiments were carried 
out to assess the joint microenvironment pertaining in naive, CIA and ES-62 
mice in vivo. To this end, hypoxia levels in cells from the joints were assessed 
using a hypoxia-sensing probe, the drug pimonidazole that had been injected 
intraperitoneally 24 hours before culling the mice. Once activated in an 
oxygen-dependent manner in vivo, pimonidazole will bind covalently to thiol-
containing proteins specifically in hypoxic cells. Thus, following isolation ex 
vivo, cells containing pimonidazole can be detected by flow cytometry using a 
FITC-conjugated monoclonal antibody specific for the probe (M & M section 
2.3.1). Joint cells extracted from CIA, ES-62 and naïve mice were pooled by 
treatment group and analysed for pimonidazole staining (Figure 3-5A). It 
revealed two clear populations, with some cells displaying low levels of 
pimonidazole yet others displaying stronger staining indicative of a higher 
hypoxic state. Focusing on the cells exhibiting higher levels of hypoxia, it 
appears than there are more “high hypoxic” cells derived from CIA, compared 
to ES-62 mice (Figure 3-4E), consistent with the ES-62-mediated suppression 
of pro-inflammatory cells infiltrating the joint contributing to this decrease in 
local hypoxia. 
During arthritis many inflammatory cell types are found infiltrating the joint, 
including B and T lymphocytes as well dendritic cells, macrophages or 
granulocytes, particularly neutrophils. Once in the joint they participate in 
the maintenance of the pro-inflammatory environment by secreting cytokines 
and chemokines contributing to joint swelling and inflammation and also to 
bone and cartilage damage. It has previously been shown that exposure to ES-
62 reduces the levels of plasma cells as well as neutrophils infiltrating the 
joint144. Further analyses of these joint cells now shows that ES-62-treated 
mice with CIA also demonstrate a lower infiltration (Figure 3-5B) of the two 
major T cell subpopulations, CD8+ cytotoxic CT cells and CD4+ helper T cells, 
68 
 
data pertinent to the previous studies showing that ES-62 protects from CIA by 
inhibiting both the Th1 and Th17 subsets of CD4 T cells104.  
 
3.4.2 Therapeutic potential of the SMAs 
ES-62, as a potentially immunogenic protein, is probably unsuitable for use as 
a therapeutic treatment as explained earlier due to its PC moiety and the 
large protein size and therefore as the PC moiety of ES-62 is responsible for 
the protective effect of the parasite product in CIA, a library of drug-like 
SMAs modelled on the PC moiety has been designed and synthesised as the 
first step in the development of a novel class of anti-inflammatory drugs. A 
primary in vitro screen of macrophage cytokine production identified two 
SMAs, 11a and 12b that are able to recapitulate ES-62 protection in various 
models of autoimmune (CIA114,132 and the MRL/Lpr model of SLE113) and 
allergic (the OVA-induced model of asthma103 and the oxazalone-model of skin 
contact dermatitis130) inflammatory disease. Rather surprisingly, our recent 
data showed that whilst both SMAs protect against CIA, they do so by 
targeting different mechanisms associated with ES-62-mediated 
immunomodulation, with 11a mimicking its ability to suppresses pathogenic 
IL-17/IFN responses whilst 12b downregulates the inflammasome and IL-1 
production in the joints of mice with CIA by inducing NRF2-regulated anti-
oxidant cytoprotective pathways114. Since IL-17 and hypoxia/ROS have been 
reported to act on SF to promote chronic inflammation in the arthritic joint, 
it was thus decided to investigate whether the SMAs acted like ES-62 to effect 
resolution of inflammation in the joint and  investigate their effect on SF 
during CIA.  
Importantly, given that one of the main interests of the Harnett labs is to 
determine whether the SMAs 11a and 12b can be developed as potential 
therapeutics for inflammatory arthritis, the effects of the SMAs on mice with 
established arthritis were tested, with reference to the steroid methotrexate 
(MTX), a common treatment for patients with RA (Figure 3-6). Like ES-62117 
and MTX145, even when administered therapeutically after onset of disease, 
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11a and 12b act to suppress further disease progression114 (Figure 3-6 A-B). 
The parasite-derived immunomodulators are therefore efficient at both 
preventing development of inflammation and also suppressing further 
progression once disease is established114,132. Importantly, this study now 
shows that such protection is also associated with desensitisation of pro-
inflammatory SF responses. Indeed, SF derived from CIA mice treated 
therapeutically with SMAs showed a lower basal production of IL-6 as well as 
that in response to BLP but not LPS or IL-1β, relative to those from PBS-
treated CIA mice (Figure 3-6C). Reflecting its immunosuppressive nature, 
exposure to MTX inhibited responses to all stimuli, whereas the SMAs act to 
dampen MyD88 and inflammasome signalling which might render them less 
able to antagonise LPS (but not BLP) responses as these may be compensated 
by the MyD88-independent pathway of TLR4 signalling whilst IL-1β could 
potentially acutely overcome 11a and 12b protection.  
3.4.3 IL-1 overcomes the protection afforded by ES-62 and 12b 
in CIA mice 
In order to address validating that 12b confers protection by suppression of IL-
1 responses, it was investigated whether administration of IL-1β was able to 
overcome the protective effects of prophylactic administration of 12b (Figure 
3-7A). This study confirmed our previous findings114 with the clinical articular 
score and paw swelling of mice treated with 12b being significantly decreased 
(Figure 3-7B and Figure 3-7C, respectively). Moreover, whilst a 50% incidence 
of disease in the CIA cohort of mice was reached by day 23, none of the CIA-
12b mice exhibited pathology at this stage with a level of 28.5 % incidence 
only being reached for this group at cull on day 29 (Figure 3-7D). 
Administration of recombinant murine IL-1β in vivo was found not only to 
abolish 12b-mediated protection, but even to enhance disease clinical score, 
paw width (Figure 3-7B and Figure 3-7C, respectively) with disease incidence 
up to 66.7% in the CIA + IL-1β and 75 % in the 12b + IL-1β groups (Figure 3-7D). 
Such findings are corroborated by histopathological examination 
demonstrating reduced cell infiltration and bone degradation associated with 
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12b protection (Figure 3-8), which is completely abrogated by co-
administration of IL-1β, as this drives a massive cell infiltration and stimulates 
bone destruction in such 12b-treated mice. There is however no evidence of 
enhanced bone destruction or cell infiltration induced in the joints of IL-1β 
CIA mice compared to those of CIA mice with equivalent articular scores of 4 
suggesting that the administration of IL-1 is not simply creating damage per 
se. Likewise, the visible increase in infiltrating cells observed in 12b+ IL-1 
mice do not reflect an increase in cytotoxic T cells (CD3+ CD8+) or helper T 
cells (CD3+ CD4+), since the reduction of such cell populations within the 
joint induced by 12b was further enhanced by the presence of IL-1β. Although 
this may simply reflect that other cell populations such as neutrophils are 
greatly expanded under these conditions, administration of IL-1β did increase 
the proportions of those T cells populations in the CIA mice (Figure 3-9). Thus 
as IL-1 is important for the differentiation and maintenance of Th17 cells, 
this apparent decrease in the T cell population may reflect disruption of 
homeostatic networks since the change in the IL-1β levels are likely to be 
more pronounced in 12b than in the CIA mice. It may therefore, reflect the IL-
1-mediated induction of Bregs (regulatory B cells) and consequent inhibition 
of pathogenic Th responses observed recently in the antigen-induced model of 
arthritis following perturbation of the gut microbiome146,147. Thus it would be 
important to establish whether the increased cellular infiltration observed in 
the joint sections more likely reflects other cell type known to infiltrate the 
joint like Bregs or neutrophils 148,149. 
Even though ES-62 has not been shown to strongly inhibit IL-1β production, 
but rather mainly act through inhibition of IL-17 and rewiring of IL-22 
responses133,134,150, it was interesting to assess whether IL-1β could also 
overcome the protection afforded by ES-62 in vivo. This revealed that IL-1β 
can indeed overcome ES-62 protection and, as observed above in the 12b 
study, co-administration resulted in the induction of even higher articular 
scores as well as increased levels of paw swelling and disease incidence than 
observed in the CIA + IL-1β cohorts of mice (Figure 3-7). Again, these findings 
were supported by the histopathological analysis, as the exposure to IL-1β 
totally abrogated the absence of cell infiltration and bone destruction 
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exhibited in sections derived from CIA mice afforded protection by ES-62 
(Figure 3-8). Moreover, like with 12b, T cell infiltration induced by IL-1β  in 
the joint was as well supressed in an ES-62 context and such reduction of T 
cell infiltration was even stronger than for ES-62 treated mice alone (Figure 
3-9). 
 
3.5 ES-62 and 12b modify the aggressiveness of SF 
during CIA 
During RA, or in the murine CIA model surrogate, a cocktail of pro-
inflammatory signals, such as IL-17, IL-6, CCL2 and TNF-α, perpetuate 
inflammation in the joint. Although these mediators will be produced 
predominantly by the lymphocytes, neutrophils and monocytes invading the 
joint, some of these will also be generated by SF as these cells are able to 
sense the pro-inflammatory environment and can be activated via TLRs or 
cytokine receptors134,150. Thus, in turn, they produce a wide range of pro-
inflammatory factors and chemokines that maintain the pro-inflammatory 
environment and recruit more immune cells to the joints. Consistent with 
this, exposure of mice undergoing CIA to ES-62 in vivo has previously been 
reported to suppress pro-inflammatory (IL-6) responses of SF104.  
These findings were confirmed and extended here by analysis of the 
functional responses of SF derived from naive, CIA or ES-62-treated CIA mice 
(Figure 3-10). Thus, measurement of their capacity to generate pro-
inflammatory mediators ex vivo again confirmed that SF from mice with CIA 
exhibit a hyperactive phenotype (Figure 3-10). However, it revealed a 
significant decrease in spontaneous IL-6, but not CCL2, release by SF from ES-
62 (ES-62) relative to PBS (CIA) treated mice undergoing CIA: indeed, 
exposure to ES-62 resulted in SF that exhibit responses comparable to those of 
SF derived from naive mice. This cytokine and chemokine release by all three 
groups of SF was strongly stimulated by subsequent exposure in vitro to IL-
1LPS and particularly, BLP (bacterial lipoprotein), the latter likely 
reflecting the proposed key pathogenic role for TLR2 signalling in the joint in 
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RA150. Nevertheless, the SF derived from CIA mice still showed enhanced IL-6 
(to all 3 stimuli) and CCL2 (IL-1 and LPS) responses relative to SF from naive 
mice, whilst those from CIA mice exposed to ES-62 in vivo were no different 
to those from healthy mice. These data suggested that exposure to ES-62 in 
vivo can suppress development and/or maintenance of an aggressive SF 
phenotype in mice undergoing CIA. 
 
Exposure to 12b in vivo seems to be if anything even more efficient at 
suppressing the aggressive phenotype of SF as cells from such mice showed 
significantly decreased ability to produce, spontaneously or after stimulation 
with LPS or IL-17, either IL-6 and CCL2 relative to those from CIA mice ( 
Figure 3-11). Moreover, such dampening of SF aggressiveness occurs at the 
level of gene expression as the decreased release of IL-6 and CCL2 resulting 
from exposure to either ES-62 or 12b is mirrored by significant reductions in 
the mRNA levels of both IL-6 and CCL2 (Figure 3-12). Likewise, SF extracted 
from CIA mice treated with ES-62 displayed a significant decrease in the 
expression of both MMP9 and MMP13, gene products responsible for bone and 
cartilage degradation ( 
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Figure 3-13): indeed, the cells from ES-62-treated mice are completely 
refractory to the increase in MMP13 mRNA observed following stimulation with 
IL-17 in both the naive and CIA groups. Similarly, in further independent 
experiments, whilst SF from CIA mice again showed elevated levels of MMP9 
and MMP13 mRNA relative to those from naive mice, this was not the case for 
SF from mice treated with 12b and indeed the levels of MMP13 were 
significantly decreased compared to the naïve levels ( 
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Figure 3-13). Interestingly administration of IL-1β in vivo strongly enhanced 
the mRNA levels of both MMP9 and MMP13 in SF from CIA mice: however, 
whilst exposure to 12b is able to prevent this IL-1-driven increase in MMP9 
expression, there is a substantial increase in MMP13 mRNA in cells from 12b 
plus IL-1-, relative to 12b- and even the PBS-treated CIA mice, even if these 
expression levels remain significantly lower than those in CIA plus IL-1β group, 
perhaps explaining, at least in part, the enhanced severity of disease in these 
mice.  
 
3.6 Conclusions & Discussion  
The data presented in this chapter confirm the potential of ES-62, 11a and 
12b to reduce pathology in CIA. Moreover, administration of IL-1β was able to 
overcome 12b- (and ES-62) mediated protection providing supporting evidence 
that its production is a target of 12b in CIA133 and providing further support 
for the further development of such ES-62 SMA-based therapies in RA. 
Importantly, these new findings suggest that, like ES-62, 12b can act to 
functionally modulate SF aggressiveness both in terms of the perpetuation of 
inflammation and the bone and cartilage destruction that contributes to CIA 
progression. This perhaps suggests that further development of 12b in terms 
of targeting SF may avoid the immunosuppression associated with current 
immunomodulatory therapies and, for the reasons developed below, provide 
effective control of RA. 
SF have been proposed to play a key role in the perpetuation and even the 
spread of inflammation: although it is not clear whether SF are involved in the 
initiation process of RA, once inflammation is established, SF are able to 
sense the pro-inflammatory environment and respond by secreting multiple 
factors that drive the inflammation and pathology that generates the arthritic 
joint151. For example, during RA, the synovial cavity pressure increases and 
leads to the collapse of blood vessels, with consequent episodes of hypoxic 
reperfusion injury. This results in the generation of reactive oxygen species 
(ROS) that are proposed to induce modification of joint proteins that, by 
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allowing breaking of tolerance, leads to the formation of autoantibodies152. In 
addition, the localised conditions of hypoxia within the joint contribute to the 
activation and maintenance of inflammatory cell responses118,153. This altered 
pro-inflammatory microenvironment in the arthritic synovium reflects the 
hyper-proliferative and metabolically active status of cells such as SF within, 
and lymphocytes, monocytes and neutrophils invading, the joint: thus the 
ability of ES-62 to target not only DC polarization, Th17 differentiation and IL-
17 production by Th17 ɣδ T cells104 but also the hypoxic status, affects the local 
environment, making the joint less pro-arthritogenic which in turn may 
modulate fibroblast aggressiveness.  
Moreover, since SF express TLR4150 at their surface this suggests that they 
might also be directly targeted by ES-62 (and its SMAs), to inhibit the 
expression, and therefore the production, of pro-inflammatory factors such as 
IL-6, CCL2 or MMPs even within an established pro-inflammatory environment 
(Figure 3-14). This may be particularly important in the light of the evidence43 
that SF in both CIA and RA are intrinsically modified cells and not only passive 
responders to their local environment. Thus, if SF can be directly targeted by 
ES-62 and 12b, such molecules may have the capacity to interfere with this 
transformation process and prevent them from acquiring, or even reverse, an 
aggressive CIA-like phenotype, allowing the development of effective 
therapies acting in the joint in established disease.  
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Figure 3-1 Scoring the pathogenic development of the CIA mouse model 
DBA/1 mice were immunized on day 0 with type II bovine collagen (CII) and 
CFA (Freund’s adjuvant) and on day 21 with CII in PBS. Clinical articular score 
(A) and paw width (B) were monitored every other day for each mouse (n=6), 
with clinical score assessed as described in the Materials and Methods (section 
2.1 and 2.3) Data are presented as mean score ± SEM. Mann-Whitney tests 
were performed to assess statistical significance between the first and last 
days of disease model where *** p<0.001. Incidence of arthritis (C) was 
calculated by the percentage of mice with diagnosed pathology (designating a 
mouse as exhibiting arthritis once it reaches an articular score of 2). 
Incidence of diagnosed severe disease on the culling day at day 29 (D) was 
categorised as the percentage of mice with a total articular score ≥ 4. 
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Figure 3-2 Differential phenotypes between naïve and CIA joints specially 
in term of cell infiltration and vasculature leakage 
A-B: Paws from naïve (local score of 0) and CIA (local score of 3 total score of 
9), mice were collected for decalcification, sectioning and histopathology H & 
E (A) and trichrome (B) staining. In H & E (A) staining, Haematoxylin is a violet 
stain that binds to basophilic substances such as DNA, therefore it is used to 
reveal cell nuclei (purple). Eosin is a red stain that binds to acidophilic 
substances such as positively charged amino acid side chains (e.g. lysine, 
arginine) and is used to visualise collagen (pale pink). In the trichrome 
staining (B) staining reveals collagen deposition (green/blue) and erythrocytes 
(red). Black arrows are used to point out either inflammatory cell infiltration 
(CI) or bone destruction (BD). The presented pathology sections are from a 
CIA model not presented in this thesis where for the CIA mice average score = 
2.5 ± 0.8, n=12. 
C. CIA mice (average score 4.67 ± 2, n=6) were injected intravenously with 
the Evans blue dye and individual paws with local articular scores ranging 
from 0 to 3 are presented, revealing the vasculature leakage associated with 
pathology. A paw with a score of 4 from an independent experiment is shown 
in Figure 2-1). Black arrows point out the local Evans blue leakage and 
therefore tissue staining. Paws with a local score of 0 exhibit little or no 
staining, whilst those with a local score of 1 only display leakage in the toes 
or ankle. With scores of 2 and above multiple leakage points are revealed in 
both toes and ankle with leakage becoming more severe and correlating with 
the local articular score. 
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Figure 3-3 SF from CIA mice display properties consistent with aggressive 
inflammatory responses and bone destruction in the joint 
A-B: SF from naïve or CIA mice from 4 independent CIA models were pooled 
prior to expansion ex vivo. For each CIA model SF were cultured as 3 
independent cultures and IL-6 or CCL2 levels produced in 24 hours in the 
supernatant was assessed by ELISA as described in the M&M section 2.5. Here 
it is represented the mean value of each of the 4 CIA models (assayed as 
triplicate) normalised to their respective naïve fibroblast population for IL-6 
(A) and CCL2 (B) production. Mann-Whitney tests were performed to assess 
statistical significance where ** p < 0.01, *** p<0.001. 
C-D: SF from naïve and CIA mice (average score 3.17 ± 1.38, n=6) were 
extracted and plated as 3 independent cultures. Their level of IL-6 and CCL2 
mRNA levels was assessed by RT-qPCR as described in section 2.8). Results are 
expressed as the mean ± SEM of messenger RNA level relative to GAPDH and 
for statistical analysis Mann-Whitney tests were performed where ** p < 0.01 
E-F: SF from naïve or CIA mice from two independent CIA model (mean score 
3.67 ± 1.5, n=6 and mean score 4.5 ± 1.2, n=10) were pooled and cultured ex 
vivo. Independent cultures (3 for each CIA model) of SF were stimulated for 6 
hours with IL-17 (50 ng/ml) or DMEM as control. After stimulation cells were 
harvested and total RNA was extracted. Levels of MMP9 and MMP13 were 
assessed by RT-qPCR and the data are presented as mRNA levels (means of 
triplicate estimations) normalized to those of GAPDH and expressed as fold 
change. Symbols represent the values from individual cell cultures of both CIA 
models. Mann-Whitney tests were performed for each condition where, for 
statistical analysis * p < 0.05; ** p < 0.01, *** p<0.001. 
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Figure 3-4 Prophylactic administration of ES-62 reduces CIA clinical score 
as well as cell infiltration and bone destruction observed in joint sections.  
DBA/1 mice were immunized on day 0 with type II bovine collagen (CII) in CFA 
and on day 21 with CII in PBS. Mice were treated with ES-62 (2 µg each dose) 
on days -2, 0 and 21 or injected with PBS as a control (CIA mice). Clinical 
articular score (A) was monitored every other day for each mouse (n= 6 each 
group). Data are presented as mean score ± SEM. Incidence of arthritis (B) was 
calculated by the percentage of mice with pathology, with mice considered 
arthritic once a clinical score of 2 is reached. Incidence was also categorized 
as of severe disease (C) as indicated by the percentage of mice with a score 
above 4. 
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Figure 3-5 Prophylactic administration of ES-62 reduces local hypoxia and 
T cell infiltration in the joint 
A: Mice from CIA model and prophylactic treatment with ES-62 (respectively 
CIA: mean score = 4.667 ± 1.99, n=6 and ES-62 mean scores = 0.800 ± 0.800, 
n=5) were injected intra-peritoneally 24 hours before culling with 
pimonidazole (60 mg/kg) to address assessing the levels of hypoxia present in 
the joint under these differential conditions as described in the M&M section 
2.3.1. Paws were harvested and isolated joint cells from the Naive, CIA and 
ES-62 groups were pooled together. “Hypoxic” cells containing pimonidazole-
conjugates were detected using a specific FITC-conjugated monoclonal 
antibody by flow-cytometry. The data are also shown as the percentage of 
highly pimonidazole positive cells present in the joints of naïve CIA or ES-62 
treated mice. 
B-C: Paw tissue from CIA mice treated prophylactically with ES-62 (mean 
score 1.5 ± 1.145, n=6) or PBS as control (CIA mice, mean score = 3.667 ± 
1.498, n=6) were digested with collagenase and after an over-night 
incubation, non-adherent joint cells were harvested. Cells were stainind for 
flow cytometry as described in the M&M section 2.6, gated as single, live cells 
were analysed for the T cell marker CD3 and for more specific markers CD8 
(A) and CD4 (B) to distinguish respectively cytotoxic T cells and helper T cells 
by flow cytometry and the percentage of these cell population is represented 
in the double positive (CD3+CD8+ or CD3+CD4+) gates. Data are representative 
of a single experiment. 
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Figure 3-6 Therapeutic potential of the SMAs of ES-62 
A: The timeline of the therapeutic CIA model is presented. DBA/1 mice were 
immunized on day 0 with type II bovine collagen (CII) and CFA and on day 21 
with CII in PBS. From the first appearance of clinical inflammatory symptoms, 
mice were sequentially randomly allocated to blinded treatments and the 
code broken at the end of the experiment. Mice were injected s/c either with 
11a (1 µg per dose), 12b (1 µg per dose), methotrexate (50 µg per dose) or 
PBS as control (CIA mice) every three days (n=6 for each treatments). 
B: Therapeutic treatment of individual mice commenced at different times 
and initial clinical scores: thus, disease progression was normalised to the 
score on the first day of intervention for each condition. ANOVA followed by 
Tukey multiple comparison tests were performed for time points (days post 
first symptoms) and results are expressed as the mean ± SEM. For statistical 
analysis * p < 0.05; ** p < 0.01, *** p<0.001 
C: SF from the therapeutic model presented in B were extracted and pooled 
by treatment group. Following expansion ex vivo, three independent cultures 
were performed for each group treatment in which cells were  stimulated in 
vitro for 24 hours with the following stimuli: DMEM as control, BLP (0.5 
µg/ml), LPS (1 µg/ml) or IL-1β (10 ng/ml) and IL-6 release measured. by 
ELISA. Results are presented as the mean values of the independent cultures 
(each assayed in triplicate) and analysed by ANOVA  followed by the Tukey 
multiple comparison test where * p < 0.05; ** p < 0.01, *** p<0.001 
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Figure 3-7 12b and ES-62 prophylactic treatment protects against CIA 
development which is overcome by IL-1β 
CIA was induced in DBA/1 mice as described previously in Figure 3-4. 
However, in this independent model, cohorts of mice were injected 
prophylactically with 12b (1 µg per dose, dark green line, n=7) or ES-62 (2 µg, 
dark blue line, n=6) on days -2, 0 and 21 or with PBS as a control (CIA, red 
line, n=6). Additional cohorts were injected with recombinant murine IL-1β (1 
µg per dose) twice-weekly from day 21 (CIA + IL-1β, pink line n=6 and 12b + 
IL-1β, light green line n=8) as represented in the scheme (A). Clinical scores 
(B) and paw width (C) were monitored every other day for each mouse. Data 
are presented as mean score ± SEM. Incidence of arthritis (D) was calculated 
by the percentage of mice diagnosed with CIA (with clinical score above 2). 
For more clarity the results are splited in 2 graphs, showing separately 12b 
and ES-62 data both compared to the same CIA + IL-1β. 
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Figure 3-8 12b and ES-62 prophylactic treatments reduce cell infiltration 
and bone destruction in the joint, whose effect is abrogated by IL-1β. 
Paws relevant of each treatments presented in Figure 3-7:  CIA (paw score 4 
[mouse total score 9]); CIA + IL-1β (paw score 4 [mouse total score 11]); 12b 
(paw score 0 [mouse total score 0]), 12b + IL-1β: (paw score 4 [mouse total 
score 11]), ES-62 (paw score 0 [mouse total score 0]) and ES-62 + IL-1β (paw 
score 4 [mouse total score 11]). Such paws were collected for decalcification 
sectioning and histopathology H & E (on the left) and trichrome (on the right) 
staining Haematoxylin is a violet stain that binds to basophilic substances such 
as DNA, therefore it is used to reveal cell nuclei (purple). Eosin is a red stain 
that binds to acidophilic substances such as positively charged amino acid side 
chains (e.g. lysine, arginine) and is used to visualise collagen (pale pink). In 
the trichrome staining (on the right) staining reveals collagen deposition 
(green/blue) and erythrocytes (orange). Black arrows are used to point out 
either inflammatory cell infiltration (CI) or bone destruction (BD). For more 
visibility the data have been splited into PBS, ES-62, and 12b treatment 
groups. 
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Figure 3-9 IL-1β increases T cell infiltration in the joint alone but 
decreases it in presence of 12b and ES-62 
Joints from the CIA mice presented in Figure 3-7 were digested with 
collagenase, cultured overnight and non-adherent joint cells pooled in their 
treatment groups: CIA mice (mean score 3.66 ± 1.5, n=6), CIA + IL-1β (mean 
score 6 ± 1.93, n=6) 12b mice (mean score 0.71 ± 0.36, n=7) and 12b + IL-1β 
mice (mean score 7.62 ± 1.67, n=8), ES-62 (mean score 1.5 ± 1.14, n=6) and 
ES-62 + IL-1β (mean score 9 ± 1.93, n=6). Cells, gated as single, live cells were 
analysed for the T cell marker CD3 and for more specific markers CD8 (A) and 
CD4 (B) to distinguish respectively cytotoxic T cells and helper T cells by flow 
cytometry and the percentage of these cell population is represented in the 
double positive (CD3+CD8+ or CD3+CD4+) gates. For more clarity results are 
summarized in a table below. Data are representative of a single experiment. 
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Figure 3-10 Prophylactic treatment with ES-62 reduces SF pro-
inflammatory cytokines, IL-6 and CCL2, production. 
SF from Naive mice or mice with CIA, prophylactically treated with ES-62 (2 
µg each dose, mean score 0.5 ± 0.22, n=6) or PBS (CIA mice : mean score 3.17 
± 1.38, n=6) were pooled by treatment group and expanded ex vivo. Three 
independent cultures were set up for each treatment group. Levels of 
spontaneous (A and B) or IL-1β (10 ng/ml)-, LPS (1 µg/ml)- or BLP (0.5 µg/ml)-
stimulated (C and D) IL-6 and CCL2 release at 24 h were measured by ELISA. 
All results are expressed as the symbols representing the mean values for the 
independent cultures (each assayed in technical triplicate) with analysis by 
ANOVA followed by the Tukey multiple comparison test. For statistical 
analysis * p < 0.05; ** p < 0.01, *** p<0.001. The data for the spontaneous 
release of cytokine as well as under LPS stimulation, has been repeated 
successfully with another two independent animal models and has not been 
repeated for IL-1β and BLP. 
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Figure 3-11 Prophylactic treatment with ES-62 reduces SF pro-
inflammatory cytokines, IL-6 and 12b, production. 
DBA/1 mice were used for CIA and were prophylactically treated with 12b (1 
µg each dose, mean score 0.71 ± 0.36, n=7) or PBS as control (mean score 
3.66 ± 1.5, n=6). SF from those mice were extracted and pooled down by 
treatment group. After 3 weeks of ex vivo culture cells were plated as three 
independent culture for each group treatment at 0.3x10^6 cells per well. 
After stimulation with DMEM (as control, A-B), IL-17 (25 ng/ml) (C-D) and LPS 
(1 µg/ml) (E-F), supernatants were collected and IL-6 (A-C-E) and CCL2 (B-D-
F) concentrations were measured by ELISA as described in the M&M section 
(section 2.5). Data are plotted as the mean of each independent culture assay 
triplicate. ANOVA test followed by Tukey multiple comparison test was 
performed for each experiment and results are expressed as the mean ± SEM. 
For statistical analysis * p < 0.05; ** p < 0.01, *** p<0.001. This experiment has 
been repeated successfully with another animal model. 
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Figure 3-12 Inhibition of IL-6 and CCL2 mRNA expression by ES-62 and 12b 
SF from naïve, CIA (mean score 3.66 ± 1.5, n=6), ES-62 (mean score 1.5 ± 
1.15, n=6) or 12b (mean score 0.71 ± 0.36, n=7) treated mice were pooled and 
cultured ex vivo for 3 weeks. Parallel cultures from this model were used for 
RNA extraction and measurement of mRNA level of IL-6 and CCL2 by RT-qPCR 
as described in the M&M section 2.8. Levels of IL-6 and CCL2 were normalized 
to GAPDH and then expressed as a fold change. Results are expressed as the 
mean values (of triplicate analyses) from the independent cultures ± SEM. 
Data were analysed by ANOVA followed by Tukey multiple comparison test 
where * p < 0.05; ** p < 0.01, *** p<0.001. This experiment has been done only 
once. 
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Figure 3-13 ES-62 and 12b reduces SF MMP expression 
A-D: SF from naïve mice, CIA mice (mean score 3.66 ± 1.5, n=6) and ES-62 
mice (mean score 1.5 ± 1.15, n=6) were extracted, expanded for 3 weeks ex 
vivo and plated as triplicate cultures for each treatment at 0.3 10^6 cells per 
well. After stimulation with IL-17 (25ng/ml) for 24 hours after which cells 
were harvested RNA was extracted and mRNA level of MMP9 (A and C) and 
MMP13 (B and D) RNA messenger level were analysed by RT-qPCR as described 
in the M&M section 2.8. Levels of MMP9 and MMP13 were normalized to 
GAPDH and then expressed as a fold change. A Mann-Whitney t-test were 
performed for each experiment and results are expressed as the mean ± SEM. 
For statistical analysis * p < 0.05, ** p < 0.01, *** p<0.001 
E-F: SF from naïve mice, CIA mice (mean score 3.66 ± 1.5, n=6), 12b mice 
(mean score 0.71 ± 0.36, n=7) and as well CIA + IL-1β (mean score 6 ± 1.93, 
n=6) and 12b + IL-1β mice (mean score 7.62 ± 1.67, n=8) were extracted, 
expanded for 3 weeks ex vivo and plated as triplicate cultures for each 
treatment at 0.3 10^6 cells per well. Cells were synchronised in 1% FCS DMEM 
then left in 10% FCS DMEM for 24 hours after which cells were harvested RNA 
was extracted and mRNA level of MMP9 (A and C) and MMP13 (B and D) RNA 
messenger level were analysed by RT-qPCR. Levels of MMP9 and MMP13 were 
normalized to GAPDH and then expressed as a fold change. A Mann-Whitney t-
test were performed for each experiment and results are expressed as the 
mean ± SEM. For statistical analysis * p < 0.05, ** p < 0.01, *** p<0.001 
  
106 
 
 
 
 
 
 
  
107 
 
Figure 3-14 Primary model of ES-62 and 12b action on SF  
During CIA, chronic hyper-production of pro-inflammatory cytokines such as 
IL-17, IL-1β and endogenous TLR ligands stimulate SF to induce expression and 
secretion of pro-inflammatory cytokines (e.g. IL-6), chemokines (CCL2) and 
tissue- and bone-destructive mediators such as MMP9 and MMP13 in the joint. 
ES-62 and 12b are both protective in CIA and act to reduce pro-inflammatory 
cytokines and MMPs at the gene expression level in SF. 
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4. ES-62 modulates the SF responses to pro-
inflammatory cytokines. 
4.1 Introduction  
SF are key cells in the development of joint pathology in RA as they are 
involved in promoting both inflammation and bone resorption. They therefore 
present a perfect therapeutic target since any such therapy would be joint 
specific and not leave the patient open to systemic immunosuppression, as 
many current drugs do154. It is therefore crucial to understand the 
mechanisms by which these cells become activated, and maintain their 
hyperactivated pathogenic phenotype. T cell invasion of the joint seem to be 
an early event in the establishment of disease, as it occurs even before 
pannus formation155 and results in their secretion of a wide range of pro-
inflammatory mediators that shape the pathogenic environment that 
contributes to the activation and “transformation” of  SF. Indeed, several 
cytokines such as IL-17, IL-6 and IL-1β have already been identified as being 
able to induce a pathogenic phenotype of SF156. Since exposure to ES-62 
during CIA appears to suppress the development of hyperesponsive SF104, it is 
important to understand whether this reflects an ability to rewire fibroblasts 
such that they lose the capacity to respond to these cytokines in a pathogenic 
manner. As such cytokines are in themselves targets of ES-62104, this would 
effectively disrupt amplification/perpetuation of pathogenic inflammation. 
Relating to this, the pleiotropic cytokine, IL-22 plays key dual roles in 
regulating inflammation during RA: thus, it has been elegantly demonstrated 
that whilst IL-22 mediates pro-inflammatory functions early in CIA, once 
inflammation has been established it is involved in the resolution of joint 
inflammation133. Moreover, ES-62 appears to suppress CIA joint pathology, at 
least in part, by promoting rewiring the responses of SF towards the 
resolution and tissue repair functions of IL-22133 to counteract the potential 
inflammatory actions of this cytokine. Understanding the (ES-62-targeted) 
mechanism(s) by which the responses of SF to pleiotropic cytokines such as IL-
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22 can switch from pathogenic to tissue repair functions potentially offers a 
good therapeutic strategy. It is therefore necessary to dissect the downstream 
signalling responses elicited by such pleiotropic cytokines during these distinct 
functional outcomes in order to understand how ES-62 achieves such 
desensitisation of the pathogenic responses of SF. Potential targets are 
provided by evidence that IL-22, like IL-10, may be able to differentially 
induce STAT1 or STAT3 activation and IL-6 can activate either ERK or STAT3 
signalling depending on the context157. Thus, depending on the signalling 
pathway induced by the cytokine, different genes will be induced to drive 
differential effects: coupling to a  particular signalling pathway is regulated 
environmental co-signals, for example, in RASF, ERK signalling activation by 
IL-6 is enhanced by the presence of IL-1β158.  
Mitogen-activated protein kinases (MAPKs) comprise a family of 
serine/threonine protein kinases that are activated in response to a broad 
range of extracellular stimuli (mitogens, growth factors, cytokines or stress) 
acting via a variety of receptor, (cytokine and chemokine receptors, integrins, 
TLRs, Growth Factor Receptors (intrinsic receptor tyrosine kinases) and 
Antigen and Fc Receptors) types159 (Figure 4-1). Once activated MAPKs can 
translocate to the nucleus to modulate target gene expression, via 
transactivation of transcription factors. In humans, there are currently 7 
families of MAPK divided into the classical MAPKs (ERK 1/2, p38, JNK proteins 
and ERK5) and the atypical MAPKs (ERK3, ERK4, ERK7 and NLK)160. 
Dysregulation of classical MAPKs has been proposed to be central to the 
pathophysiology of RA161, these being found to be hyper-activated in the RA 
synovium162:  reflecting this, the ERK MAPK signalling cascade (Figure 4-1) is 
generally considered to be a key regulator of cell proliferation, survival and 
differentiation and indeed, its over-activation is often observed in cancer 
cells163. In RASF, the ERK pathway seems to play a major role in the 
downstream signalling of pro-inflammatory cytokines such as IL-17, TNFα, IL-1 
and IL-6, as well as perpetuating their production164. Moreover, other events 
promoting joint destruction also seem to be dependent on this signalling 
pathway. For instance, IL-1β upregulates ICAM-1 expression in an ERK-
dependent manner to enhance leukocyte adhesion165, whilst Cadherin-11 
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signals through ERK to produce MMPs166. Indeed, inhibition of ERK signalling 
can prevent the development of pathology, in the CIA mouse model of RA167. 
Likewise, JAK/STAT signalling ( 
Figure 4-2) is critical for many cytokine receptors, particularly type I and II 
cytokines, providing rapid gene induction regulating cell proliferation, 
survival, differentiation as well as pathogen resistance via the induction of 
pro-inflammatory responses168. Dysregulation of JAK/STAT signalling has been 
implicated in a number of aberrant inflammatory disorders such as irritable 
bowel disease, dermatitis and RA169 as well as cancers170. Indeed the key roles 
for JAK/STAT signalling in RA171 has generated interest in the therapeutic 
potential of inhibitors of JAKs (Jakinibs) and more recently, STATs172. For 
example, focusing on the synovium, in RA patients, STAT1 expression and 
activation (generally associated with IFN signalling) has been reported to be 
at a high level, particularly in T cells, B cells and fibroblasts isolated from the 
intimal lining173: perhaps consistent with this, STAT4, that is required for Th1 
and consequent IFN-mediated responses, is also highly expressed in the 
synovium and also appears necessary for the development of proteoglycan-
induced inflammatory arthritis in mice 174. Likewise, a role for STAT5 has been 
implicated in RA pathogenesis: this follows demonstrations that CCL13, which 
acts as an attractant for inflammatory cells and can exhibit 
immunomodulatory actions on stromal cells, is produced by RASF in response 
to IL-6 in a STAT-5, ERK and P38 MAPK dependent manner. However, In RASF 
STAT3 signalling has been shown to be particularly important as indeed, the 
survival of RASF is dependent on STAT3 activation175 and it is well established 
that STAT3 is activated in response to TNF, IL-6 and IL-1β176. Moreover, and 
pertinently to this project, STAT3 signalling has been reported to be 
responsible for the rewiring of RASF, generation of Th17 responses as well as 
the production of MMPs and RANKL, the latter mediators resulting in 
osteoclast differentiation177. STAT molecules are fine tuners of downstream 
signaling and can target a wide range of genes in a context-dependent 
manner. Therefore, it is important to analyse how STAT3 is activated in SF 
although the balance between STAT3 and STAT1, which can be modulated by 
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IFNs, will be of particular interest here since IL-22 may exhibit its pleiotropic 
effects in CIA by differentially inducing proliferative STAT3- or apoptosis-
inducing STAT1 signalling. Such tight regulation of STAT3/STAT1 balance 
could potentially explain the rewiring by ES-62 of IL-22 responses from 
pathogenic towards those promoting resolution of inflammation and tissue 
repair. 
In this chapter the main aim is to understand how ES-62 regulates the 
capacity of SF to respond to the various pro-inflammatory cytokines present in 
the joint during inflammation, and more precisely, determining whether:  
- ES-62 affects SF directly rather than as a result of downregulation of 
the local pro-inflammatory environment, in vivo? 
- ES-62 inhibits pathogenic activation of ERK pathways? 
- ES-62 downregulates STAT3 and/or upregulates STAT1 signalling? 
- ES-62 resets the STAT3/STAT1 balance by inducing IFNs or SOCS 
proteins to induce STAT1 and inhibit STAT3 activation, respectively? 
Answering these questions will inform on the mechanism by which ES-62 can 
render the aggressive phenotype of SF hyporesponsive to the pro-
inflammatory environment and/or induce a protective phenotype during the 
development of CIA. 
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4.2 ES-62, and its SMAs, directly modulate the capacity 
of SF to respond to pro-inflammatory cytokines and 
TLR ligands. 
In the previous chapter it was established that in vivo treatment with ES-62 
reduced the aggressiveness of SF responses when compared to those from the 
disease untreated mice (CIA SF). Although this could be explained by ES-62 
acting to reduce inflammation in the joint, it was important to determine 
whether ES-62 could act directly on SF. ES-62 can act directly on a number of 
cells, including T cells and dendritic cells and this action is TLR4 dependent, 
since TLR4 KO cells do not respond to ES-62178, and results in the 
downregulation of MyD88 and consequent inhibition of downstream functional 
responses104,179. Likewise, its SMAs, 11a and 12b, but not the inactive 19o 
compound, also act to downregulate MyD88132. Interestingly, therefore, as SF 
express TLR4 at their surface180, hypothetically they can be directly targeted 
by ES-62 (and potentially by extension its SMAs), acting intrinsically to 
prevent SF activation. In vitro treatment of SF, expanded from mice with CIA 
ex vivo, with ES-62 and the SMAS 11a and 12b revealed that these molecules 
could directly modulate cell activity. Thus, in vitro, ES-62 (≥ 0.25 µg/ml) is 
able to reduce the ability of SF derived from mice undergoing CIA (CIA), to 
produce IL-6 in the presence or absence of LPS, a surrogate for endogeneous 
TLR4 ligands (Figure 4-3A). The SMAs 11a and 12b both also directly 
modulated LPS-induced IL-6 production by the SF although only 11a 
significantly reduced basal IL-6 production (Figure 4-3B). It was therefore 
decided to investigate whether ES-62 modulated MAPK and/or STAT signalling 
to intrinsically prevent the SF activation during inflammatory arthritis. 
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4.3 ES-62 suppression of the capacity of SF to respond 
to external pro-inflammatory molecules is 
associated with inhibition of the ERK signaling 
pathway.  
As MAPKs play central roles in driving the production of cytokines and MMPs in 
RAs, they have been presented as good candidate targets for therapeutics161. 
Pertinently, in SF, ERK signalling is crucial for IL-6 secretion164,181: thus, in 
terms of ES-62 therapeutically rewiring these cells it was important to 
determine which pathogenic stimuli could activate this pathway. 
Interestingly, therefore, given their disease initiating potential, whilst IL-17 
can stimulate ERK activation in SF, as evidenced by the dual (thr/tyr) ERK 
phosphorylation, this did not appear to be the case for IL-22, or indeed the 
TLR4 ligand, LPS either at 20 min post-stimulation (Figure 4-4), or over a 0-
120 min time course for naïve and CIA SF (results not shown). Moreover, and 
consistent with the idea of ERK driving SF pathogenicity, inhibition of IL-17-
mediated ERK activation using the MEK PD98059 inhibitor (Figure 4-5A) 
resulted in a significant decrease of IL-6 production by SF from CIA mice in 
response to either IL-17 or IL-17 combined with IL-22 (Figure 4-5B). Similarly, 
the level of MMP9 and MMP13 was significantly reduced with the inhibitor in 
response to IL-17 stimulation (Figure 4-5C). Consistent with the proposal that 
SF are desensitised to IL-22 pro-inflammatory signalling during established 
disease, such in vitro stimulation with IL-22 alone did not significantly induce 
IL-6 production and if anything, tended to suppress the IL-17-mediated 
response. 
In addition, it appears that SF from mice with CIA display higher levels of ERK 
activation than SF from naïve mice (Figure 4-6) and this may be consistent 
with the idea that CIA SF are tumor-like cells and display a deregulated 
intracellular signalling network compared to naïve SF. As seen previously with 
the BALB/c SF (Figure 4-4), IL-17 is able to induce strong ERK activation in SF 
from both naive and CIA mice on the DBA/1 background (Figure 4-6) 
Interestingly IL-22 displays a different activity depending on the disease 
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status of the derived SF.  Thus, in naïve SF, IL-22 by itself does not really 
modulate ERK activation, but can efficiently inhibit ERK activation otherwise 
induced by IL-17: however in cells from CIA mice, consistent with its 
inflammation-resolving activity in established disease, IL-22 strongly reduces 
the elevated basal ERK activation and tends to weakly antagonise the limited 
further hyperactivation observed in response to IL-17, the latter perhaps 
reflecting its marginal suppression of IL-6 production under these conditions 
of acute exposure to IL-22 (Figure 4-6A). In addition, ES-62 was extremely 
efficient in inhibiting ERK signaling induced by IL-17 stimulation in SF from 
naive mice, however this capacity to inhibit such responses was largely 
revoked in CIA SF (Figure 4-6): collectively, these data may suggest that ES-62 
could act on healthy SF to prevent their pathogenic activation but once the 
aggressive phenotype is established, such acute in vitro exposure to ES-62 is 
not sufficient to dramatically suppress the elevated ERK signalling observed in 
SF derived from mice with CIA.  
Importantly, therefore, SF from CIA mice treated with ES-62 in vivo exhibited 
levels of basal ERK activation comparable than those seen in SF from naive 
mice and profoundly lower levels than those observed with CIA SF fibroblasts 
stimulated with IL-17, which demonstrated strong hyperactivation of ERK 30-
60 min post-stimulation in vitro. Moreover, SF obtained from CIA mice in 
which the administration of recombinant IL-22 in vivo resolved joint 
inflammation (SF derived from the relevant mice in Pineda et al.133), likewise 
exhibited IL-17-resistant profile comparable to that observed with SF from 
naive mice or ES-62-treated mice (Figure 4-7A). As well, such effect of ES-62 
on ERK activation is observed after 24 hours stimulation with IL-17 (Figure 
4-7B). Moreover, 24 hours stimulation reveals to be enough to bring naïve SF 
to a level of ERK activation even higher than CIA SF. These findings therefore 
perhaps provide further support for ES-62 acting to harness the inflammation-
resolving activities of IL-22 in the joint133 to intrinsically desensistise SF 
responses, as well as suppressing the production of IL-17 that promotes the 
aggressive SF phenotype133. 
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4.4 ES-62 modulates the capacity of SF to respond to 
pro-inflammatory cytokines by targeting STAT 
pathways 
As described in section 4.1, STATs, particularly STAT3, are activated 
downstream of many cytokines implicated in RA pathogenesis, such as IL-17, 
IL-6 and IL-1182,183. Moreover, IL-22 exhibits pleiotropic functions reflecting 
its ability to differentially activate either proliferative STAT3175 or apoptosis -
inducing STAT1184 signalling. Thus, it was of interest to investigate whether 
ES-62 achieved its desensitisation of SF responses to IL-17 by targeting STAT3 
and/or STAT1 in addition to its modulation of ERK activation in CIA SF. 
 
4.4.1 IL-17 drives CIA SF aggressiveness through STAT3 
activation, which can be reduced by ES-62 
Perhaps reflecting the role of IL-17-driven STAT3 in SF pathogenicity175, a 
pilot study in BALB/c fibroblasts (Figure 4-8) showed that IL-17, but not LPS or 
IL-22 acutely induces STAT3 phosphorylation in such healthy cells, despite IL-
22 promoting pathogenic SF rewiring during initiation of CIA133 and RA185. 
However, IL-22, a member of the IL-10 family has previously been shown to 
have the capacity to signal via STAT3 and STAT1, depending on the micro-
environmental context186 and thus, a further study was realised in SF from 
naïve DBA/1, which are prone to CIA to determine whether this lack of IL-22-
STAT3 signalling suggested that STAT3 was not important for this cytokine’s 
effects or alternatively, SF from healthy BALB/c were not suitably 
“conditioned” to respond to this pro-inflammatory mediator Figure 4-9.  
 
Perhaps reflecting this, on this mouse (inflammatory) genetic background, 
treatment with IL-22 alone also appears to induce STAT3 phosphorylation in 
these SF from naive mice (Figure 4-9A-B). As well once combined to IL-17, IL-
22 reduced IL-17 potential to induce STAT3, which again highlights the 
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protective role of IL-22 in pro-inflammatory environment. Interestingly, 
therefore, pre-treatment of naïve SF in vitro with ES-62 efficiently reduced 
IL-17-mediated STAT3 activation by suppressing STAT3 phosphorylation. 
 In addition analysis of STAT3 phosphorylation in resting SF from ES-62-treated 
mice revealed that such cells exhibited reduced levels of phosphorylated 
STAT3 compared to those from CIA SF or naïve SF (Figure 4-9C). 
Thus, the role of STAT3 in driving IL-17 and/or IL-22 –mediated rewiring of SF, 
was assessed by investigating the effect of 5.15 DPP, a STAT3 inhibitor, on the 
levels of IL-6 produced by CIA SF exposed to these stimuli  Figure 4-10). After 
validating the efficacy of this inhibitor (at 50 µM, 5.15 DPP should inhibit in 
theory at least 50% of STAT3 activity ( Figure 4-10A-B). Such inhibition of 
STAT3 activation prevented the production of IL-6 induced by IL-17, or IL-17 
plus IL-22 supporting the idea that Il-17-stimulated STAT3 promotes and 
maintains the pathogenic SF phenotype (Figure 4-10C). By contrast, the little 
or no IL-6 production resulting from exposure of pathogenic CIA SF to IL-22 is 
not modulated by the inhibitor, findings consistent with the apparent inability 
of IL-22 to stimulate any of ERK, STAT3, or IL-6 production in SF from CIA in 
the established phase of disease, where this cytokine rather seems to play a 
role in inflammation resolution. Interestingly, whilst 5.15 DPP also 
significantly induced a decrease in the MMP9 expression induced by IL-17 
(Figure 4-10D), there was no significant effect on MMP13 expression, perhaps 
indicating some differential regulation of these effector proteases. In any 
case, STAT3, like ERK, indeed seems to be a pathogenic driver of IL-17-, but 
not IL-22 mediated CIA SF responses. 
 
4.4.2  ES-62 promotes STAT1 activation 
ES-62 has been shown to protect against CIA not only by reducing the 
production of IL-17 and SF sensitivity to IL-17104, but also by increasing IL-22 
production in the joint and resetting its signaling towards desensitisation of SF 
responses133. As mentioned previously IL-22 is a member of the IL-10 family 
that is able to activate either STAT3 or STAT1, depending on the 
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inflammatory context186. Consistent with its pathogenic role in (IL-17-
mediated) SF transformation, STAT3 has previously been shown to induce SF 
survival and proliferation175 and here, IL-6 and MMP9 expression. By contrast, 
STAT1 induces a set of pro-apoptotic genes173. Therefore, since ES-62 can 
suppress STAT3 activation, it is of interest to understand whether this is 
accompanied by an upregulation of counter-regulatory STAT1 signalling. 
Pertinently, STAT1 is usually activated by IFNs (IFNɣ or IFNα and IFNβ187) and 
IFNβ has found to be protective in the joint during the established phase of 
disease in the CIA model188. It was therefore investigated whether ES-62 can 
induce IFNβ production and consequently STAT1 activation (Figure 4-11).  
Acute treatment of SF from naive mice with IFNβ (but not IL-6 which has been 
shown rather to drive pathogenic STAT3 activation177), was found to stimulate 
STAT1 activation (Figure 4-11A), whilst more chronic treatment (24 h) induced 
an increase in the expression of STAT1 protein (Figure 4-11B). Interestingly, as 
this was not recapitulated by ES-62 directly, the finding that ES-62 SF 
constitutively displayed phosphorylated STAT1 (Figure 4-11C-D), suggested 
that this may be as a result of ES-62 promoting IFNβ production by SF in 
response to inflammation in the joint. Consistent with this, analysis of SF 
from naive, CIA or ES-CIA mice showed that when such cells were 
subsequently exposed to IL-17 in vitro, those exposed to ES-62 in vivo were 
able to significantly upregulate IFNβ expression at the mRNA level (Figure 
4-11E). Collectively, therefore, these data may suggest that as a result of the 
high levels of IL-17 signalling in the joint, ES-62 induces IFNβ expression that 
can facilitate the induction and activation of STAT1, whilst downregulating 
STAT3 signalling to reset IL-22 towards inflammation resolution during CIA. 
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4.5 ES-62 and 12b mediated modulation of SF 
sensitivity to cytokines is associated with induction 
of suppressors of cytokine signaling (SOCS) 
The SOCS protein family are involved in the inhibition of the JAK-STAT 
signaling pathways and hence have frequently been implicated as being 
dysfunctional in autoimmune dysregulation189. SOCS1, cloned in 1997 by Starr 
et al190 despite being able to inhibit IFNɣ signaling has been shown to be 
highly expressed in RA patients191 and proposed to act by promoting SF 
motility192. However, another well studied SOCS family member is SOCS3 that 
is widely-established suppressor of STAT3 signaling189. Therefore, as ES-62 
targets both IFN and IL-17 in CIA, to further understand how ES-62 regulates 
JAK/STAT responses to cytokines in SF, it was decided to next investigate its 
effect on SOCS1 and SOCS3 expression (Figure 4-12). First of all, consistent 
with the pathogenic effector role of IFN, it appears that CIA SF express less 
SOCS1 mRNA than SF from naive mice. Rather counter intuitively therefore, 
SF from CIA mice express more SOCS3 mRNA than those from naïve SF: 
however, this may be evidence of a homeostatic negative feedback loop to 
limit inflammation, as exposure to either ES-62 or 12b in vivo induced 
significant increases in the expression of both SOCS1 and SOCS3 at the mRNA 
level. Such upregulation of SOCS1 by 12b is was well seen at protein level 
(Figure 4-13A) and abrogated by IL-1β but even more interestingly mice 
treated therapeutically with 12b, where disease progression is stopped by 
12b, display a strong SOCS1 production in their SF potentially acting as a 
negative feedback loop and allowing the resolution of inflammation (Figure 
3-13B). 
 
4.6 Discussion and conclusions 
The proposal that IL-17 is important in driving SF pathogenicity7,28,105 is 
further supported by the data presented in this chapter. In addition, they also 
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provide more evidence that activation of both the ERK and STAT3 signaling 
pathways is required for the induction of pathogenic response genes, namely 
mediators of inflammation (IL-6) and tissue and bone destruction (MMP9 & 
MMP13). By contrast, the role of IL-22 appears to be more complicated, as, 
despite its pro-inflammatory role in the initiation phase of CIA, it did not 
appear to activate either ERK or STAT3 signalling. Rather, and consistent with 
its inflammation-resolving role in established disease, it reduces the 
activation of both ERK and STAT3, but not to the same extent as ES-62. These 
data are therefore perhaps consistent with ES-62 mediating its effects on SF, 
at least in part, by promoting IL-22 production, as indicated by previous 
studies that showed that blocking of IL-22 during the established phase of CIA 
abolishes protection afforded by ES-62133.  
Nevertheless, these new data also suggest that both ES-62 and its SMAs can 
prevent the acquisition of a pro-inflammatory, bone destroying phenotype of 
SF by directly targeting SF, presumably at least in the case of ES-62 through 
subversion of TLR4 signalling, which has previously shown to be necessary to 
perpetuate Th1 and Th17 response in RA150. Thus, in addition to suppressing 
the aggressive phenotype of SF in CIA by ES-62 acting to reduce the levels of 
IL-17 in the joint104, it appears that the more recent data suggesting that it 
also acts to modulate the phenotype of SF such that they will no longer 
efficiently respond to IL-17 may reflect these new findings that ES-62 
efficiently prevents IL-17 from stimulating both ERK and STAT3 activation in 
SF during CIA.  
The molecular mechanisms involved in this desensitisation are not clear but 
appear to involve ES-62 inducing STAT1 signalling that likely acts to 
counteract STAT3 signalling, perhaps by inducing apoptosis of the aggressive 
SF. Moreover, this rebalancing of STAT1/STAT3 signalling provides a potential 
mechanism for the hypothesis that ES-62 promotes rewiring of IL-22 signalling 
in SF to an anti-proliferative/anti-inflammatory phenotype as this cytokine 
has the capacity to differentially couple to STAT1/STAT3 depending on the 
context193. Nevertheless, the data presented here suggest that ES-62 may not 
directly induce STAT1 expression but rather that this effect may be secondary 
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to its induction of IFNβ, a cytokine which has been shown to be protective in 
CIA. Indeed, mice lacking IFNβ display more severe disease in the CIA model 
not only in terms of SF phenotype, but also with respect to the development 
of pathogenic osteoclasts and macrophages, but not T cell, responses 194. 
Thus, we can hypothesize that ES-62 resets IL-22 towards inflammation 
resolution by switching the balance of the downstream signaling towards 
STAT1, thanks to the production of IFNβ, and as well as the reduction of IL-
17-mediated activation of STAT3 (Figure 4-14).  
The mechanisms involved have not been fully dissected, but there are various 
ways to desensitise cells, such as for instance reducing the level of cytokine 
receptors at the surface, or as shown here by inhibiting their downstream 
signaling pathways and/or promoting feedback loops involving negative 
regulators like the SOCS family members. Indeed, this preliminary 
investigation of the mechanisms underpinning the modulation of STAT3 
signaling revealed that both ES-62 and 12b promoted the expression of SOCS1 
and 3, molecules that negatively regulate JAKSTAT signalling. These findings 
are consistent with ES-62 desensitising SF to both Th1 (IFNɣ  STAT1 signalling 
is inhibited by SOCS1195) and TH17- (IL-1, IL-6 and IL-17 STAT3 signalling is 
inhibited by SOCS3189) driven inflammatory responses in the joint, in addition 
to reducing the absolute levels of these pathogenic cytokines. Certainly, 
directly targeting the downstream effectors potentially allows ES-62 to 
control the actions of many cytokines that exhibit convergent signalling and 
some of the potential mechanisms for regulating these are investigated in 
chapters 5 and 6.  
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Figure 4-1 An introduction to the ERK signalling pathway 
This is a generic model of the ERK signalling pathway utilised by a range of 
receptors including cytokine and chemokine (GPCR) receptors or integrins, 
TLRs, Growth Factor Receptors (intrinsic receptor tyrosine kinases) and 
Antigen and Fc Receptors. For example, with tyrosine kinase receptors, once 
the ligand binds it causes receptor dimerization and consequent 
phosphorylation of its cytoplasmic domain. This phosphorylation enables 
adaptors (Shc, GRB2, Crk, etc.) to bind the receptor attracting the relevant 
guanine nucleotide exchange factors (SOS, C3G, etc.) required to transduce 
the signal to small GTP-binding proteins (Ras, Rap1), which in turn activate 
the core unit of the cascade composed of a MAPKKK (Raf), a MAPKK (MEK1/2), 
and MAPK (ERK). Once activated, ERK can translocate to the nucleus, where it 
can phosphorylate a variety of transcription factors regulating gene 
expression, as well as having some cytosolic functions where it phosphorylates 
multiple substrates such as cPLA2, SOS, EGFR, PDEs, Mnk or RSKs to activate 
the subsequent downstream pathways196.  
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Figure 4-2 An introduction to the STAT signalling pathway  
This model provides a generic overview of STAT signalling, where cytokine, 
binding to its receptor induces its oligomerization, resulting in activation of 
relevant JAK kinases. JAK-mediated phosphorylation (on tyrosine) of the 
receptor provides binding sites for STATs, which contain phosphotyrosine 
recognising SH2 domains. Once bound, the STATs also become phosphorylated 
and dimerize allowing them to translocate to the nucleus to regulate target 
gene expression. Such STAT signalling is usually transitory since their target 
genes include the SOCS (suppressor of cytokine signaling) family that act, 
amongst the various functions of SOCS proteins, directly or indirectly to 
inhibit JAK/STAT activation. Other signalling elements that contribute to 
negative feedback are the protein tyrosine phosphatases (PTPs) that can also 
inhibit JAK activity and/or dephosphorylate the cytokine receptor as well as 
the PIAS family that target STATS. The functional outcome of JAK STAT 
signalling depends on the particular STAT recruited and its specific set of 
target genes. 
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Figure 4-3 ES-62, and its SMAs 11a and 12b modulate in vitro SF 
production of pro-inflammatory cytokines in response to pro-inflammatory 
stimuli. 
(A). SF from CIA mice were pooled (mean score 2.43 ± 0.84, n=7) and 
expanded ex vivo. Three independent cultures from this mouse model were 
plated at 104 cells per well in a 96 wells-plate and once synchronised 
overnight in 1% DMEM were treated in vitro for 2 hours with various 
concentrations of ES-62 (none, 0.25 µg/ml, 0.5 µg/ml and 1 µg/ml) prior to 24 
hours stimulation with LPS (1 µg/ml) or DMEM (as control) 10% FCS. 
Supernatants were collected and IL-6 release measured by ELISA. Data are 
plotted as the mean values of each of the independent cultures, with each 
culture being assayed in triplicate. Statistical analysis was by one-way ANOVA 
with the Tukey multiple comparison post-test where* p < 0.05; ** p < 0.01, *** 
p<0.001.  
(B) SF from naïve or CIA (mean score 4.7 ± 1.5, n=10) mice were pooled and 
expanded ex vivo. From this animal model cells were plated at 104 cells per 
well in order to have 3 independent culture for each in vitro treatment. Once 
synchronised overnight in 1% DMEM, SF were treated in vitro for 2 hours with 
the SMAs 11a and 12b prior to 24 hours stimulation with LPS (1 µg/ml), or as 
control, in DMEM 10% FCS. Supernatants were collected and IL-6 release 
measured by ELISA. Data are plotted as the mean values obtained from each 
independent culture, assayed in triplicated. Statistical analysis was by one-
way ANOVA with the Tukey multiple comparison post-test where* p < 0.05; ** 
p < 0.01, *** p<0.001.  
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Figure 4-4 IL-17 stimulates ERK signaling in SF from naive BALB/c mice 
SF were extracted from BALB/c mice and expanded ex vivo. After stimulation 
with LPS (1 µg/ml), IL-17 (25 ng/ml), IL-22 (25 ng/ml), or DMEM (as control) 
for 20 minutes, cells were then analysed for phosphorylated ERK (pERK, red 
line) and total ERK (tERK, blue line) expression identified by staining using 
specific antibodies (relative to an isotype control antibody, black line) and 
flow cytometry as described in the M&M section (section 2.4). Data are 
presented as percentage of max on the Y axis and fluorescence intensity of 
pERK or tERK expression on the X axis. 
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Figure 4-5 pd98059 MEK inhibitor suppresses IL-17-stimulated IL-6, MMP9 
and MMP13 production by CIA SF  
A: SF were extracted and pooled from naïve or CIA (mean score 4.5 ± 1.24, 
n=10) cohorts of mice and expanded ex vivo. Cells from this animal model 
were plated as independent triplicate for each in vitro treatment group at a 
concentration of 104 cells per well. Before being analysed for ERK activation 
by the FACE assay (as described in the M&M section 2.6), cells were treated 
for 2 hours with DMEM or the MEK inhibitor, pd98059 (IE, 25 µM197) before 
being stimulated for 20 minutes with IL-17 (25 ng/ml) or with DMEM (as 
control) and then analysed for ERK activation. ERK activation is represented 
as the ratio of OD values of pERK/tERK expression and data are expressed as 
the mean ± SEM of statistical analysis was by 1-way ANOVA with the Tukey 
post test where * p < 0.05.  
B-C: SF were extracted and pooled from naïve or CIA (mean score 4.5 ± 1.24, 
n=10) cohorts of mice and expanded ex vivo. Cells from this animal model 
were plated as independent triplicates for each in vitro treatment group at a 
concentration of 0.3 10^6 cells per well in a 6 well-plate. Before being 
analysed for cytokine secretion by the ELISA, or mRNA expression by RT-qPCR 
assays (as respectively described in the M&M section 2.5 and 2.8), cells were 
treated for 2 hours ± pd98059 (iE, at 25 µM197) and then stimulated with IL-17, 
IL-22 both (at 25 ng/ml), or medium (none) for 24 hours. Supernatants were 
collected and IL-6 release was measured by ELISA (B) Results are expressed as 
the mean ± SEM of culture triplicates each assayed in technical triplicate. 
Statistical significance was shown using Mann-Whitney T-test where * p < 0.05; 
** p < 0.01, *** p<0.001. Moreover, total RNA was extracted to measure MMP9 
and MMP13 mRNA levels relative to GAPDH by qRT-PCR (C). Results are 
expressed as the mean ± SEM of culture triplicates each assayed in technical 
triplicate. They are represented as well relative to the house keeping gene 
mRNA level, GAPDH. Statistical significance was shown using the 1-way ANOVA 
with the Tukey post test, where * p < 0.05; ** p < 0.01, *** p<0.001. 
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Figure 4-6 IL-17 induces ERK activation, while IL-22 and ES-62 reduces it in 
CIA SF  
A: SF were extracted from naïve and CIA mice (mean score 2.42 ± 0.84, n=7) 
and expanded ex vivo. After pre-treatment with ES-62 (1 µg/ml) for 24 hours 
stimulation and stimulation with IL-17 (25 ng/ml), IL-22 (25 ng/ml) for 20 
minutes, cells were analysed for phosphorylated ERK (pERK, red line) and 
total ERK (tERK, blue line) expression identified by staining using specific 
antibodies (relative to an isotype control antibody, black line) and flow 
cytometry as described in the M&M (section 2.4). Data are presented as 
percentage of max on the Y axis and fluorescence intensity of pERK or tERK 
expression on the X axis. 
B: Quantification of the % of Max (representing the normalised cell number) is 
realised and the ratio of the % of max pERK/tERK is represented in a graph 
(n=1). No stimulation is in grey, IL-17 in red, IL-22 in purple, IL-17 + IL-22 in 
bright green and IL-17 + ES-62 in dark blue. 
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Figure 4-7 ES-62 and IL-22 in vivo reduce as well ERK activation induced 
by IL-17 
A: SF were extracted from naïve, CIA (mean score 2.8 ± 1, n=7), CIA ES-62 
treated mice (mean score 0.8 ± 0.8, n=5), as well as those treated 
therapeutically with rIL-22 in vivo (from the previously published animal 
model by Pineda et al133. mean score 3.14 ± 0.8, n=4) and were expanded ex 
vivo as plated as three independent cultures for each group treatment. Cells 
were stimulated with IL-17 (25 ng/ml) for up to 120 minutes, with time points 
every 20 minutes. To assess levels of phosphorylated ERK, cells were 
permeabilised and stained for phosphorylated ERK (pERK) and total ERK (tERK) 
expression by the FACE assay and the data are presented as the OD ratio of 
pERK/tERK expression and results are expressed as the mean values of the 
independent cultures (each assayed in triplicate) ± SEM. This experiment is 
representative of two sets of independent cultures from two different animal 
model except of the rIL-22 data which were not repeated.  
B: SF were extracted from naïve, CIA (mean score 4.5 ± 1.241, n=10) and ES-
62 treated mice (mean score 1.714 ± 1.063, n=7) and expanded in vivo. Cells 
from each treatment were plated at the concentration of 0.3 10^6 cells per 
wells in a 6 wells-plate as independent cultures for each treatment group. 
After stimulating the cells for 24 hours with IL-17 (25 ng/ml), total proteins 
were extracted used for pseudo-quantification of pERK and GAPDH by Western 
blot as described in the M&M section 2.7. Semi quantification by ImageJ of 
the pERK (both bands together) is presented as relative to GAPDH protein 
level. Data are represented as the mean + SEM. Statistical significance was 
shown using the 1-way ANOVA with the Tukey post test, where * p < 0.05 and 
** p < 0.01 
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Figure 4-8 STAT3 phosphorylation is induced by IL-17 in SF from BALB/c 
mice 
SF were extracted from BALB/c mice and expanded ex vivo. After stimulation 
with LPS (1 µg/ml), IL-17 (25 ng/ml), IL-22 (25 ng/ml) or DMEM (as control) 
for 20 minutes, cells were analysed for expression of phosphorylated STAT3 
(PSTAT, red line) and total STAT3 (tSTAT3, blue line) by staining with specific 
antibodies relative to their isotype control (black line) by flow cytometry as 
described in the M&M section. Data are present as a percentage of max 
response on the Y axis (normalized cell count) and fluorescence intensity of 
pSTAT3/tSTAT3 expression on the X axis. 
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Figure 4-9 ES-62 reduces STAT3 activation by IL-17 in naive SF 
A: SF were extracted from naïve mice and expanded ex vivo for 3 weeks. 
After synchronizing them overnight in 1 % DMEM, some cells were pre-treated 
with ES-62 (1 µg/ml) for 24 hours before stimulating all cells with IL-17 (25 
ng/ml), IL-22 (25 ng/ml), both cytokines, or DMEM as control for 20 minutes. 
Cells were thereafter harvested permeabilised and stained intracellularly for 
phosphorylated STAT3 (pSTAT3, red line), total STAT3 protein (tSTAT3, blue 
line) and isotype (black line) as described more precisely in the M&M section. 
Cells were analysed then by flow cytometry. Data are represented as % of max 
in the Y axis as explained in the M&M and the fluorescence intensity in the X 
axis  
B: Quantification of the mean fluorescence intensity (MFI) is realised and the 
ratio of the MFI pSTAT3/ MFI tSTAT3 is represented in the graph where DMEM 
control is in black, IL-17 is in red, IL-22 in purple, IL-17 + IL-22 in bright green 
and IL-17 + ES-62 in dark blue. 
C: SF were extracted from naïve, CIA (mean score 3.17 ±, n=6) or ES-62 (mean 
score 0.5 ± 0.22, n=6) treated mice and expanded ex vivo for 3 weeks and 
were plated at 1 10^6 cells per well and synchronised overnight in DMEM 1 % 
FCS. Total proteins were extracted from unstimulated cells in triplicates and 
pSTAT3 protein was revealed by Western blot. Semi-quantification by ImageJ 
of pSTAT3 level relative to the constitutive tERK is represented as well. This 
experiment is representative of 2 independent experiments. 
  
139 
 
140 
 
 Figure 4-10 Inhibition of STAT3 activation reduces IL-17-stimulated 
production of IL-6 production and MMP9 by CIA SF 
A- (A) SF extracted from CIA mice (mean score 4.5 ± 1.24, n=10) were 
pulled down and grown ex vivo for 3 weeks. The STAT3 inhibitor 5.15 
DPP potentiality was assessed on those cells. Cells were plated at 1 
10^6 cells per well in a 6 wells plate. After a pre-treatment for two 
hours with 5.15.DPP (50 µM198) and stimulation for 20 minutes with IL-
17 (25ng/ml) or with DMEM as control, total protein was extracted and 
phosphorylated STAT3 (pSTAT3) as well as total STAT3 (tSTAT3) 
proteins were revealed by Western blot, as described in the M&M 
section 2.7. (B) Semi-quantification using ImageJ was done and data 
are presented as a ratio of tSTAT3/tSTAT3 and relative to tERK levels 
(B). This experiment has been done only once. 
C-D: SF extracted and pooled from CIA (mean score 4.5 ± 1.24, n=10) cohorts 
of mice and expanded ex vivo. Cells from this animal model are the same than 
the one used in the Figure 4-5B-C (unstimulated control is the same). SF were 
plated as independent triplicate for each in vitro treatment group at a 
concentration of 0.3 10^6 cells per well in a 6 wells-plate. Before being 
analysed for cytokine secretion by the ELISA or mRNA expression by RT-qPCR 
assays (as respectively described in the M&M section 2.5 and 2.8). Cells were 
treated with 5.15.DPP (iST, at 50 µM) and stimulated with IL-17 and/or IL-22 
both (at 25 ng/ml) or DMEM as control for 24 hours. Supernatants were 
collected and IL-6 release was measured by ELISA (C) Results are expressed as 
the mean ± SEM of culture triplicates each assayed in technical triplicate. 
Statistical significance was shown using Mann-Whitney T-test where * p < 0.05; 
** p < 0.01, *** p<0.001. Moreover, total RNA was extracted to measure MMP9 
and MMP13 mRNA levels relative to GAPDH by qRT-PCR (D). Results are 
expressed as the mean ± SEM of culture triplicates each assayed in technical 
triplicate. They are represented as well relative to the house keeping gene 
mRNA level, GAPDH. Statistical significance was shown using the 1-way ANOVA 
with the Tukey post test, where * p < 0.05; ** p < 0.01, *** p<0.001. 
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Figure 4-11 ES-62 promotes upregulation of IFNβ expression in presence of 
IL-17 under inflammatory conditions and induces STAT1 activation. 
A: SF were extracted and pooled from naïve DBA mice and expanded ex vivo. 
Cells were plated as three independent cultures for each treatment group of 
this animal model. After stimulation for 20 minutes with IFNβ (10ng/ml) and 
IL-6 (10 ng/ml), or DMEM as control, total protein was extracted and 
phosphorylated or total STAT1 protein (respectively pSTAT1 and tSTAT1) and 
the constitutive ERK protein (tERK) were revealed by Western blot, as 
described in the M&M section 2.7. This experiment has been realised only 
once. 
B: SF were extracted and pooled from naïve DBA/1 mice and expanded for 3 
weeks ex vivo. Cells were plated at a concentration of 104 cells per well, as 
triplicates for each treatment group. After treatment for 24 hours with ES-62 
(1 µg/ml) and IFNβ (10 ng/ml) cells were fixed and permeabilised for FACE 
assay as described in the M&M section 2.6. Total STAT1 protein level was 
revealed and data are represented as the OD value measured by the assay. All 
Results are expressed as the mean ± SEM. Statistical significance was shown 
using the 1-way ANOVA with the Tukey post test where *** p<0.001 
C-D: SF were extracted from naïve, CIA (mean score 3.167 ± 1.376, n=6) and 
ES-62 (mean score 0.5 ± 0.22, n=6) treated mice and expanded for 3 weeks ex 
vivo. Cells were plated in a 6 wells plate at a concentration of 1.106 cells per 
well as independent triplicate cultures for each treatment group. Total 
protein was extracted and phosphorylated STAT1 protein and the house 
keeping GAPDH protein were revealed by Western blot as described in the 
M&M section 2.7 (D). The semi quantification by ImageJ of pSTAT1 relative to 
GAPDH is represented as well (E). All Results are expressed as the mean ± 
SEM. Statistical significance was shown using the 1-way ANOVA with the Tukey 
post test. 
E: SF were extracted from from naïve, CIA (mean score 4.5 ± 1.24, n=10) and 
ES-62 (mean score 1.71 ± 1.06, n=10) treated mice and expanded for 3 weeks 
ex vivo. Cells were plated in a 6 wells plate at a concentration of 1.106 cells 
per well in independent triplicate culture for each conditions. After 
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stimulation with IL-17 (25 ng/ml) for 6 hours or DMEM as control, total RNA 
was extracted and level of IFNβ messenger RNA was quantified using RT-qPCR 
as described in the M&M section 2.8. All Results are expressed as the mean ± 
SEM. Statistical significance was shown using the 1-way ANOVA with the Tukey 
post test where *** p<0.001. Such experiment has been successfully 
reproduced with another independent animal model. 
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Figure 4-12 ES-62 and 12b upregulate SOCS expression in SF. 
SF were extracted from naïve, CIA (mean score 3.67 ± 1.5, n=6), ES-62 (mean 
score 1.5 ± 1.15, n=6) and 12b (mean score 0.71 ± 0.36, n=7) treated mice and 
expanded for 3 weeks ex vivo. Cells of each treatment group were plated as 
triplicate cultures. Total RNA was recovered from biological triplicates of 
each cell type and messenger level of SOCS1 and SOCS3 was measured relative 
to the house keeping gene GAPDH by RT-qPCR as described in the M&M 
section 2.8. All results were expressed as the mean ± SEM. Statistical 
significance was shown using the 1-way ANOVA with the Tukey post test, 
where * p < 0.05; ** p < 0.01, *** p<0.001. This experiment has been done only 
once. 
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Figure 4-13 Therapeutic and prophylactic treatments with 12b upregulate 
SOCS1 protein level in SF 
A: DBA/1 mice were therapeutically treated with 12b or PBS as control as 
previously described in the Figure 3-6. SF from those mice were extracted, 
pooled by treatment group and expanded ex vivo. Total protein was extracted 
and SOCS1 was revealed by Western blot as described in the M&M section 2.8. 
Semi-quantification has been realised using the software ImageJ and data are 
represented as relative to total ERK protein level. 
B: SF from the model previously displayed in Figure 3-7 were extracted from 
naïve mice, CIA mice (mean score 3.66 ± 1.5, n=6), CIA + IL-1β (mean score 6 
± 1.93, n=6) 12b mice (mean score 0.71 ± 0.36, n=7) and 12b + IL-1β mice 
(mean score 7.62 ± 1.67, n=8). Total protein was extracted and SOCS3 was 
revealed by Western blot as described in the M&M section 2.8. Semi-
quantification has been realised using the software ImageJ and data are 
represented as relative to total ERK protein level. 
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Figure 4-14 ES-62 regulation of SF downstream signaling, a summary 
ES-62 makes SF less responsive to pro-inflammatory signals like IL-17 and IL-
1β, consequently reducing their subsequent production of IL-6, CCL2 or MMPs. 
It appears to achieve this by suppressing pathogenic ERK and STAT3 signal 
transduction. Moreover, ES-62 also appears to promote the induction of IFNβ 
in response to IL-17-associated inflammation to to induce STAT1 activation. In 
addition to counter-acting STAT3 signalling, this provides the potential for a 
switch in IL-22 downstream signaling from STAT3 to STAT1 allowing conversion 
of pathogenic IL-22 signalling to that associated with inflammation-resolution. 
In addition, such pro-inflammatory signaling pathways can be regulated 
thanks to the SOCS 1 and 3 proteins respectively potent inhibitors of IFNɣ and 
STAT3 are found upregulated by ES-62 and 12b. 
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5. microRNAs as key modulators of signal 
integration  
5.1 Introduction 
The data presented above support the hypothesis that ES-62 can directly 
target SF during CIA to prevent them from producing pro-inflammatory and 
tissue destruction factors. It appears to be able to rewire these cells to 
modulate the panel of genes expressed at mRNA and protein levels as well as 
reducing their sensitivity to IL-17 and consequently re-setting control of the 
expression of IL-17 targeted genes. Thus, in the following studies (Chapters 5 
& 6) the mechanisms by which ES-62 can control gene expression both directly 
at translation and transcription level are investigated, with focus here in this 
chapter, on modulation of gene translation by miRNAs during CIA.  
MicroRNAs (miRNAs) are short non-coding RNAs (around 20 nucleotides in 
length) that regulate gene expression either by inducing targeted mRNA 
degradation or inhibiting mRNA translation. In particular, they target single 
strand mRNA via base-pairing with complementary sequences. The 
consequence of such pairing can be the cleavage of the mRNA, or 
alternatively its destabilization through shortening of its polyA tail or a 
reduction in translation efficiency, since the ribosome is no longer able to 
properly bind the mRNA. Whatever the mechanism, the end result is a strong 
reduction in target gene translation implicating miRNAs as key regulators of 
cell function: as a proof of their importance, miRNAs are extremely well 
conserved in eukaryotes, both in plants and animals199. In humans, the 
genome encodes for thousands of miRNAs which seem to be able to target 
approximately 60% of transcribed genes, allowing them to control a large 
network of target genes. Reflecting reports of their efficient control of cell 
differentiation status200, their dysregulation has been implicated in enabling 
cell reprogramming, dedifferentiation and cell transformation in cancer 201. 
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Thus, as SF appear to be reprogrammed and display a “transformed” 
phenotype in CIA, it has been proposed that this may potentially reflect 
impairment of the microRNA network contributing to the acquisition of their 
aggressive features. Indeed, a number of studies investigating the expression 
of a wide range of miRNAs have lead to the discovery of both the selective 
upregulation and downregulation of their expression, as well associations of 
certain miRNA polymorphisms in RA (Table 5-1) and specifically, RASF when 
compared to the profile found in normal SF202.  
For example, miR-146a has been proposed to be crucial for the regulation of 
pathogenesis of RA as the rs2910164 polymorphism has been found to be 
associated with autoimmune disease susceptibility203, whilst upregulation of  
miRs155 and 146a has been associated with the (dys)regulation of cytokine 
signalling. Both miR-155 and -146a are expressed at increased levels in SF 
from RA patients and animal models, as well as in a range of other 
tissues204,205. Consistent with its polymorphisms being a key susceptibility 
factor in RA, miR-146a is found to be further upregulated in RASF upon 
stimulation by IL-1β and LPS and shown to negatively regulate TLR signalling 
by directly targeting IRAK-1 (interleukin-1 receptor-associated kinase) and 
TRAF-6 (TNF receptor associated factor) expression, suggesting that it 
normally acts to mediate protection against aberrant inflammation. This 
hypothesis is supported by the recent observations of Nakasa et al. showing 
the inhibitory effect of miR-146a on bone destruction in a mouse CIA 
model206. By contrast, miR-155 was highlighted as a potential key driver of RA 
when Blüml et al. showed a lack of development of CIA in miR-155 -/- mice207 
and miR-155 was found to be expressed at very elevated levels in RA 
patients208.  
MiRNA 155 is the most described miRNA in autoimmunity204 and is known to 
target the anti-inflammatory inositol phosphatase SHIP1, the absence of 
which increases disease severity in the K/BxN serum transfer model of RA, 
and acute agouty arthritis209. Consistent with this, miR-155 is upregulated by 
TNF-α, IL-1β and TLR ligands, and further enhances TNF-α production, yet 
perhaps surprisingly promotes the downregulation of MMP-1 and MMP-3. A 
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potential explanation for these apparently contradictory findings with respect 
to RA pathogenesis could be that miR-155 normally acts to initiate "safe" 
inflammation that at high levels homeostatically induces protective 
mechanisms to counterbalance its proinflammatory effect. However, in 
addition to promoting TLR4 signalling by upregulating MyD88, TAB2 and IKKε 
miR155 can also negatively target SOCS1, therefore inhibiting negative 
feedback loops and maintaining pro-inflammatory signals210,211.  
Thus, as ES-62, 11a and 12b enable CIA SF to recover or remain in a healthier 
phenotype, it was hypothesised that these molecules may mediate such 
modulation, at least in part, via control of miRNA expression. This idea is 
supported by the fact that TLR pathways, which are targeted by ES-62 and its 
SMAs, regulate the translation of some of these miRNAs, namely miR-155, 
miR-146 and miR-132 212-214 215. Specifically, in this chapter the aims were to 
investigate whether: 
- The potential candidate miRNAs implicated in regulating RA are 
expressed in SF and their expression modulated by pathogenic 
mediators 
- Such miRNA expression can be modulated by ES-62 and/or its SMAs.  
- Analyse the consequences of such miRNA regulation by ES-62 and SMAs 
on the pro-inflammatory phenotype of SF and identify potential 
targets. 
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5.2 Screening of candidate miRNA targets of ES-62 in 
SF 
Thirteen candidate miRNAs were selected on the basis of their demonstrated 
activity as regulators of inflammation, and having being shown to deregulated 
in CIA mice and/or RA patient samples (Table 5-1). MicroRNAs 155 and 146a 
are the most studied microRNAs in RA: both are expressed at increased levels 
in RA patients and in a large range of cell types, but more specifically in SF, 
in animal models205,208,216. In addition, miR-125a is considered to be a 
potential RA biomarker because it is found at high levels in patients’ serum, 
although it is not known whether it is expressed by SF217. Several miRNAs, 
such as the miR-19 family218 miR-23b219 and miR-125a217, have been included 
for their ability to regulate the NF-B pathway which is a therapeutic target 
in RA217,219 and also modulated by ES-62 and its SMAs in CIA104,132. MiR-203 and 
miR-346 have also been implicated in the pathogenicity of inflammatory 
arthritis, being a regulator of MMP-1 and IL-6 expression220 and targeting a 
TNFα inhibitor221,222, respectively. MiR-34a has been, in addition selected as 
candidate for the study since its KO it resistant to CIA development (data not 
published yet), while miR-34a* has been described anti-inflammatory 
miRNA223. Only miR-24-1 has not been previously studied in inflammatory 
arthritis: however microarray analysis by the Harnett group revealed that a 
SMAs of ES-62, namely 12b upregulated expression of this miRNA in 
macrophages stimulated with LPS in vitro132.  
A major goal of this study was to identify whether microRNAs can be 
modulated by ES-62 (and its small molecule derivatives, 11a and 12b) in order 
to address their potential role in mediating the protection afforded against 
CIA by these immunomodulators. Thus, to establish optimal conditions for 
studying the expression of miRNAs in SF from naive and CIA DBA/1 mice, the 
transcriptional kinetics of 3 candidate miRNAs implicated in RA pathogenesis, 
relative to the constitutively expressed miRNA Hs-RNU6-2, were analysed in 
resting and LPS-stimulated SF derived by explant culture from normal BALB/c 
mice (Figure 5-1A). LPS was chosen as a model stimulus, not only as a 
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surrogate for TLR4-acting DAMPs generated by tissue damage in the joint, but 
also because it is well established that whilst the effects of ES-62 are TLR4 
dependant, it acts to subvert such signalling. This analysis revealed 
differential expression kinetics of the miRNAs: thus, while miR-155 seems to 
progressively and strongly accumulate over 24 hours stimulation with the 
classical pro-inflammatory TLR4 ligand LPS, miR-146 was only weakly 
upregulated, peaking at 6h following LPS stimulation. By contrast, exposure to 
LPS does not modulate the high constitutive expression of miR-125a. Thus, for 
a screen of candidate miRNAs potentially modulated by ES-62 and its SMAs, it 
was proposed to identify which, if any, of these miRNA are expressed in SF 
derived from pooled naive (score 0) and CIA (mean score 4.7 ± 1.48, n=10) 
mice under steady state conditions (medium) and following 6 hours of LPS 
stimulation (Figure 5-1B). In terms of validation of significant miRNA 
induction, if their expression was detected within 31 cycles, corresponding to 
a relative level of expression of 0.1 when Hs-RNU6-2 expression was used as 
the reference standard, these data were considered to be above the threshold 
of “real” expression122. Amongst all the miRNAs tested, the following five 
were found highly expressed under steady-state conditions: miR-155, miR-
125a, miR-34a, miR-19b-1 and miR-23b and generally at comparable but 
higher levels in CIA-SF, relative to naive-SF. However, exposure to LPS 
differentially regulated the levels of many of the individual miRNAs: thus 
whilst miR-24-1, miR-146 and miR-203 were only detected around the 
threshold level in SF from both naive and CIA mice, miR-146 and miR-203 
could be induced somewhat by LPS stimulation in SF from both CIA and naïve 
mice. Interestingly, CIA SF maintain (with or without LPS-stimulation) a higher 
level of miRNA expression compared to the naïve SF for the following miRNAs: 
miR-23b-2, 24-1, 34a 125a, 146, 155 and 203. Furthermore, certain miRNAs 
were considered not to be expressed by SF at all as their levels were below 
the significance threshold: miR-19b-2, miR-124* and miR-346-2. Therefore, 
further analysis was only performed with the following candidates: miR-19b-1, 
miR-23b, miR-24-1, miR-34a, miR-125a, miR-146, miR-155 and miR-203.  
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5.3 miRNA-155 expression in response to the pro-
inflammatory environment is reduced by the SMAs 
and ES-62. 
As a first step, the potential modulatory effects of the SMAs 11a and 12b were 
tested on this panel of miRNAs in vitro in SF from CIA mice under conditions 
(6h) designed to mimic the steady-state “aggressive” phenotype (medium) 
and also following LPS stimulation or exposure to two pro-inflammatory 
mediators typically present in the arthritic joint (IL-1β and IL-17), that are 
known targets of the SMAs 12b and 11a, respectively114,132. Data showing 
miRNA expression level are presented (Figure 5-2) and summarised in Table 
5-2). Firstly, this analysis showed that all miRNAs were upregulated in SF from 
CIA, relative to naive mice, whilst expression of miR-146 miR-155 and miR-203 
was, as predicted by the literature, upregulated by LPS. However, perhaps 
rather surprisingly, given previous indications in the literature, no 
downregulation of miR-23b due to an overproduction of IL-17219 was observed 
in SF from CIA. This lack of effect in CIA SF may reflect that this was a 
snapshot of miRNA expression at 6 h and also that this in vitro assay does not 
recapitulate the cocktail of pro and anti-inflammatory signals occurring in the 
joint in vivo. Nevertheless, it highlights that it is difficult to predict from such 
screens what is likely to happen in vivo, where cells interacting in structured 
microenvironments will integrate multiple signals to regulate miRNA 
expression. Clearly, the effects of in vitro exposure to 11a and 12b (relative 
to miRNA expression in SF from CIA mice under each condition) are dependent 
on the precise stimulation. For example, for miR-146, 155 and 203 that are 
upregulated by LPS stimulation, both 11a and 12b decrease their expression 
levels, but differential effects according to the stimuli can be observed. For 
instance, for miR-146 11a and 12b increase the miRNA level under IL-17 
stimuli, while they decrease it under LPS or IL-1β stimuli.  
Since the miRNAs are expressed under LPS stimulation we decided to 
investigate the effects of exposure to ES-62 and its SMAs, both in vitro and in 
vivo, on miRNA expression in CIA SF treated with LPS to mimic their 
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induction/maintenance during ongoing chronic inflammation in disease. 
Although, LPS-stimulation of SF from naive mice might similarly provide a 
surrogate for initiation of inflammation, where miRNAs where elevated (19b, 
23b, 24-1, 125a, 146, 155) in CIA relative to naive SF under steady-state 
conditions treatment of CIA SF with either SMA generally reverted miRNA 
expression back to levels observed in naive SF, and so it was decided to focus 
on the ability of the SMAs to antagonise the ongoing inflammatory responses 
in established disease. This showed that pre-exposure to 11a and 12b induced 
a significant decrease in the LPS-stimulated miR-34a and 155 levels in CIA SF 
(Figure 5-3), whilst miR-23b was again decreased by 11a and elevated by 12b. 
However, the anti-inflammatory miR-146 does not seem to be affected at all 
by in vitro exposure to 11a and 12b under conditions of LPS stimulation. 
Interestingly, therefore, investigation of the in vivo effect of 12b on several 
of these miRNAs (Figure 5-4), using LPS-stimulated SF derived from indicated 
cohorts of mice, confirmed that exposure to 12b resulted in SF that displayed 
a lower level of miR-155 compared to SF from CIA mice. However, under 
these in vivo modulatory conditions, a significant increase in the two anti-
inflammatory miRNAs miR-146 and miR-23b was also observed, perhaps 
indicating a role for the inflammatory microenvironment in promoting these 
negative feedback effects. Indeed since miR-146 is known to downregulate 
TLR/IL-1R pathway224 maybe 12b downregulates IL-1β production114 by 
inducing miR-146. 
Likewise, to determine whether these in vivo effects of 12b were mimicking 
the effects of ES-62, SF explanted from naïve, CIA or ES-62 treated mice 
treated in vitro with LPS were analysed for expression of the candidate 
miRNAs (miRs-19b, -23b, -34a, -146 and -155) of major interest. This again 
revealed that all of these miRNAs tended to be expressed at higher levels in 
LPS-stimulated SF from CIA relative to naive DBA/1 mice. However, of these, 
only miR-155 manifests a significant change in expression following exposure 
to ES-62 in vivo, with the levels in SF from CIA-ES-62 mice being brought back 
to levels found in SF from naïve mice (Figure 5-5). Unlike 12b however, 
exposure to ES-62 does not result in significant upregulation of miR-23b or 
miR-146. Nevertheless, this proved proof of principle that ES-62 may mediate 
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at least some of its effects on SF by modulating the miRNA network and 
importantly, by targeting miR-155 that has been shown to play a pivotal role 
in regulating pathogenesis207.  
 
5.4 miR-155 a potent regulator of SF signaling 
To investigate whether downregulation of the activity of the pathogenic miR-
155 provides a molecular mechanism for any of the hyporesponsiveness 
associated with SF from ES-62-treated mice with CIA, miRNA mimic 155 was 
transfected into naïve, CIA and ES-62 SF to determine whether it could 
overcome the suppression of LPS-induced secretion of IL-6 and CCL2 normally 
observed in SF from CIA mice treated with ES-62 in vivo (Figure 5-6). Under 
conditions of steady state, SF from all cohorts of mice transfected with miR-
155 produced significantly more IL-6 and CCL2 than those treated with the 
negative control miRNA (siRNA). Although under these conditions, both the 
naive+miR-155-5p and the CIA-ES-62+miR-155-5p cohorts resemble the 
“aggressive” phenotype of the control CIA group, neither of these SF cohorts 
is converted to the hyper-aggressive status of CIA -miR-155-5p group. 
Consistent, with what is observed in untransfected cells (eg Figure 3-3). Thus, 
CIA SF produces significantly more IL-6 and CCL2 than the naïve and ES-62 SF 
when transfected with either control siRNA or miR-155-5p. Moreover, under 
these steady state conditions, the protection by ES-62 is conserved, and with 
respect to CCL2, even enhanced relative to SF from naive mice, when the 
cells are transfected with miR-155-5p.  
Perhaps surprisingly, when these SF were stimulated with LPS and already 
producing miR-155, the addition of the miR-155 mimic resulted in 
hyperproduction of the cytokines relative to that obtained with the control 
siRNA. Intriguingly, under the conditions pertaining in the presence of miR-
155-5p, the protective effects resulting from exposure to ES-62 in vivo were 
lost, and again, this was particularly pronounced with respect to CCL2. These 
data therefore appear to suggest that the levels and/or integration of miR-
155 signalling with other pathogenic effects is crucial to the maintenance of 
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SF hyporesponsiveness following exposure to ES-62. Thus, in steady-state ES-
62 SF, in the absence of additional proinflammatory signals generated by LPS, 
addition of the miR155 mimic is not sufficient to counter the ES-62-induced 
hyporesponsive state as exemplified by the reduced ERK and STAT3 signalling 
observed in these cells (Chapter 4). Likewise, in the siRNA condition, the 
levels of miR155-induced by LPS in ES-62 SF may not be sufficient or stable to 
fully integrate with other pathogenic signals resulting from this TLR ligand. 
However, LPS-coupled signalling in the context of the elevated levels of miR-
155 provided by the mimic appears to provide a sufficient platform to break 
the ES-62-induced hyporesponsiveness. 
Perhaps pertinent to this, miR-155 has previously been shown to be able to 
directly target SOCS1225 and SOCS3226 in some cells. As these have also been 
identified as potential targets of great interest to our study, the effects of 
the miRNA-155 mimic on SOCS1 and SOCS3 mRNA expression in SF from the 
various cohorts of mice were also determined (Figure 5-7). As suggested by 
our studies in Chapter 4, our control siRNA steady-state data indicate that 
whilst SOCS1 and SOCS3 are downregulated in SF from CIA relative to naive 
mice, this appears to be at least partially prevented by exposure to ES-62 in 
vivo and this profile is amplified in LPS-treated cells for SOCS1. However, this 
protection is not associated with accompanying inhibition of LPS-induction of 
IL-6 in these cells, despite reports of the role of SOCS1 in inhibiting LPS-
stimulation IL-6 release in macrophages by targeting JAK2/STAT5/p50 
signalling227. Interestingly, therefore in terms of the hypothesis that induction 
of miR-155 during CIA contributes to at least some of the downregulation of 
SOCS1, our data confirm that SOCS1 indeed appears to be a target of miR-155 
in SF since under steady-state conditions the addition of the miRNA totally 
abrogated SOCS1 mRNA expression in SF from all cohorts of CIA mice and the 
high levels of SOCS1 pertaining in SF from naive and ES-62 SF following 
stimulation with LPS are significantly reduced, but only to a level comparable 
with control CIA-ES-62 SF. Collectively, these data further support the 
likelihood that ES-62-mediated protection in these cells is not SOCS1-
mediated. Moreover, when the miR-155 cells are stimulated with LPS, CIA SF 
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no longer express SOCS1, presumably due to the high level of miR-155 and/or 
its integration with other TLR4 signals downregulating SOCS1.  
Intriguingly, although, SOCS3 induction does not appear to be targeted by 
miR-155 in SF from naïve and CIA mice, transfection with the miRNA-155 
mimic rather surprisingly strongly upregulated SOCS3 expression in SF from 
ES-62-CIA mice. Such an important rise could potentially be induced by the 
inhibition of miR-155 effects by ES-62 resulting in SOCS mRNA accumulation 
rather than its potential degradation. 
In any case the ability of ES-62-conditioned SF to maintain or even elevate 
SOCS1 and SCOC3 levels in the presence of LPS + miR-155-5p is rather 
counter-intuitive to the loss of their hyporesponsive phenotype, however, at 
least in the case of SOCS3, it may provide another mechanism in terms of 
negative feedback inhibition of STAT3 signalling228,229 by ES-62 (Chapter 4) to 
restrain the effects the hyper-Il-6 production by these cells230. 
In addition, it is known that miR-155 can deeply control a cell status by 
binding and regulating DNMT1 protein activity and therefore induce abherrant 
DNA methylation of the genome, at least in HEK293T and HCT116 cells231. 
Therefore, the impact of miR-155 in DNMT1 protein level has been analysed 
(Figure 5-8). The study reveals that miR-155 do not directly regulated DNMT1 
mRNA, level but do affect DNMT1 protein level with specially a strong 
decrease of DNMT1 in CIA SF under stimulation with LPS. This could explain 
somehow why in CIA SF we observe such a low level of DNMT1 while miR-155 
is found strongly upregulated, if miR-155 somehow drives DNMT1 suppression 
or degradation. 
 
5.5 Discussion and Conclusions  
Modulation of the miRNA network by ES-62 and the SMAs in SF is an efficient 
way to rewire and control cell aggressiveness and control its responses to the 
pro-inflammatory signal due to the proven ability of several miRNAs to 
regulate relevant downstream signaling as previously summarize for our 
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candidate miRNAs (Table 5-1). In particular, miRNA-155 the expression of 
which is induced by TLR4 signalling and efficiently reduced by both ES-62 and 
its SMAs is of potential relevance as a well-known target of miR155 is the 
suppressor of cytokine signaling SOCS1 which downregulates the IFNɣ 
signalling that is a pathogenic in RA/CIA 191,192,195 and a target of ES-62141,232. 
Indeed, SOCS1 inhibits IL-6-driven Th1 differentiation233. Interestingly, 
therefore, data in this thesis (chapter 4) suggest that ES-62 can upregulate 
SOCS1 and thus the finding that ES-62 reduces miR-155 levels suggests that 
this might provide a contributing mechanism to prevent the decrease in SOCS1 
occurring during CIA and enabling SF resistance to IFNɣ signals (Figure 5.9). 
Likewise, the increased level of SOCS3 observed in presence of both miR-155 
and ES-62 might also be caused by an accumulation of SOCS3 mRNA resulting 
from ES-62 suppression of miR-155 levels and if so, it could perhaps explain 
how ES-62 inhibits IL-6 and IL-17-STAT3 activity. Perhaps amplifying this, in T 
cells, miR-155 has been reported to have the ability to promote Th-17 
differentiation and activity by targeting SOCS1225,234. Therefore, this could 
potentially bring another mechanism by which ES-62 inhibits Th17 
differentiation.  
In summary it appears that ES-62 can control SF responses to the pro-
inflammatory environment by controlling the cell response at various levels. 
Thus, while in chapter 4 it is shown to control the signaling pathways directly 
downstream of IL-6/Il-17, here it is shown to control important regulators of 
such signaling pathways, the miRNAs. Thus, by demonstrating action via 
miRNAs at the feedback loop levels, this provides a molecular mechanism for 
inhibition of pathogenic STAT3 signalling: the final step is to investigate 
whether ES-62 regulates SF response to the pro-inflammatory environment by 
regulating targeted gene expression. In addition, since miR-155 is enable to 
regulate DNMT1 protein level within the cell, potentially by a direct binding 
to the protein231, ES-62 and the SMAs could potentially act to another level of 
cell phenotype regulation by directly acting on the global DNA methylation. 
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Table 5-1 List of candidate miRNAs potentially expressed by SF in CIA and 
regulated by ES-62 and/or its SMAs 
All miRNAs have been selected for being previously identified as being 
involved in inflammatory arthritis and miR-24-1 is found upregulated by 12b in 
macrophages. 
miRNAs Action on signaling pathways Known targets Up-down 
regulated in 
patients /CIA 
Pro-anti 
inflammatory 
Reference 
miR-19b-1 
miR-19b-1* 
miR-19b-2 
Upregulate TLR2 
Induce NFkB 
A20/Tnfaip3 -Rnf11 
Fbxl11/Kdm2a -
Zbtb16 
--- Pro 218 
miR-23b Induce NFkB pathway TAB2 - TAB3- IKK-α Downregulated in 
patients and CIA 
Anti 219 
miR-24-1 Upregulated by the SMA of ES-62 
12b in vitro in macrophages 
stimulated with LPS 
--- --- --- 114 
miR-34a KO resistant to CIA + increased 
SOCS3 
--- --- Pro Not 
published yet 
miR-34a* Inhibition of induced apoptosis 
resistance 
XIAP Downregulated in 
patients and CIA 
Anti 223 
miR-124 Overexpression reduces MCP-1  Down-regulated 
in RASF 
-- 220 
miR-125a Induce NFkB pathway TNFAIP3 Upregulated in 
patients plasma 
--- 217 
miR-146 Downregulate TLR/IL1 pathway IRAK-1 
TRAF6 
Upregulated in 
patients + CIA 
Anti 203,205,206 
miR-155 Enhance TNFα production SOCS1 
SHIP1 
Upregulated in 
patients + CIA 
Pro 204, 208, 213, 215 
miR-203 Upregulate in MMP-1 and IL-6 
expression 
--- Upregulated in 
CIA 
Pro 220 
miR-346-2 
  
Downregulate TNFα inhibitor 
Indirectly downregulate IL-18 
Tristetrapolin Upregulated by 
LPS 
Pro 221, 222 
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Figure 5-1 Profile of miRNA expression in SF 
A: SF were extracted from BALB/c mice and expanded ex vivo for 3 weeks. 
Cells were stimulated with LPS (1μg/ml) for up to 24 h as indicated: miR-155, 
miR-146 and miR-125a levels were quantified by qRT-PCR as described and 
data normalised relative to Hs-RNU6-2 expression levels. 
B: SF were derived from groups of Naive (score of zero) or CIA (mean score 
4.7 ± 1.48, n=10) mice and stimulated ± LPS (1 μg/ml) for 24 hours. The 
miRNA levels of candidate miRNAs (Table 5-1) were quantified by qRT-PCR 
and data normalised relative to Hs-RNU6-2 expression levels. All gene 
expression determined as  ≤0.1 fold of Hs-RNU6-2 expression was considered 
to be background as described by Qiagen122 
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Figure 5-2 Screening of potential miRNA targets of SMAs, 11a and 12b  
SF extracted and expanded ex vivo from Naive or CIA (mean articular score 
4.7 ± 1.48, n=10) mice to were pre-treated overnight in vitro with the SMAs 
11a and 12b (both at 5 µg/ml) and then further stimulated for another 6 hours 
with IL-1β (10 ng/ml), IL-17 (25 ng/ml) or LPS (1 µg/ml). Candidate miRNAs 
Table 5-1 were quantified by RT-qPCR (as described in the M&M 2-8) as 
indicated by fold change relative to the endogenous control Hs-RNU6-2 from a 
single experiment (n=1). 
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Table 5-2 Summary of in vitro regulation of miRNAs by 12b and 11a  
This table summarizes the data previously presented in figure 5-2. Red and 
green arrows represent respectively downregulation and upregulation of 
miRNA levels by the SMAs 11a and 12b in response to the various stimuli IL-1β, 
IL-17 or LPS. 
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Figure 5-3 SMAs 12b and 11a decrease expression of miR-155 in SF from 
CIA mice, in vitro 
SF from Naïve and CIA (mean score 4.7 ± 1.48, n=10). After being plated at a 
concentration of 0.3 10^6 cells per well as triplicate culture for each 
treatment group, cells were pre-treated overnight with the SMAs 11a and 12b 
(5 µg/ml for each molecule) and then further stimulated with LPS (1 µg/ml) 
for 6 hours, in vitro. miRNAs -19b, -23b, -34a, -146, -155, and -203* were 
quantified by RT-qPCR and normalised relative to the level of the endogenous 
control Hs-RNU6-2 as described in the M&M section 2.8. Data are from three 
independent cultures for each treatment group are represented as fold 
change relative to the CIA condition. 
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Figure 5-4 Exposure to 12b in vivo upregulates expression of miRNAs 146 
and 23b and downregulates expression of miR-155 in SF from mice 
undergoing CIA 
SF were extracted pooled and expanded ex vivo from naïve mice or CIA mice 
treated in vivo with 12b (mean score 0.714 ± 0.360, n=7) or PBS (CIA, mean 
score 3.667 ± 1.5, n=6). Cells were plated at a concentration of 0.3 10^6 cells 
per well in a 6 wells-plate as triplicate culture for each group treatment. 
After stimulation for 6 hours with LPS (1 µg/ml) and levels of the miRNAs -
19b, -23b, -34a, -146, -155, and -203* quantified by RT-qPCR relative to the 
level of the endogenous control Hs-RNU6-2 as described in the M&M section 
2.8. Analysis by ANOVA followed by the Tukey multiple comparison test was 
performed and results are expressed as the mean ± SEM, where * p < 0.05; ** p 
< 0.01, *** p<0.001.  
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Figure 5-5 in vivo ES-62 decreases miR-155  
SF were extracted pooled and expanded ex vivo from naïve mice or CIA mice 
treated in vivo with ES-62 (mean score 0.8 ± 0.8, n=6) or PBS (CIA, mean score 
4.67 ± 2, n=6). Cells were plated at a concentration of 0.3 10^6 cells per well 
in a 6 wells-plate as triplicate culture for each group treatment. After 
stimulation for 6 hours with LPS (1 µg/ml) and levels of the miRNAs -19b, -
23b, -34a, -146, -155, and -203* quantified by RT-qPCR relative to the level of 
the endogenous control Hs-RNU6-2 as described in the M&M section 2.8. 
Analysis by ANOVA followed by the Tukey multiple comparison test was 
performed and results are expressed as the mean ± SEM, where * p < 0.05; ** p 
< 0.01, *** p<0.001.  
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Figure 5-6 A miR-155 mimic promotes SF aggressiveness   
SF from Naïve mice, CIA mice (mean score 3.17 ± 1.37, n=6) and CIA mice 
treated in vivo with ES-62 (mean score 0.5 ± 0.22, n=6) were plated at a 
concentration of 0.3 10^6 cells per well as independent culture triplicate for 
each of the following treatments. Cells were transfected for 24 hours with 
miR-155-5p mimic (50 nM), whilst being stimulated or not with LPS (1 µg/ml). 
Cell supernatants were assessed for IL-6 and CCL2 production by ELISA as 
described in the M&M section 2.5. Data are expressed as the mean (of 
triplicate assays) ± SEM of three independent cultures and analysed by ANOVA 
followed by the Tukey multiple comparison test where * p < 0.05; ** p < 0.01, 
*** p<0.001. Such experiment has been successfully repeated independently 
using SF extracted from the same animal model. 
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Figure 5-7 A miR-155 mimic can regulate SOCS expression in SF 
SF from naïve mice, CIA mice (mean score 3.17 ± 1.37, n=6) and CIA mice 
treated in vivo with ES-62 (mean score 0.5 ± 0.22, n=6) were plated at a 
concentration of 0.3 10^6 cells per well as independent culture triplicate for 
each of the following treatments. Cells were transfected with miR-155-5p 
mimic (50 nM) whilst being stimulated with LPS (1 µg/ml) for 6 hours. Total 
RNA was extracted mRNA levels of SOCS1 and SOCS3 assessed by qRT-PCR as 
described in the M&M section 2.8 with data presented as relative to the levels 
of the endogenous control, GAPDH. Data were analysed by ANOVA followed by 
the Tukey multiple comparison test and expressed as the mean ± SEM where 
n=3 independent cultures and * p < 0.05; ** p < 0.01, *** p<0.001. Only 
relevant statistics are displayed on the graph. 
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Figure 5-8 miR-155 regulates DNMT1 protein, but not mRNA level 
A-B: SF used in Figure 5-6 from Naïve mice, CIA mice (mean score 3.17 ± 1.37, 
n=6) and CIA mice treated in vivo with ES-62 (mean score 0.5 ± 0.22, n=6) 
were plated at a concentration of 0.3 10^6 cells per well as independent 
culture triplicate for each of the following treatments. Cells were transfected 
for 24 hours with miR-155-5p mimic (50 nM) whilst being stimulated or not 
with LPS (1 µg/ml) as in Figure 5-6. Total protein was collected in order to 
reveal DNMT1 protein level by Western blot as described in the M&M method 
section 2.7. Semi-quantification of DNMT1 and GAPDH is done by ImageJ. Data 
are represented as relative to GAPDH protein level. Such experiment has been 
realised only once. 
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Figure 5-9 Model of the role of miR-155 in SF aggressiveness and its 
modulation by ES-62 and 12b 
By reducing miR-155 expression, ES-62 and 12b prevent its downregulation of 
SOCS1 resulting in dampening of cytokine signaling. In addition, the elevated 
expression of miR-155 due to inflammation primes an ES-62-mediated increase 
in SOCS3 expression that can potentially act to inhibit STAT3 signals. As a 
consequence of this dampening of JAK/STAT signalling, there is a reduction in 
the production of pro-inflammatory mediators and MMPs reflecting a less 
aggressive phenotype of SF.  
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6. SF activation during RA establishment: role of 
DNA methylation 
6.1 Introduction 
Acquisition of an aggressive phenotype by RASF or CIA SF is associated with 
the expression of new sets of genes, including those involved, for instance, in 
apoptosis resistance235, matrix degradation and production of pro-
inflammatory factors134. Moreover, such changes in their gene expression 
profile are conserved even after isolation from the pro-inflammatory 
environment ex vivo, highlighting that this is an intrinsic and permanent 
modification of the genomic expression profile. Such changes in gene 
expression or silencing are usually regulated by epigenetic processes involving 
modifications of histones (methylation and acetylation) and/or DNA 
(methylation). DNA methylation is by far the most studied and understood 
epigenetic process, usually being associated with stable gene silencing. 
Consistent both with this and the induction of pro-inflammatory genes in RA, 
previous studies have highlighted that cells from patients, and in particular 
their RASF, are globally hypomethylated85. Following on from this, a study on 
the DNA methylome of RASF has revealed that specifically, genes involved in 
migration, adhesion or matrix-degradation are amongst those 
hypomethylated236. It seems that this global hypomethylation reflects an 
increased polyamine metabolism in RASF that causes a decrease in S-adenosyl-
L-methionine levels86 as well as a decrease in DNMT1 activity124.  
Thus, the core aims of this chapter were to investigate whether: 
 murine SF similarly undergo a decrease in global DNA methylation during 
CIA and if so, address identifying events that can trigger such a change in 
the epigenetic landscape.  
 global DNA demethylation is sufficient and responsible for transformation 
of the responses of SF from naïve mice to the aggressive phenotype seen in 
CIA mice.  
184 
 
 the protection afforded against CIA by ES-62 (and its SMA 12b) that is 
associated with prevention and/or desensitisation of the aggressive SF 
phenotype reflects ES-62 and 12b counteracting the global DNA 
demethylation events that occur in SF during inflammation. 
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6.2 CIA SF are epigenetically modified cells  
Previous studies revealed that RASF display a lower global level of DNA 
methylation than those from OA patients85. It was therefore hypothesised that 
the stably aggressive phenotype of SF from CIA, relative to those from naive 
mice126, reflects that such SF have acquired a novel epigenetic landscape 
during initiation and progression of disease.  This hypothesis is supported by 
our finding of a decrease in global DNA methylation in CIA SF, which display a 
44% decrease in the levels of global methylation compared to naïve SF (Figure 
6-1A). Various mechanisms are involved in regulating DNA methylation levels 
as it can be an active process mediated by DNA demethylases or, as proposed 
for proliferating tissue such as the pannus, this can occur passively with DNA 
hypomethylation resulting due to the lack of maintenance of DNA 
methylation237. In mammals, maintenance of DNA methylation during cell 
division is achieved by the DNA methylase, DNMT1 whilst DNMT3a/3b appear 
to be the major enzymes responsible for de novo methylation. Interestingly, 
therefore, a decrease in the protein levels of DNMT1 has been shown to 
correlate with the observed global demethylation of DNA in RASF124. Similarly, 
it is now shown here that whilst there is a significant decrease in the levels of 
DNMT1 mRNA, this is not the case for DNMT3a in SF from CIA, relative to those 
from naive mice (Figure 6-1B). Moreover, such downregulation of DNMT1 is 
translated to the protein level, where substantially lower levels of DNMT1 
protein are observed in CIA SF compared to naïve SF (Figure 6-1C). Little or no 
DNMT3a protein, however was detected in resting SF from either naive or CIA 
mice by Western blot (data not shown). Collectively, therefore, these data 
are consistent with the human studies suggesting that SF undergo epigenetic 
landscape reprograming of (at least) their DNA methylation profile that could 
explain, at least in part, previous observations about the acquisition of an 
unusual aggressive phenotype during CIA. 
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6.3 Pro-inflammatory cytokines contribute to the 
epigenetic transformation of SF during CIA 
Previous in vitro studies by Nakano et al126 suggested that the cytokine, IL-1β 
that is pathogenic in RA/CIA may be one of the pro-inflammatory factors that 
can drive global demethylation of DNA in RASF. It is known that an early first 
step in RA pathogenesis, that occurs before SF activation, is T cell infiltration 
within the synovial membrane238: this may suggest that by establishing a local 
pro-inflammatory environment, such T cell responses could contribute to SF 
transformation by inducing global demethylation of their DNA. To test this 
hypothesis, it was investigated whether chronic exposure to cytokines 
associated with pathogenic Th responses126 can induce global DNA 
demethylation in SF from naive mice. Thus, the ability of IL-17, IL-22 and IL-
1β, the latter of which can promote both Th17/Th22 responses239, to 
modulate the global status of DNA methylation of SF from naive mice was 
tested. All of these cytokines were able to induce global DNA demethylation 
relative to control untreated (Naive) cells, with IL-22 being the least effective 
with a 38 % decrease, whilst IL-17 induced a 46 % decrease that was not 
further enhanced by co-stimulation with IL-22. IL-1β exhibited the strongest 
effect with a 60 % decrease (Figure 6-2A), mirroring the effects reported for 
human SF. To explain whether the decrease in DNA methylation reflected the 
changes in DNMT expression observed following induction of CIA in vivo, 
changes in the protein levels of DNMT1 and DNMT3 were also analysed. As 
expected IL-1β, IL-17 and IL-17 plus IL-22 together decreased the levels of 
DNMT1 compared to those seen in untreated SF (Naïve). However, 
surprisingly, IL-22 actually upregulated DNMT1 expression. Moreover, IL-22, 
and to a lesser extent IL-17, also induced an increase in DNMT3a expression, 
whilst expression of this enzyme was not substantially modulated by 
treatment with IL-1β or IL-17 plus IL-22 (Figure 6-2B and C). Therefore, these 
data suggested that chronic exposure to pro-inflammatory cytokines in vivo 
might indeed be able to modulate the DNA methylation landscape by virtue of 
regulating the expression levels of both DNMT1 and DNMT3a. Interestingly and 
perhaps reflecting that it induced the strongest global demethylation of DNA, 
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IL-1β downregulated both DNMT1 and 3a. By contrast, whilst both IL-17 and 
IL-22 play important roles in initiating CIA104,133, they appear to do so by 
distinct mechanisms. Thus consistent with the overall pattern associated with 
CIA in vivo, treatment with IL-17 or IL-17 plus IL-22 resulted in DNA 
hypomethylation predominantly via downregulation of DNMT1 and presumably 
consequently, induction of pro-inflammatory mediators: however, treatment 
with IL-22 alone increased expression of DNMT1 and 3a suggesting that it may 
act to silence anti-inflammatory factors, an activity that may be partially 
shared by IL-17 via its induction of DNMT3. However, this cannot be the full 
story as treatment with IL-22 results in global DNA demethylation suggesting 
that it either downregulates another DNMT, inactivates DNMT1/3 or induces 
active demethylase activities.  
 
6.3.1 Global DNA demethylation resulting from chronic 
exposure to cytokines in vitro is associated with 
hyperproduction of IL-6 
To address whether global DNA demethylation of naive SF induced by pro-
inflammatory cytokine in vitro is sufficient to remodel such normal SF to an 
aggressive CIA-like SF, their IL-6 production was determined. The basal and 
pro-inflammatory (IL-1β, IL-17 and LPS) mediator driven IL-6 production by 
such demethylated fibroblasts was indeed found to be significantly hyper-
induced in IL-1β-treated and, to a lesser extent, IL-17- and IL-17 plus IL-22-
treated fibroblasts (Figure 6-3A). However surprisingly, given the DNA 
methylation data, IL-22-treated cells did not produce more IL-6 than the 
naïve fibroblasts, rather if anything, in the IL-1 and LPS-stimulated cultures, 
they exhibited hyporesponsive cytokine responses. Moreover, whilst the 
hyper-cytokine promoting mediators resulted in a reduction in the numbers of 
SF at the end the two weeks culture perhaps reflecting their terminal 
differentiation to the aggressive phenotype, IL-22 maintained cell 
survival/proliferation (Figure 6-3B). This may therefore suggest however, that 
in the initiating phase of CIA, IL-22 may act to promote SF hyperplasia, 
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invasion of the synovium and pannus formation, thereby promoting 
pathogenesis. Therefore, cell aggressiveness in terms of hyper-cytokine 
production generally seems to correlate with DNA demethylation as does the 
observed cell cycle arrest, a phenomenon often observed during cell 
reprogramming and dedifferentiation240. 
 
6.3.2 Is the global DNA demethylation observed in CIA 
dependent on ERK and/or STAT3 signalling? 
As demonstrated earlier in this thesis (Figure 4-4 and Figure 4-8), ERK and 
STAT3 signalling appears to be constitutively activated in SF from CIA 
presumably because of the chronic IL-17 signalling in the joint during 
initiation and progression of CIA/RA. As chronic in vitro treatment of naive SF 
with IL-17 can induce similar levels of global DNA hypomethylation to that 
observed with CIA in vivo it was hypothesised that the constitutive activation 
of STAT3 and ERK could be important to the induction and maintenance of the 
global demethylated state of DNA associated with aggressive CIA SF. 
Certainly, it has been proposed that there is a close relationship amongst 
STAT3 and ERK signalling and DNA methylation. Indeed, STAT3 has been 
shown to directly bind to DNMT1 and HDAC1 and cause epigenetic 
remodelling241,242. Likewise, the ERK pathway has been implicated in the 
modulation of DNMT1 with consequent impact on DNA methylation243. Thus, 
for instance, inhibition of ERK signalling in CD4+ T cells by oxidative stress 
during lupus, results in suppression of DNMT1 thereby inducing global DNA 
demethylation244. Moreover, HDAC1-mediated regulation of DNMT1 has been 
shown to be ERK dependent243. To explore the potential importance of ERK 
and STAT3 signalling in driving the DNA demethylation associated with CIA, 
the effects of ERK- and STAT3-selective inhibitors on the in vitro induction of 
global DNA demethylation by IL-17 and IL-1β were tested. Whilst the 
inhibitors were shown to selectively inhibit their projected targets (Figure 4-5 
and  Figure 4-10) they did not themselves affect global DNA methylation, 
presumably due to the low basal levels of STAT3 and ERK signalling in these 
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cells. However, the ERK pathway inhibitor Pd98059 significantly suppressed 
the DNA demethylating effects of both IL-17 and IL-1β (Figure 6-4). Likewise, 
the STAT3 inhibitor appeared to impede the effects of IL-17, and to a lesser 
extent IL-1β, albeit this did not reach significance perhaps reflecting that this 
inhibitor did not fully inhibit STAT3 activity. However, the data clearly show 
that the global DNA demethylation observed in SF exposed to either of the 
pro-inflammatory cytokines, IL-17 and IL-1β, is ERK dependent as summarized 
in the Figure 6-5. 
 
6.4 Is inhibition of DNMT1 sufficient to induce SF 
aggressiveness?  
The above experiments dictated direct investigation of whether global DNA 
demethylation, and more specifically DNMT1 inhibition, is necessary and 
sufficient to reprogram naïve SF to an aggressive CIA-like phenotype. In order 
to investigate this hypothesis, the DNMT1 inhibitor, 5-azacytidine was used: 5-
azacytidine is a nucleoside analogue that can be incorporated into DNA and 
inhibit DNA methylation by preventing DNMT1 from binding. Indeed, 
Karouzakis et al. 124 reported that the exposure of SF from a trauma patient 
to 5-azacytidine reproduced the aggressive phenotype of RASF. Consistent 
with this, SF from naïve DBA/1 mice treated for one week with 5-azacytidine 
exhibited levels of global DNA methylation that were reduced by 
approximately 50% (Figure 6-6A) and secreted higher levels of IL-6 
spontaneously (Figure 6-6B). However, no difference could be detected in IL-6 
production by naive or 5-aza cells stimulated with either IL-17 or IL-1 
suggesting that whilst demethylation may be sufficient for some degree of 
hyperactivity, the actions of chronic cytokine signalling can further enhance 
this. Nevertheless, these data provided direct evidence that inhibition of 
DNMT1 by 5-azacytidine can induce a CIA SF like aggressive phenotype in 
naïve fibroblasts. 
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6.5 Does the protection against CIA afforded by ES-62 
and 12b reflect effects on the epigenetic 
landscape? 
6.5.1 Modulation of DNA methylcytosine levels by ES-62 and 
12b  
Collectively, the data presented above support the hypothesis that inhibition 
of DNMT1 and hence consequent global demethylation of DNA likely 
contributes to the acquisition of an aggressive SF phenotype in CIA. Since ES-
62 and 12b are able to prevent and/or counteract development of this 
aggressive phenotype during CIA it was important to assess whether these 
immunomodulators could directly regulate DNMT1 expression and hence 
global DNA methylation in SF during CIA. Therefore, SF were extracted from 
mice undergoing CIA that had been treated in vivo with PBS, ES-62 or 12b: in 
addition, some of these mice were concurrently treated IL-1β (Figure 6-7A 
and B) as this cytokine, which is pathogenic in RA/CIA177, is not only the 
target of 12b (and to a lesser extent ES-62) in CIA114, but also is the most 
effective mediator at inducing DNA hypomethylation in vitro. Indeed, 
exposure to IL-1β in vivo abrogates protection by ES-62 and 12b and further 
increases the severity of CIA in PBS-treated mice. Consistent with this, the 
lower levels of global DNA methylation displayed by SF from PBS-CIA mice 
were further reduced by exposure to IL-1β in vivo. Interestingly, therefore, 
whilst 12b acts to promote global methylation of DNA and hence presumably 
suppress inflammatory responses, somewhat counterintuitively, this is further 
promoted by co-administration of 12b and IL-1β, possibly suggesting the 
triggering of homeostatic inflammation-resolution mechanisms in this latter 
group of mice that exhibit severe disease. However, more surprisingly, 
exposure to ES-62 induced an even stronger global DNA hypomethylation 
profile than that of PBS-CIA (± IL-1β) although, and as seen with the 12b 
treatment, in this case exposure to IL-1β appeared to counter-act ES-62-
induced global DNA demethylation. 
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Consistent with its ability to induce global hypomethylation of DNA, in vivo 
exposure of mice undergoing CIA to ES-62, but not 12b, further downregulates 
the expression of DNMT1 and DNMT3a in SF to even below the levels seen in 
mice undergoing CIA at the mRNA level (Figure 6-7C and D). Although this 
further suppression did not translate to the protein level (Figure 6-7D and E), 
reflecting their hypomethylated status, these cells still exhibited reduced 
levels (comparable to those seen in SF from CIA mice) of DNMT1, whilst 
DNMT3a protein expression was not detected in SF from any of the groups 
(data not shown). By contrast, and as originally predicted based on its 
protective effects, treatment with 12b significantly increased the mRNA 
levels of DNMT1 and DNMT3a, compared to those in CIA SF, returning them to 
levels observed in naïve SF. 
Although, the data obtained with ES-62 appear counterintuitive to the 
hypothesis that global DNA hypomethylation in SF is associated with the 
pathogenic phenotype, such global analysis does not inform on the genes 
regulated: hence these data may suggest that ES-62 induces expression of 
anti-inflammatory/tissue protective genes to counteract pathology in the 
joint rather than simply prevent/reverse the upregulation of pro-
inflammatory genes, a hypothesis that supports the therapeutic potential of 
ES-62 in established joint disease. 
 
6.5.2 ES-62 may also impact on the epigenetic landscape by 
upregulating HDAC1  
The epigenetic landscape is shaped by many factors in addition to DNA 
methylation, such as various modifications of histones. Indeed, there are 
close interactions between histone modifications and DNA methylation, a 
good example being the correlation between histone acetylation (often 
associate with upregulated gene expression) and DNA methylation245 (Figure 
6-8). Moreover, as it has been reported that HDAC1 can directly bind DNMT1 
and regulate its activity246, it was of particular interest to investigate whether 
differential expression of HDAC1 by SF derived from CIA mice, treated with 
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PBS or ES-62, could potentially explain the diametrically opposite phenotypic 
results associated with strong global DNA demethylation under these 
conditions. Analysis of HDAC1 expression by ES-62- CIA- and Naïve SF revealed 
a strong upregulation of this enzyme by ES-62 (Figure 6-9), suggesting that in 
the context of global DNA hypomethylation this may have anti-arthritogenic 
effects, perhaps by silencing some pro-inflammatory genes or alternatively, 
by inducing some inflammation-resolving, tissue repair genes. Intriguingly, 
therefore, analysis of the effect of chronic cytokine treatment of SF in vitro 
revealed a correlation between the most demethylated and aggressive cells 
(IL-1β and IL-17 plus IL-22) and least HDAC1 expression (Figure 6-10). 
Collectively therefore, these data support the hypothesis that upregulated 
HDAC1, at least in the context of severe DNA hypomethylation, might be 
associated with protection against the development/maintenance of the 
aggressive SF phenotype, and provide a mechanism to explain why SF with 
demethylated DNA from ES-62-treated mice display a protective phenotype.  
 
6.5.3 Understanding the mechanisms underpinning ES-62 
modulation of the epigenetic landscape – site dependent 
demethylation? 
The data presented in this chapter clearly demonstrate that the genome of 
CIA SF is hypomethylated and to our surprise, is further globally demethylated 
in SF from CIA-mice exhibiting protection afforded by ES-62. Thus, it is 
important to understand which promoter sites are targeted for 
demethylation. Pertinently, therefore, a particular SF methylome signature 
has already been identified from RA patients that reveals the demethylation 
of specific sites such as STAT3, CASP1, IL-6 or CXCL12 known to be involved in 
SF aggressiveness247-249. To attempt to reveal genes targeted by DNA 
demethylation in RASF that are potentially regulated by ES-62, a cross array 
bioinformatics analysis was performed (Table 6-1). This analysis was based on 
the two previously published arrays, the DNA methylome signature published 
by Nakano et al248 and the expression profile of RA synovial membranes 
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exposed in vitro to ES-62 by Harnett et al99. Genes identified in both arrays 
are summarised in Table 6-1 and provide a first hint of potential sites at 
which ES-62 can modulate the DNA methylation profile and include prediction 
of known targets of ES-62 action such as downregulation of IL-1 (via 
downregulation of caspase 1). Such genes therefore represent potential 
candidates for further investigation and they provide proof of concept that 
the hypomethylation of DNA in SF from ES-62-treated CIA mice may be 
regulating different promoter sites from those activated during CIA resulting 
in responses to counteract the pro-inflammatory expression profile induced in 
CIA SF. 
 
6.6 Discussion and Conclusions 
The data presented in this chapter confirm the hypothesis that SF extracted 
from CIA mice are indeed intrinsically epigenetically modified cells, exhibiting 
global hypomethylation of their DNA predominantly due to a decrease in 
DNMT1 expression. Such transformation of the epigenetic landscape of naive 
SF can be recapitulated in vitro by chronic exposure to several pro-
inflammatory cytokines, implicated in RA pathogenesis, as evidenced by this 
driving DNA demethylation and associated hyper-production of IL-6. Perhaps 
surprisingly, this was not the case for IL-22, which has been shown to be 
critical to the initiation of CIA, with this mediator exhibiting differential 
effects on the levels of DNMT1 and DNMT3a, relative to the other pro-
inflammatory cytokines tested. In addition, it is possible that IL-22 acts via a 
different mechanism, perhaps inducing DNA methylation to silence anti-
inflammatory/tissue protective genes expression. Nevertheless, the data 
arising out of concomitant treatment with IL-17 plus IL-22 underlines that, in 
vivo, integration of all signals during inflammation determines the resulting 
levels of DNA methylation. In particular, they highlight the importance of the 
local environment and its role in signal integration in remodelling the SF 
epigenetic landscape contributing to its pathogenic phenotype (Figure 6-11). 
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Global DNA demethylation therefore indeed provides a good explanation for 
the transformation of SF to an aggressive phenotype during the induction of 
CIA: however, the effects of ES-62 on DNA methylation raise the question as 
to whether global DNA demethylation of SF constitutes a good marker for SF 
aggressiveness as previously suggested, since exposure to ES-62 induces an 
even stronger global demethylation of DNA than that observed in SF from CIA 
mice. Thus, it is possible that whilst a certain level of demethylation may be 
pathogenic, more profound demethylation may result in the induction of 
homeostatic control mechanisms to effect resolution of inflammation and 
instigate tissue repair mechanisms. Indeed, such a mechanism may reflect the 
reports that in distinct types of cancers, DNA demethylation can result in 
dramatically opposite effects in different cell types81,250. This reinforces that 
it is crucial to identify the specific sites of demethylation rather than focusing 
on global effects. Indeed, even if cells are globally hypomethylated, certain 
promoters such as that of the death receptor 3 gene (DR3; a member of the 
pro-apoptotic Fas gene family) have been found to be hypermethylated in 
some RA patients87. Bisulfite sequencing could reveal which sites are 
differentially targeted in SF from CIA and CIA-ES-62-treated mice and 
predictions by the cross array analysis have already provided proof of concept 
that some genes expressed by DNA demethylation in RASF may be silenced by 
ES-62 and vice versa.  
Finally, the disconnect in action between ES-62 and 12b is intriguing and may 
reflect that this SMA can only recapitulate certain of the properties of the 
parasite molecule. Nevertheless, the apparent hypermethylation induced by 
12b might explain its protection against CIA in terms of its inhibition of IL-1β 
production114. Indeed as Firestein and colleagues reported, and confirmed 
here with CIA SF, prolonged exposure of SF to IL-1 induces global 
demethylation of DNA by decreasing DNMT1 and 3a expression and activity248, 
promoting the pathogenic phenotype of these key arthritogenic cells in the 
joint.  
  
195 
 
Figure 6-1 CIA SF display global DNA demethylation relative to SF from 
naive mice and this is associated with reduced expression of DNMT1  
A: SF were isolated from naïve and CIA mice from 3 different animal models 
(mean score 3.6 ± 1.5, n = 6; mean score 4.5 ± 1.3, n=10 and mean score 2.5 ± 
0.8, n=12). Genomic methyl cytosine levels were measured as described in the 
M&M section 2.9 with the OD values obtained, normalised to the value of 
untreated fibroblasts from naive mice (considered as 100% genomic 
methylation). This experiment represents three independent mouse model 
experiments which shows that SF from CIA mice exhibit in average 79.3% of 
methyl cytosine ± 11.6, n=3 relative to those from naive mice. 
B and C: SF were isolated from naïve and CIA mice (mean score 3.6 ± SEM, n = 
6). Cells were plated at a concentration of 0.3 10^6 cells per well in a 6 wells-
plate as independent triplicate or duplicate cultures for each treatment 
condition (respectively for mRNA and protein extraction) for 24 hours. Total 
mRNA was extracted and DNMT1 and DNMT3a expression at the mRNA level 
were analysed by qRT-PCR as described in the M&M section 2.8. Triplicate 
estimations from each culture and the mean levels were normalised to GAPDH 
expression and expressed as a mean fold change ± SEM (n=3) (B). Expression of 
DNMT1 at the protein level from independent duplicate cultures was 
determined by Western blot (C) total ERK protein level is as well revealed as 
control for protein loading. 
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Figure 6-2 Pro-inflammatory cytokines can modulate in vitro the global 
DNA methylation profile of SF from naive mice  
Naïve SF were plated at 0.3 x 106 cells/ml and as individual culture for the 
different treatment groups. For 2 weeks cells were stimulated with daily 
addition of the indicated cytokines, IL-22, IL-17 or both together (2.5 ng/ml 
each) and IL-1β (1 ng/ml). At the end of the treatment, genomic DNA and 
proteins were extracted for further analysis.  
A: Genomic methyl cytosine level was measured and presented as the 
absolute OD value relative to the naïve OD value. Considering the untreated 
fibroblasts from naive mice (Naive) as 100% genomic methylation, the average 
methylation after the treatment is expressed as percentage on the figure. 
This experiment has been successfully repeated three time independently. 
B: DNMT1 and DNMT3a protein expression was determined by Western blot 
analysis and the levels in the 3 independent cultures from the cell extracted 
from the same naïve mouse and levels relative, to GAPDH was quantified 
using the software ImageJ (C) and expressed as the mean values ± SEM. 
ANOVA tests followed by Tukey multiple comparison test were performed 
where * p < 0.05; ** p < 0.01, *** p<0.001. This experiment has been realised 
only once. 
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Figure 6-3 Global DNA demethylation induced by cytokines is associated 
with development of an aggressive SF phenotype   
SF from Naïve mice treated in vitro with cytokines as described in  Figure 6-2 
were assessed for live cell concentration at the end of the chronic exposure 
experiment (A). Such cells were re-plated in triplicate cultures for each 
treatment group (104/well) and synchronised overnight in DMEM 1% FCS prior 
to stimulation for 24 h with IL-17 (25 ng/ml), IL-1β (10 ng/ml), LPS (1 µg/ml) 
or medium alone in DMEM 10% FCS. Cell supernatants were collected and IL-6 
release was measured by ELISA. Data are expressed as the mean (or means of 
triplicate estimations) ± SEM of n=3 independent cultures and analysed using 
one-way ANOVA and the Tukey multiple comparison post-test where * p < 
0.05; ** p < 0.01, *** p<0.001 as compared to the untreated (naïve) condition. 
Data are from a single experiment. 
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Figure 6-4 IL-17- and IL-1β-induction of global DNA demethylation is 
dependent on ERK and STAT3 signalling  
SF from Naïve mice were treated for two weeks daily as in  with IL-17 (2.5 
ng/ml) and IL-1β (1 ng/ml) as described in the figure 6-2, in the presence of 
the MEK (ERK pathway) inhibitor, PD98059 (25 µM) or the STAT3 inhibitor 5.15 
DPP (50 µM) as previously used in Figure 4-5 and  Figure 4-10. Genomic DNA 
was extracted from the treated cells and the levels of methyl cytosine 
determined and data presented as mean absolute OD values from 3 
independent cultures. In addition, the relative percentage of global 
methylation when normalised to the “naïve” untreated cells (100% 
methylation) is shown on the figure. The data are expressed as mean values ± 
SEM, with ANOVA and Tukey multiple comparison tests performed, with * p < 
0.05; ** p < 0.01, *** p<0.001 indicated for relevant statistics. 
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Figure 6-5 Hypothetical model of the events underpinning the global DNA 
demethylation occurring in SF during CIA 
Proinflammatory and pleiotropic cytokines, such as IL-17, IL-22 and IL-1β, are 
present in affected joints during CIA. By promoting ERK and STAT3 signalling, 
IL-17 and IL-1 modulate levels of DNMT1 and DNMT3a thereby inducing global 
changes in the epigenetic DNA methylation landscape. Such changes in global 
DNA methylation allow the expression of sets of genes promoting CIA. 
However, IL-22 does not appear to utilise these pathways and so for its 
pathogenic effects during disease initiation, IL-22 may act via as yet 
undefined signals to silence anti-CIA genes, providing an additional 
mechanism to explain the acquisition of an aggressive SF phenotype during 
CIA. 
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Figure 6-6 The DNMT1 inhibitor, 5-azacytidine induces global DNA 
hypomethylation and associated hyper-production of IL-6 
Naïve SF were plated as independent triplicate cultures and treated daily for 
a week by the addition of the DNMT1 inhibitor 5-azacytidine (1 μM) dissolved 
in DMEM with 10% FCS.  
A: Genomic DNA was assessed for methyl cytosine levels after treatment, with 
the data presented as the means of absolute OD values from 2 independent 
cultures. In addition, the relative percentage of global methylation 
normalised to the naïve untreated cells (100% methylation) is shown on the 
figure. This experiment has been successfully repeated independently three 
times. 
B: From parallel cultures, such cells after treatment were plated (104/well 
and stimulated for 24 h with IL-17 (25 ng/ml), IL-1β (10 ng/ml) or DMEM 10% 
FCS as control. Supernatants from independent triplicate culture were 
collected and IL-6 concentration measured by ELISA. Data were expressed as 
the mean (of means of triplicate analyses) ± SEM and ANOVA followed by 
Tukey multiple comparison tests were performed where * p < 0.05; ** p < 
0.01, *** p<0.001 for the relevant statistics. These sets of data are 
representative of two independent studies. 
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Figure 6-7 ES-62 and 12b differentially modulate the global DNA 
methylation status of SF from mice undergoing CIA 
A: All SF used for the following experiments were isolated from the CIA mouse 
model experiment presented in figure 3-7 and represented again to facilitate 
awareness of the disease scores of the particular treatment groups.  
B: SF were derived from the joints from mice undergoing CIA treated with PBS 
(CIA, mean score 3.66 ± 1.5, n=6), PBS + IL-1β (CIA+ IL-1β, mean score 6 ± 
1.93, n=6), 12b (mean score 0.71 ± 0.36, n=7), 12b + IL-1β (mean score 7.62 ± 
1.67, n=8), ES-62 (mean score 1.5 ± 1.15, n=6) or ES-62 + IL-1β (mean score 9 
± 1.93, n=6). Genomic methyl cytosine levels were measured as described in 
the M&M section and presented as normalised to level (100%) found in SF 
derived from naïve mice. Data are from a single CIA model. 
C: SF derived from the CIA and naive mice treated in vivo as described above, 
namely, naïve untreated, or CIA mice exposed to PBS (CIA, mean score 3.66 ± 
1.5, n=6), 12b (mean score 0.71 ± 0.36, n=7) or ES-62 (mean score 1.5 ± 1.15, 
n=6) plated as independent triplicate culture for each treatment group and 
were assessed for their levels of DNMT1 and DNMT3a mRNA by RT-qPCR as 
described in the M&M section (2.8). Levels were normalised to GAPDH and 
expressed as a fold change for the three independent cultures where data are 
expressed as mean± SEM, n=3 and statistical analysis was by ANOVA followed 
by the Tukey post-test where * p < 0.1 ** p < 0.01 and *** p < 0.001.  
D: SF extracted from joints from naïve or CIA mice, the latter treated with 
PBS (CIA, mean score 3.66 ± 1.5, n=6) or ES-62 mice (mean score 1.5 ± 1.15, 
n=6) were analysed for DNMT1 protein levels by Western blot and the levels of 
expression relative to ERK were quantified using Image J software. Data were 
obtained from 3 independent cultures and were representative of two such 
independent studies. ANOVA tests followed by the Tukey multiple comparison 
test were performed and results were expressed as the mean ± SEM, n=3, 
where ** p < 0.01 
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Figure 6-8 Importance of the balance between DNA methylation and 
promoter acetylation to gene expression 
The balance between the levels of DNA methylation and histone acetylation in 
a particular promoter region determines the potential accessibility of the 
promoter to transcription factors. Thus, a heavily DNA-methylated and poorly 
acetylated promoter will be in the heterochromatin state and will be 
permanently repressed, while the presence of highly acetylated histones and 
poorly methylated DNA in a promoter region results in euchromatin and 
constitutive gene expression. All states in between allow inducible gene 
expression. 
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Figure 6-9 Exposure to ES-62 in vivo upregulates HDAC1 expression in SF 
from CIA mice  
SF derived from ES-62-treated CIA mice (mean score 0.5 ± 0.22, n=6), CIA 
mice (mean score 3.17 ± 1.38, n=6). Such cells were pooled by treatment 
group and plated as independent triplicate culture and naïve mice were 
analysed for protein expression of HDAC1 by Western blot and the levels 
relative to GAPDH were quantified using Image J software. Data are shown 
from 3 independent cultures and represented by mean ± SEM, n=3 and ANOVA, 
followed by the Tukey multiple comparison test, was performed where ** p < 
0.01 
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Figure 6-10 Induction of DNA demethylation following chronic exposure to 
cytokines in vitro is associated with modulation of HDAC1 expression 
SF derived from naive mice were chronically exposed for two weeks to IL-17 
(2.5 ng/ml), IL-22 (2.5 ng/ml), both cytokines, or IL-1β (1 ng/ml) as described 
in figure 6-3. At the end of the treatment, total cellular protein was 
recovered and the levels of HDAC1 determined by Western blot analysis and 
quantified relative to GAPDH using Image J software. The data shown 
represents the levels found in three independent cultures and analysis by 
ANOVA followed by the Tukey multiple comparison test where results were 
expressed as the mean ± SEM and * p < 0.1. 
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Table 6-1 Cross-array referencing of genes modulated by ES-62 in Synovial 
Membranes from an RA patient with SF genes undergoing regulation via 
DNA methylation in RA 
Previously published array data from Nakano et al251 and Harnett et al99 were 
cross-analysed to identify genes characteristic of the signature  DNA 
methylome of RASF that are also modulated by ES-62 in the synovial 
membrane of an RA patient, in vitro. Such genes were classified in four 
categories: upregulated by ES-62 and hypermethylated in RASF, upregulated 
by ES-62 and demethylated in RASF, downregulated by ES-62 and 
hypermethylated in RASF and downregulated by ES-62 and demethylated in 
RASF. 
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Figure 6-11 Model of how ES-62 and 12b act to modulate the epigenetic 
landscape in SF. 
ES-62 and 12b are able to regulate the levels (mRNA and protein) of DNMTs 
and therefore, the global DNA methylation profile of SF. Interestingly, whilst 
protection afforded by 12b induces an increase in global DNA methylation 
(potentially associated with silencing of pathogenic genes), that resulting 
from exposure to ES-62 is perhaps surprisingly associated with a decrease in it 
(potential induction of inflammation-resolving and tissue protective genes) 
However, the ES-62-mediated decrease in DNMT1 and DNA methylation is 
accompanied by an increase in HDAC1, that presumably contributes to the 
modification of the genetic landscape observed under conditions of CIA. Such 
changes in the epigenetic landscape presumably reflect the silencing of some 
pro-inflammatory genes and induction of anti-inflammatory genes. 
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7. General discussion 
7.1 Drug development from helminth-derived products 
Parasitic worms are common infectious agents of humans in developing 
countries. Helminths have been infecting humans for a long time as evidenced 
by the discovery of eggs in mummified faeces that are thousands of years 
old252, as well the testimonies of helminth infections related in ancient 
writings such as the Bible, the writings of Hippocrates or Egyptian papyri. 
They present a serious risk to health and indeed, it has been estimated, firstly 
in 1947 by Stoll and then confirmed by the CDC, that about 37% of the 
worldwide population is infected by parasitic worms253,254. Such parasites like 
the guineaworm, ascariasis or schistosomiasis are responsible for many 
disorders if left untreated whilst the best known effects of nematode 
infection are blindness and elephantiasis255.  
However, despite being a major health issue, infection with parasitic worms 
correlates with a low incidence rate of asthma and allergies as corroborated 
by the recent dramatic increase in these disorders in developed and 
dewormed countries256,257. These observations support the hygiene hypothesis, 
a theory suggesting that in the “too clean” environment found in Western 
countries the immune system will not mature properly and fail to react 
properly to contact with pathogens resulting in its overreaction to some 
environmental triggers causing asthma and allergies in children. Consistent 
with this, in animal models, helminth infection have been shown to be 
protective for a number of immunopathological diseases90,91. Such 
observations have led to increased interest in studying the effects of 
helminths in patients with immune disorders and this has identified increasing 
evidence that patients with multiple sclerosis display less severe symptoms 
when infected with helminths258. In addition, a recent study from Panda et 
al259 revealed that in Odisha (India) RA patients were free of filarial infection 
in an area where helminth infection is considered as endemic. Indeed, 
collectively, such studies have driven the development of various helminth-
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based clinical trials for Inflammatory bowel disease like Crohn’s disease92,93, 
coeliac disease94 or ulcerative colitis95 as well rhinitis97.  
One explanation for their protective effects against immune disorders is that 
as some helminth species, like tapeworm, are able to live for up to 30-40 
years, they need to keep the host healthy and control the immune system in 
order to hide and survive. The study of patient’s urine or serum revealed the 
presence of immunomodulatory excretory-secretory molecules in the helminth 
secretome98. One of the first and most studied immunomodulatory ES 
molecules is ES-62 isolated for the first time in 1989 by Harnett et al110. ES-62 
is a 62 kDa protein and is the major ES product secreted by the filarial 
nematode Acanthocheilonema viteae. It is a PC-containing homotetrameric 
glycoprotein that exhibits therapeutic potential in various mouse models of 
inflammatory disorders260 such as the OVA-induced airway hypersensitivity 
models of asthma103 , MRL/lpr model of lupus102 as well as the CIA model of 
RA104. In this thesis ES-62 has been confirmed to protect against CIA 
development and new information about its ability to act directly at the site 
of inflammation and joint damage by modifying the functional phenotype of 
SF, andthe molecular mechanisms involved, has been presented. 
 
7.2 In vivo treatment with ES-62, or its SMAs 11a and 
12b, reduces SF aggressiveness 
As shown by Pineda et al104,133, ES-62 prevents the development of CIA in mice 
by resetting the IL-17/IL-22 axis. Thus, ES-62 was first found to downregulate 
pathogenic IL-17 responses in CIA mice, by targeting an IL-17 producing 
cellular network comprising dendritic cells, ɣδ T cells and CD4+ T cells. 
Indeed, ES-62 suppresses the level of IL-17-producing CD4+ and ɣδ T cells by 
modulating DC-mediated priming and polarization of such T cell responses as 
well as also directly attenuating IL-1-mediated maintenance of Th17 
responses by reducing MyD88 expression in Th17 cells. However, while it 
reduces IL-17 production in the joint, ES-62 strongly increases IL-22 
production, the latter a cytokine shown to be pathogenic in early disease 
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phase but able to promote resolution of inflammation in the late established 
phase of disease261. Exposure to ES-62 suppresses the early systemic 
pathogenic production of IL-22 and promotes that driving resolution in the 
joints. Such counter-regulatory control of the IL-17/22 axis by ES-62 seem to 
be a consistent mechanism of ES-62 action since it is also targeted in other 
contexts such as asthma and lupus. Thus, in the OVA induced airway 
hypersensitivity model, suppression of disease was due to the reduction of the 
pathogenic IL-17 response101. However, in the MRL/Lpr lupus model as well as 
in asthma, disease was reduced by ES-62 suppressing pathogenic IL-22 
responses and increasing IL-17A production during established disease, 
demonstrating that as like IL-22 in RA, IL-17A appears able to play a dual role 
in both lupus and asthma, being pathogenic prior onset of disease whilst 
acting to promote resolution of inflammation once the disease is 
established101-102. 
In this thesis, the protective effect(s) of ES-62 on CIA mice was reaffirmed, 
with its actions on SF highlighted. Thus, it was demonstrated that SF 
extracted from ES-62-treated mice were less sensitive to pathogenic signals, 
such as TLR ligands, IL-17 or IL-1β, than those from PBS-treated mice with 
CIA. Such modulated SF were less aggressive, both in terms of their ability to 
perpetuate inflammation and mediate bone destruction, due to their reduced 
production of the pro-inflammatory cytokine, IL-6 the chemokine, CCL2 and 
the MMPs, MMP9 and MMP13. IL-6 is well established as a pathogenic driver in 
RA, being found in high levels in patients’ serum and synovial fluid9: IL-6 acts 
to promote neutrophil migration, osteoclast maturation, VEGF-stimulated 
pannus proliferation as well as the maturation of B cells and Th17 cells158. It 
has therefore been proposed to be a good therapeutic target and consistent 
with this, the anti-IL-6R antibody, Tocilizumab has given promising results in 
various phase III clinical trials in improving the physical condition of 
patients262. CCL2 (MCP-1) is likewise found abundantly in RA patient serum 
and synovial fluid and appears to be crucial for the attraction of pro-
inflammatory leukocytes, particularly monocytes, to the joint263. MMP9 and 
MMP13 are respectively a gelatinase and a collagenase and both of these MMPs 
are found at elevated hyper-activated levels in RA synovial fluid: moreover, 
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there is a strong correlation between the levels of MMP9 and MMP13 and the 
disease severity of patients and thus, they are often used as potent clinical 
markers of disease activity in early RA264.  
Thus, the intracellular signalling driven by pro-inflammatory signals like IL-17 
or IL-1β resulting in the production of IL-6, CCL2 or MMPs was investigated in 
order to understand better how ES-62 may functionally reduce SF 
aggressiveness. The mechanisms unravelled in this thesis are developed below 
with the pathogenic mechanisms and their subversion by ES-62/12b 
summarized in, respectively. 
 
7.3 ES-62 modulates pro-inflammatory cytokine 
signalling 
To modulate functional responses resulting from the pro-inflammatory 
environment in the arthritic joint (Figure 7-1), ES-62 can potentially control 
various factors. For instance, ES-62 is well known to reduce MyD88 expression 
levels in a variety of cell types, such as mast cells265, dendritic cells, 
macrophages266, T cells109 and kidney cells102 in order to downregulate the 
inflammatory potential of TLR/IL-1R pathways and/or perhaps, switch to a 
MyD88-independent response. For example, with respect to the latter, the 
MyD88-dependent TLR4 pathway drives NFκB and consequently inflammatory 
gene transcription: however, when TLR4 signalling is MyD88 independent it is 
conducted through TRIF and IRF3267 which induces IFNβ gene transcription268-
270. Usually such production of IFNβ is observed after repeated stimulation of 
TLR3 and TLR4 receptors in order to attenuate NFκB activation. Here, ES-62-
exposed SF were shown to express IFNβ following stimulation with the 
pathogenic cytokine IL-17, a response that was absent in SF from naïve and 
CIA mice. Interestingly, therefore, increasing data suggest therapeutic 
potential for IFNβ in RA in terms of its ability not only to downregulate driven 
production of the pro-inflammatory cytokines, IL-1β and TNFα in vitro but 
also its capacity to reduce MMP1 and increase IL-10 and IL-1 receptor agonist 
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levels, in vivo271,272. Moreover a pilot study in 12 patients showed significant 
improvement after 3 months of treatment with IFNβ273-275. 
Data further supporting a protective role for IFN were presented in this 
thesis as, in addition to confirming that IFNβ signals through STAT1, it was 
shown to enhanced the expression of STAT1 protein and as well as its 
activation (phosphorylation) and STAT1 induced gene expression is usually 
associated with growth restraint and/or promotion of apoptosis184,276,277, 
responses counter-regulatory to the pathogenic STAT3-mediated pro-
survival/proliferative signalling observed in RASF175. Moreover, STAT3 is 
crucial for CCL2 production following IL-6 or IL-1β stimulation278,279 as well as 
being important for MMP9 and MMP13 production, the latter at least in 
chondrocytes280,281. Intriguingly, therefore, ES-62-exposed SF were also shown 
to display a higher level of STAT1 phosphorylation compared to SF from naïve 
and CIA mice, whilst such ES-62 SF also appeared to exhibit downregulated 
levels of pathogenic STAT3 signalling.  Indeed, given that IL-22 can signal 
through both STAT3 and STAT1193 and that it has been shown to be pro-
inflammatory in early arthritis, potentially signaling through STAT3171,175, yet 
inflammation-resolving in the joint in established disease133, such a dual role 
of ES-62 in switching the balance from pathogenic STAT3 to potentially 
protective, pro-apoptotic STAT1 signalling in SF might provide a  mechanism 
for ES-62-mediated rewiring IL-22 function towards resolution of 
inflammation133. Certainly, ES-62 only promotes IL-22 production and its 
resolution function in the joint during established disease (Figure 7-2).  
Such a ‘STAT switch’ from STAT3 to STAT1 could therefore explain how SF 
become insensitive to the pathogenic actions of IL-22 and indeed to other pro-
inflammatory signals liked IL-6 and IL-17 that also signal via STAT3 (Figure 
7-1). This capacity of ES-62 to effect the STAT switch could potentially reflect 
its priming of induction of IFNβ to not only promote STAT1 activation but also 
upregulate SOCS expression, which are key controllers of STAT pathways189. 
Consistent with this, exposure to ES-62 was found to increase SOCS1 and 
SOCS3 expression in SF from mice undergoing CIA (Figure 7-2). Of particular 
relevance, SOCS3 is known to be an inhibitor of STAT3 and its overexpression 
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was shown to block STAT3 signalling and result in a reduction of CIA severity, 
even more efficiently than expression of a STAT3 dominant negative 
construct282. Likewise, previous studies have shown that SOCS1 inhibits JAK 
activity by preferentially binds to such kinases through its SH2 domain to 
consequently inhibit JAK activity via interactions with its KIR domain leading 
to its degradation in a mechanism involving its SOCS box189. Such an action 
would decrease the JAK-STAT signalling of many cytokine receptors, such as 
IL-2, IL-4, IL-7, IL-12 or IL-15 and as well IFNα/ but its major target remains 
IFNɣ283,284 which is pathogenic in RA192. In addition, SOCS1 also seems to be 
able to directly supress TLR signaling, as SOCS1 knock out cells are more 
sensitive to TLR ligands even in a IFNɣ-deficient background285.  
Such upregulation of SOCS1 by ES-62 can potentially be achieved both by 
direct induction of its expression, but also by reduction of the levels of miR-
155, which can directly target its messenger RNA. Both the in vivo and in vitro 
ES-62 experiments presented here, revealed that exposure to ES-62 can 
significantly reduce miR-155 expression induced in response to LPS. Moreover, 
the ability of miR-155 to target and reduce SOCS1 mRNA levels in SF was 
confirmed, suggesting that by decreasing miR-155 levels ES-62 relieves the 
inhibition of SOCS1 mediated by miR-155. One consequence of the resulting 
elevated levels of SOCS1 could be the observed reduction in STAT3 activation 
since the ability of SOCS1 to target JAK kinases enables it, like SOCS3 to 
inhibit STAT3 signaling286. As a proof of concept, overexpression of miR-155 in 
human laryngeal squamous cell carcinoma induced not only a reduction in 
SOCS1 levels but also an elevation of STAT3 expression and activation234. 
Moreover, STAT3 activation has been shown, via a positive feedback loop, to 
induce miR-155 for instance in Th17 cells to promote autoimmune uveitis287. 
Therefore, such downregulation of miR-155 by ES-62 could explain, at least in 
part, the STAT3 inhibition observed in ES-62 SF.  
Modulation of the miRNA network by ES-62 is potentially important due to its 
ability to rewire the intracellular signaling network of SF since a single miRNA 
can regulate thousands of genes and therefore control multiple pathways214. 
Pertinently, miRNA-155 appears to be particularly involved in the 
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pathogenesis of RA207 (Figure 7-1), being implicated in the control of  cell 
proliferation, inflammation and resistance to apoptosis207,213. Interestingly, 
given the observed suppression of ERK signalling in SF by ES-62, amongst all 
the cell signaling pathways controlled by miR-155, ERK signalling seems to be 
a key miR155 target in many cell types288-290: thus, the efficient inhibition of 
ERK activation by ES-62, may in part reflect its ability to suppress miR-155 
and consequently, upregulation of ERK activation. Downregulation of ERK 
activation has the potential to strongly reduce SF aggressiveness as it is 
crucial for production of IL-6 production291, MMP9 induced by CCL2292 as well 
as that of MMP13293. Interestingly, therefore, the inflammation-resolving 
actions of IL-22, administered to the paws of mice once inflammation was 
established133, were also associated with the ability of this treatment to 
recapitulate ES-62-mediated inhibition of ERK signalling in SF derived from 
CIA mice (Figure 7-2).  
 
7.4 ES-62 prevents SF acquiring a “mesenchymal-
fibrotic” phenotype  
In the 1980s, Fassbender hypothesised that the pannus-mediated destruction 
of cartilage could be caused by the invasion of ‘tumor-like’ immature 
mesenchymal cells generated by dedifferentiation of fibroblasts and that such 
mesenchymal cells redifferentiated once cartilage destruction was 
accomplished294. This hypothesis of a tumor-like phenotype of pathogenic 
RASF is supported by many of their characteristics such as their STAT3 
addiction and resistance to apoptosis175,235,295,296, acquisition of motility135 and 
mosaic chromosomal aberration297. Moreover, these characteristics of RA/CIA 
SF are conserved even following their isolation and culture ex vivo, supporting 
the idea of an intrinsic cell modification during inflammation. Although these 
cells are not tumor cells per se, as for instance, they do not metastasise, they 
appear to undergo a similar process to that of tumor cell transformation. For 
example, one of the processes that is similar to that occurring in RA synovial 
membranes is the epithelial mesenchymal transition (ECM), a process that 
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drives multiple changes in a polarized epithelial cell that allows it to assume 
the functional phenotype of a mesenchymal cell, such as cell migration, tissue 
invasion and resistance to apoptosis298. Fibroblasts are prototypical 
mesenchymal cells299 and thus distinguishing them from a mesenchymal stem 
cell is still problematic300,301 especially as they seem to be closer in phenotype 
than previously recognized302. Therefore, “transformation” (activation) of SF 
during RA is believed to process through a mechanism similar to EMT resulting 
in them gaining a mesenchymal/fibrotic phenotype303,304. Reflecting this, the 
data presented in this thesis support the hypothesis that CIA SF and naïve SF 
display functionally distinct phenotypes, even following isolation from the 
pro-inflammatory joint and culture for several weeks ex vivo. Thus, CIA SF are 
cells that appear to be more sensitive to pro-inflammatory cytokines, exhibit 
an altered miRNA network and display constitutive activation of ERK and 
STAT3. ERK and STAT3 signaling pathways are necessary for EMT induction305 
and indeed, blockade of STAT3 suppresses EMT in pancreatic cancer cells306. 
Therefore, suppression of ERK and STAT3 signaling by ES-62 may reduce the 
activation/transformation of SF and prevent their acquisition of the 
pathogenic aggressive  “mesenchymal-fibrotic” phenotype.  
Interestingly, a key signaling pathway in EMT, and more generally in cell 
differentiation, is the Wnt cascade: although Wnt activity was not measured 
in this study, ES-62 SF were found to exhibit high protein expression levels of 
HDAC1, a well-known inhibitor of the Wnt/β-catenin pathway307. Indeed, 
inhibition of HDAC1 has been found to be important for cell dedifferentiation 
as this results in induction of Wnt signaling308. Perhaps of relevance therefore, 
microarray analysis of gene expression of RA synovial membranes revealed 
that in vitro treatment of these cells with ES-62 strongly induced, 
(approximately 4-fold compared to the control samples) Wnt inhibitory factor 
1 (WIF1), as well as AMOTL2 and CRYBB299 which are respectively Angiomotin 
Like 2 and Crystallin Beta B2 known to be efficient wnt inhibitors309. 
Collectively, these data suggest that potentially, by inhibiting Wnt signaling 
ES-62 suppresses SF activation/transformation by targeting the known 
pathogenic effects of Wnt signaling in inducing MMPs, RANKL, and cytokines 
such as IL-6, IL-8 and IL-15310,311.  
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7.5 ES-62 impacts on gene expression by modulating 
the epigenetic landscape 
Usually, in tumor cell transformation, cell differentiation or EMT, the 
epigenetic landscape is remodelled, driving the acquisition of new features 
and a ‘dedifferentiated’ cell state. Many events can induce changes in the 
epigenetic landscape, including cell reprogramming induced by chronic 
inflammation, as described for instance for melanoma cells312. 
Reprogramming induced by chronic inflammation following infiltration of the 
joint with e.g. pathogenic T cells has been proposed to provide a potential 
explanation for the acquisition of the aggressive phenotype of CIA-SF 
developing in early RA or CIA313. Amongst the various epigenetic modifications 
possible, changes in the DNA methylation profile have been implicated as a 
driving force in the regulation of cell differentiation status, and is usually 
involved in cell transformation314,315. Therefore, in this thesis the impact of 
pro-inflammatory cytokine signalling and its modulation by ES-62 on global 
DNA methylation of SF during CIA was analysed. As proposed previously124,248 
and confirmed in this thesis, CIA SF exhibit global DNA hypomethylation and 
display lower expression levels of DNMT1 than naïve SF. Such global DNA 
demethylation appears associated with disease, and indeed, gene array 
analysis of the effects of the DNMT1 inhibitor 5-azacytidine indicated that 
such treatment enabled human OA SF to acquire a RA-like aggressive 
phenotype124. However, the data presented here show that whilst 5-
azacytidine treatment is sufficient to drive a more aggressive phenotype in 
terms of elevated basal levels of IL-6 release by SF from naive mice, acute 
stimulation with cytokines can further enhance this, at least in vitro. 
Moreover, the finding that SF from CIA treated with ES-62 in vivo display the 
highest levels of hypomethylation shows that global DNA demethylation is not 
always associated with acquisition of aggressiveness. Indeed, in vivo 
treatment with ES-62 resulted in SF that exhibit even less DNMT1 mRNA 
expression than CIA SF and consistent with this, display further DNA 
demethylation.  
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This suggests that in vivo exposure to ES-62 does not simply prevent SF 
transformation, but actually induces differential rewiring of the epigenetic 
landscape presumably in order to allow expression of genes driving the 
resolution of inflammation or cell apoptosis. ES-62 is not the only reagent to 
induce DNA demethylation and DNMT1 inhibition, while protecting SF from 
developing an aggressive phenotype: a good example of a similar effect is 
daphnetin316, a compound derived from Chinese medicine, (7, 8-
dihydroxycoumarin) extracted from Daphne odora Var. Marginata, has been 
shown to downregulate DNMT1, DNMT3a and DNMT3b expression in rat CIA SF 
resulting in the protective expression of the pro-apoptotic genes DR3, PDCD5, 
FasL and p53.  
Thus, global DNA methylation might not always be a sign of SF aggressiveness, 
although the DNA methylation signature may be of use in distinguishing early 
and longstanding arthritis patients317 and their specific pathogenic 
processes318. However, the new data presented here underline that it is 
important to focus on the specific sites of methylation, as potential anti-
inflammatory therapeutics such as ES-62 are likely to induce methylation 
profiles distinct from the SF disease signature since the cells will respond 
differently to the modulated inflammatory environment. For example, ES-62 
reduces the effect of IL-17 and IL-1β by suppressing ERK and STAT3 activation, 
signals which are necessary for induction of global DNA demethylation 
observed for these two cytokines, in vitro. Such suppression of ERK and STAT3 
signalling by ES-62 could possibly enable a modification of the methylome 
profile as STAT3 and ERK act together with DNMT1 in order to regulate 
specific gene expression241-243 (Figure 7-2). Indeed, STAT3 has been reported 
to directly bind to DNMT1 and regulate its activity, for instance to allow 
PTPN6 promoter silencing241 and the epigenetic silencing of SHP-1, a tumor 
suppressor in malignant T lymphocytes242. Moreover, in lupus T cells, ERK 
dependent modulation of DNMT1 expression contributes to the regulation of 
CD11a and CD70 expression319, resulting in T cell proliferation and activation 
contributing the development of autoimmunity. Importantly, HDAC regulation 
of DNMT1 activity appears to be ERK dependent243 and HDAC1 can form a 
complex with DNMT1, Rb and E2F in order to regulate specific promoters 
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important for cell proliferation and resistance to apoptosis320,321. Since in vivo 
exposure to ES-62 results in higher expression of HDAC1 in SF than that 
observed in CIA fibroblasts, the combination of modulating both DNMT1 and 
HDAC1 rather than just DNMT1, STAT3 or other potential co-factors might, 
whilst maintaining a low level of global DNA methylation, enable a new 
protective epigenetic profile.  
The role of HDAC1 in RA is however very complex: although this study suggests 
it to be protective since it is induced by ES-62 and could potentially regulate 
Wnt activity in SF, some studies have revealed the use of HDAC inhibitors to 
be protective in CIA models322 as evidenced by them having various anti-
inflammatory effects such as reducing IL-6 production323. Moreover, HDAC1 
has been shown to support cell proliferation and survival although it has 
(perhaps consistent with the ES-62 effects) ben shown to be associated with 
reducing MMP-1 production324. In addition, alteration of the histone 
modification profile appears to be a key event in establishment of RA, 
especially in terms of SF activation323 and their production of IL-6325. Thus, it 
is important to keep in mind that regulators like HDAC1 have a multitude of 
co-factors that impact on their activity depending on the context of local 
environment320,321, as exemplified by the ability of IL-22 to both induce 
inflammation and contribute to its resolution in CIA.  
 
7.6 Developing efficient clinical drugs from ES-62 
Studying the actions of parasitic worm-derived immunomodulators in order to 
potentially develop safer therapies for inflammatory disorders is currently of 
particular interest: this focus has arisen since such molecules have emerged 
as the result of millennia of evolution allowing generation of ‘safe’ 
immunomodulators that benefit both host and parasite. By contrast, 
conventional anti-inflammatory therapies are usually strongly 
immunosuppressive with numerous and, potentially serious, side effects. 
Thus, information gained from parasitic immunomodulatory mechanisms, such 
as those exploited by ES-62, is very useful to our understanding of the 
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pathogenicity of inflammatory disorders and may reveal novel safe and 
effective therapeutic targets. For instance whilst protection by ES-62 
confirmed the importance of IL-17 in CIA pathogenicity104 it revealed the bi-
phasic effect of IL-22 in driving both pathogenesis and inflammation 
resolution133.  
However, since ES-62 is a large and potentially immunogenic molecule it 
cannot be used directly as therapeutics. This is the reason why SMAs based on 
the active moiety of ES-62, PC, were designed and screened for their 
immunomodulatory properties. Two SMAs, 11a and 12b, were chosen, on the 
basis of their anti-inflammatory properties in vitro, for testing of their ability 
to supress CIA. Confirming and extending previous findings of their 
therapeutic potential in RA114,132, data in this thesis revealed that both SMAs 
are very efficient in reducing CIA both prophylactically and therapeutically.  
It is unlikely that the SMAs will mimic ES-62 perfectly since their interactions 
at the surface or within the cell may well be different to that of ES-62. 
However, it has been previously shown that whilst both SMAs 11a and 12b can 
downregulate MyD88 expression113,114, they differentially mimic certain 
features of ES-62 action, namely that 11a acts through inhibiting IL-17 
production132 and 12b suppresses IL-1β production by regulating the 
inflammasome in an NRF2-dependent manner114. Thus, the potential for these 
SMAs to mimic the actions of ES-62 on SF was investigated in this thesis. This 
revealed that SF treated with either 11a and 12b in vitro displayed reduced 
cytokine production that was associated with lower levels of expression of the 
pro-inflammatory miRNA, miR-155 and induction of SOCS expression, actions 
reminiscent of those of ES-62. However, it is not yet clear whether these 
effects are achieved by the same mechanism: indeed, SF derived from CIA 
mice exposed to a prophylactic regime of 12b treatment in vivo display a 
distinct epigenetic landscape to that of SF from CIA mice treated with ES-62. 
Thus 12b appears to act to increase DNMT1 expression and global DNA 
methylation presumably to drive the silencing of many pro-inflammatory 
genes and/or anti-apoptotic genes otherwise induced during CIA suggesting 
that it acts to prevent or reverse the hypomethylation associated with 
pathogenesis. By contrast, although both 12b and ES-62 effect protection, ES-
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62 does not simply appear to prevent the epigenetic remodelling, but rather 
to induce a distinct landscape associated with inflammation resolution and 
tissue repair that could be exploited for treatment of established disease.  
Thus, to apply such research for clinical purposes, more deep investigation 
using the SMAs 11a and 12b is required, as although they mimic certain of its 
effects, they appear to potentially act through (additional) different 
mechanisms to ES-62. In particular, it would be interesting to see the effects 
of 11a and 12b on the epigenetic landscape of SF when the SMAs are 
administered therapeutically to determine whether they mimic ES-62’s 
effects under this inflammatory context. Nevertheless, such SMAs provide 
excellent starting points for the further development of parasitic worm-based 
drugs for clinical trials especially since preliminary data suggests that they 
display low toxicity and good tolerability profile (unpublished data, Harnett, 
Harnett and Suckling).   
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Figure 7-1 Model of the signalling network underpinning SF aggressiveness 
in CIA 
Production of proinflammatory factors such as IL-6 and CCL2 and mediators of 
bone destruction, including MMP9 and MMP13 are induced in SF in response to 
signalling by pathogenic mediators, such as IL-17, IL-1β and TLR ligands. 
Signalling via their receptors induces activation of a variety of downstream 
elements converging on the STAT3 and ERK pathways to regulate the miRNA 
network, rewire the epigenetic landscape and induce pathogenic gene 
expression. Interestingly, IL-22 plays a dual role being pro-inflammatory 
during pathogenesis and resolving inflammation during established disease: 
for example, under the later conditions, when IFNβ is also produced in the 
joint, IL-22 can potentially induce STAT1 activation to promote expression of 
anti-inflammatory genes. 
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Figure 7-2 Model of the molecular mechanisms by which ES-62 and 12b 
reduce CIA SF aggressiveness 
ES-62 and 12b can directly target SF to reduce the production of the pro-
inflammatory molecules IL-6 and CCL2, as well as the mediators of bone 
destruction, MMP9 and MMP13. This is achieved by their ability to modulate 
the activation of various signalling elements resulting from the pro-
inflammatory environment of the joint. For example, ES-62 modulates STAT3 
and ERK signalling downstream of the IL-17A receptor as well as controlling 
the miRNA landscape in order to induce a nugatory feedback loop 
orchestrated by SOCS molecules. Moreover, ES-62 promotes IFNβ production 
when the cells are exposed to IL-17. Therefore, IFNβ stimulates STAT1 
phosphorylation and potentially enables IL-22 to switch its downstream 
signaling towards STAT1 and induces the expression of genes promoting 
resolution of inflammation. Likewise, the suppression of STAT3 signalling 
reduces the ability of proinflammatory cytokines to signal via this pathway. 
Integration of signals results in regulation of DNMT and HDAC1 expression 
enabling ES-6 to rewire the epigenetic landscape and induce expression of a 
protective set of genes. Whilst sharing some of the actions of ES-62, 12b is 
differentially found to reduce SF sensitivity to pro-inflammatory mediators by 
regulating miR-155 and SOCS expression in the context of increasing DNMT1 
levels and consequently, the global DNA methylation associated with silencing 
of pathogenic genes.  
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